On this page
Quick Reference
Overview and Recommendations
Key Facts
- •Staphylococcus aureus is a Gram-positive, coagulase-positive coccus and the leading cause of death from bacteremia worldwide, with an estimated 300,000 deaths annually and a case fatality rate of 15-30% even with appropriate therapy, making it one of the most lethal bacterial pathogens.
- •The organism is classified by methicillin susceptibility into MSSA (methicillin-susceptible) and MRSA (methicillin-resistant), the latter mediated by the mecA gene on SCCmec elements; MRSA accounts for ~40% of invasive isolates globally and carries a higher recurrence risk (sHR 1.69).
- •Virulence is driven by a potent arsenal: Panton-Valentine leukocidin (PVL) causes necrotizing pneumonia and recurrent SSTIs; TSST-1 triggers toxic shock syndrome; α-hemolysin mediates lung tissue destruction; and biofilm-forming strains (especially CC8/spa t008) predict higher readmission rates in device-related infections.
- •The spectrum of disease spans from superficial furuncles and cellulitis to life-threatening bacteremia, infective endocarditis, vertebral osteomyelitis, and toxin-mediated syndromes, with metastatic seeding occurring in >30% of bloodstream infections.
- •In the United States, the age-adjusted incidence of S. aureus bacteremia is 33.9 per 100,000 person-years, with highest rates in older adults, males, Black individuals, and people who inject drugs; community-associated MRSA (USA300 clone) disproportionately affects prisoners, athletes, and men who have sex with men.
Clinical Importance
- •Suspect S. aureus infection in any patient with purulent skin abscesses, recurrent furuncles, or rapidly progressive cellulitis, especially in young, otherwise healthy individuals without healthcare exposure, this pattern is classic for CA-MRSA (USA300).
- •In patients with fever and risk factors such as indwelling catheters, injection drug use, hemodialysis, or recent hospitalization, obtain two sets of blood cultures before starting antibiotics; a single positive bottle represents true infection in 89.8% of cases.
- •Ask specifically about new back pain (suggests vertebral osteomyelitis or spinal epidural abscess), joint pain (septic arthritis), chest pain or hemoptysis (septic pulmonary emboli from right-sided endocarditis), and headache or focal neurologic deficits (CNS infection).
- •Examine for skin abscesses, heart murmurs (especially new or changing murmurs suggest endocarditis), joint effusions, spinal tenderness, and neurologic deficits, the presence of a prosthetic valve or cardiac device raises the likelihood of seeding.
- •Order blood cultures from two separate sites, and send an MRSA nares PCR swab, a negative result has a negative predictive value of 96.5% for ruling out MRSA pneumonia and bloodstream infection, enabling early de-escalation of anti-MRSA therapy.
- •Perform transthoracic echocardiography (TTE) in all patients with S. aureus bacteremia; proceed to transesophageal echocardiography (TEE) if there is persistent bacteremia ≥48 hours, persistent fever >72 hours, metastatic foci, or an implantable cardiac device, TEE increases endocarditis detection from 2-15% to 14-28%.
- •Measure time to blood culture positivity (TTP): a TTP <13 hours independently predicts infective endocarditis (OR 3.59) with a negative predictive value of 96% for ruling out endocarditis when longer.
- •For suspected S. aureus pneumonia, consider the diagnosis in patients with severe community-acquired pneumonia, especially if preceded by influenza, presenting with hemoptysis, rapid respiratory decline, and cavitary lesions on imaging.
- •When evaluating a patient with positive blood cultures, assess for persistent bacteremia: repeat cultures at 24-48 hours, persistent positivity ≥2 days confers a 90-day mortality of 39% and mandates aggressive source control and search for metastatic infection.
- •In cases of prosthetic joint infection (PJI), suspect S. aureus when a patient with a prior arthroplasty develops acute pain, swelling, and erythema of the joint within a median of 1 day after positive blood culture; PJI occurs in 19% of SAB patients with preexisting hardware.
- •For children, a limp or refusal to bear weight may be the only sign of acute hematogenous osteomyelitis; the metaphysis of long bones (femur, tibia, humerus) is most commonly involved.
- •Always consider differential diagnoses: necrotizing fasciitis (severe pain out of proportion), gout (crystal analysis), viral pneumonia (PCR panels), and nonbacterial thrombotic endocarditis (modified Duke criteria).
Diagnosis and Treatment
- •Initiate empiric anti-MRSA therapy when local MRSA prevalence exceeds 10-20%, the patient has severe sepsis or septic shock, or there are risk factors for MRSA (prior colonization, injection drug use, hemodialysis, recent hospitalization).
- •For suspected MRSA bacteremia or endocarditis, administer vancomycin 15-20 mg/kg IV every 8-12 hours with a target AUC/MIC ratio of 400-600 mg·h/L (trough 15-20 µg/mL if AUC monitoring unavailable); alternative: daptomycin 6 mg/kg IV once daily for bacteremia, 8-10 mg/kg for endocarditis.
- •For suspected MSSA bacteremia, start cefazolin 2 g IV every 8 hours (preferred over antistaphylococcal penicillins due to significantly lower risk of acute kidney injury, NNT=18); if penicillin-susceptible, benzylpenicillin 1.8 g IV every 4 hours is an option.
- •For uncomplicated skin abscess, perform incision and drainage and consider adjunctive oral antibiotics: trimethoprim-sulfamethoxazole (160/800 mg) one double-strength tablet orally twice daily or clindamycin 300-450 mg orally three times daily for 5-7 days.
- •For severe SSTI with systemic toxicity, use intravenous vancomycin or daptomycin; linezolid 600 mg IV/orally every 12 hours is an alternative with good tissue penetration and lower nephrotoxicity.
- •Achieve source control urgently: remove all infected intravascular catheters within 72 hours (failure to do so increases 90-day mortality), drain abscesses ≥5 cm, debride necrotic tissue, and for native valve endocarditis consider early valve surgery if heart failure, uncontrolled infection, or embolic complications develop.
- •De-escalate anti-MRSA therapy to a β-lactam (cefazolin or antistaphylococcal penicillin) when MRSA nares PCR returns negative (NPV >96%) and cultures confirm MSSA, this reduces nephrotoxicity and cost; de-escalate by day 4 of therapy when possible.
- •Use therapeutic drug monitoring for vancomycin: target an AUC0-24/MIC of 400-600 (assuming MIC 1 mg/L); Bayesian dosing is preferred; avoid relying solely on trough monitoring.
- •Duration of therapy: 14 days for uncomplicated bacteremia (negative follow-up cultures at 48-72 hours, no endocarditis, no metastatic foci, defervescence within 72 hours); 4-6 weeks for complicated bacteremia (endocarditis, deep-seated infection, persistent bacteremia ≥48 hours).
- •Consider early oral switch in clinically stable, low-risk patients with uncomplicated bacteremia who have cleared blood cultures and have a removable source: the SABATO trial showed noninferiority of oral step-down after 5-7 days of IV therapy (13% vs 12% composite outcome); use linezolid 600 mg orally twice daily for MRSA or cephalexin 500 mg orally four times daily for MSSA.
- •For left-sided endocarditis, the POET trial supports oral switch after at least 10 days of IV therapy with noninferior outcomes (9.0% vs 12.1%); oral options include a fluoroquinolone plus rifampin or linezolid.
- •Avoid routine addition of gentamicin, it increases nephrotoxicity without improving survival; avoid rifampin as adjunctive therapy for uncomplicated MRSA bacteremia (ARREST trial showed no benefit, HR 0.96).
- •Avoid dual β-lactam therapy (e.g., vancomycin plus anti-MRSA β-lactam) for MRSA bacteremia, CAMERA2 showed no improvement in 90-day mortality and increased acute kidney injury (23% vs 6%).
- •For persistent MRSA bacteremia ≥5 days despite optimized vancomycin, switch to daptomycin 8-10 mg/kg IV daily plus ceftaroline 600 mg IV every 8 hours, this combination showed reduced in-hospital mortality in a pilot trial (0% vs 26%).
- •Monitor renal function daily during treatment with vancomycin or antistaphylococcal penicillins; monitor creatine phosphokinase (CPK) weekly if on daptomycin; monitor complete blood count weekly if on linezolid for more than 2 weeks due to risk of thrombocytopenia.
- •Refer to infectious diseases specialist for all cases of S. aureus bacteremia and endocarditis, ID consultation reduces 10-year mortality (HR 0.42) and risk of new bacteremia (OR 0.45).
- •For prosthetic joint infection, manage with surgical debridement, retention of prosthesis (DAIR) combined with rifampin-containing regimen if debridement is adequate; success rates are 69% for hip and 54% for knee.
- •For osteomyelitis, treat with 4-6 weeks of parenteral or highly bioavailable oral therapy after adequate debridement; longer courses (>6 weeks) do not improve outcomes in fracture-related infection.
- •Do not base therapy solely on vancomycin MIC ≥2 µg/mL, consider alternative agents (daptomycin, ceftaroline, ceftobiprole) as failure rates are high.
- •In ICUs, implement universal decolonization with chlorhexidine bathing and intranasal mupirocin to reduce MRSA clinical isolates (HR 0.63) and all-pathogen bloodstream infection (NNT=54 to prevent one BSI).
Board Review — High Yield
- •Persistent bacteremia ≥2 days, 90-day mortality 39% vs 22% for 1 day.
- •MRSA nares PCR NPV >96%, enables safe de-escalation of empiric anti-MRSA therapy.
- •Cefazolin preferred over antistaph penicillins for MSSA, lower AKI risk (SNAP, CloCeBa).
- •Vancomycin AUC/MIC target 400-600, replaces trough monitoring alone.
- •POET trial, oral switch noninferior in left-sided endocarditis after ≥10 days IV.
- •CAMERA2, adding β-lactam to vancomycin for MRSA BSI increased AKI without mortality benefit.
- •ARREST, no benefit of adjunctive rifampin for S. aureus bacteremia.
- •SABATO trial, early oral switch (5-7 days IV) noninferior in low-risk SAB.
- •REDUCE MRSA, universal decolonization in ICU reduces all-cause BSI (NNT=54).
- •Mupirocin resistance, associated with usage >25 DDD/1000 patient-days.
Deep Dive — Evidence Details
Definition, Classification and Causative Organisms
- ▸Staphylococcus aureus is the leading cause of death from bacteremia worldwide, with a 15-30% case fatality rate.
- ▸MRSA accounts for a substantial proportion of invasive infections and contributes to over a million global deaths attributable to antimicrobial resistance annually.
- ▸Classification by resistance (MSSA vs MRSA), acquisition setting (community vs healthcare), and clinical syndrome is essential to guide empiric therapy and predict outcomes.
Staphylococcus aureus is a Gram-positive, coagulase-positive coccus that causes a broad spectrum of human infections, ranging from minor skin and soft-tissue infections to life-threatening bacteremia, endocarditis, pneumonia, and osteomyelitis.
Also Called / Synonyms
- Staph infection
- MRSA (methicillin-resistant S. aureus)
- MSSA (methicillin-susceptible S. aureus)
- CA-MRSA (community-associated MRSA)
- HA-MRSA (healthcare-associated MRSA)
- S. aureus bacteremia (SAB)
Clinical Significance
S. aureus is the leading cause of death from bacteremia worldwide, with a case fatality rate of 15-30% and an estimated 300,000 deaths per year [58]D5. It is the most common pathogen isolated from skin and soft-tissue infections, prosthetic joint infections, and infective endocarditis [43]D5[64]D5. Invasive MRSA infections occur at a rate of 31.8 per 100,000 in the United States, with highest rates among older adults, Black individuals, and males [83]C4. Globally, MRSA contributed to approximately 1.27 million deaths attributable to bacterial antimicrobial resistance in 2019 [21]B2c.
Classification Axes
S. aureus infections are classified along several axes that guide empiric therapy and prognosis.
| Category | Type | Key Features | Examples |
|---|---|---|---|
| By resistance | MSSA | Susceptible to β-lactam ; treated with cefazolin or antistaphylococcal penicillins [12]B3b[15]A1b[22]A1b | Bacteremia, SSTI |
| MRSA | Resistant to methicillin due to mecA gene carriage; requires , , or ceftobiprole [1]A1c[14]A1b[58]D5 | Bacteremia, SSTI, pneumonia | |
| By setting | Community-associated (CA) | Occurs in healthy individuals without healthcare risk factors; often involves USA300 clone [47]D5[54]D5[63]D5 | Purulent SSTI, necrotizing pneumonia |
| Healthcare-associated (HA) | Onset in hospitalized or institutionalized patients; typically multidrug-resistant [42]D5[43]D5 | Bacteremia, device-related infections | |
| By syndrome | Skin/soft-tissue | Cellulitis , abscess, wound infection [2]A1c[59]D5 | Furuncle, carbuncle |
| Bacteremia | Positive blood cultures; persistent ≥2 days carries 90-day mortality of 39% [28]B2b[58]D5 | Catheter-related, endovascular source | |
| Pneumonia | Community-acquired, hospital-acquired, or ventilator-associated [7]A1b[11]B2a | MRSA pneumonia | |
| Endocarditis | Left-sided or right-sided; often with metastatic seeding [13]A1b[16]A1b[68]C4 | Native valve, prosthetic valve | |
| Osteoarticular | Osteomyelitis, septic arthritis, [46]D5[56]B3b[98]C4 | Hematogenous, contiguous spread |
Persistent bacteremia, defined as ≥2 days of positive blood cultures while on active antibiotics, is a critical prognostic marker that mandates aggressive source control and echocardiography [28]B2b[58]D5. The microbiologic basis of resistance, including staphylococcal cassette chromosome mec (SCCmec) types and virulence factors such as Panton-Valentine leukocidin, is discussed in the next section.
Pearl: Classification by resistance (MSSA vs MRSA), acquisition setting (community vs healthcare), and clinical syndrome is essential to guide empiric therapy and predict outcomes.
Microbiology and Pathogenesis
- ▸S. aureus virulence results from coordinated expression of MSCRAMMs, pore-forming toxins (α-hemolysin, PVL), superantigens (TSST-1, enterotoxins), and biofilm machinery, regulated by agr, SaeRS, and ArlRS systems.
- ▸PVL is strongly associated with SSTIs but not with worse outcomes in bacteremia; CA-MRSA clone USA300 owes its success to ACME acquisition plus PVL and α-hemolysin.
- ▸Small colony variants and intracellular persistence explain therapy-refractory chronic infections; biofilm-forming CC8/spa t008 strains predict higher readmission rates.
Beyond its Gram-positive coccal morphology and catalase-positive identification, S. aureus possesses a formidable armamentarium of surface adhesins, secreted toxins, and immune-evasive molecules that together dictate the spectrum and severity of human infection. The organism's capacity to cause disease depends not on one factor but on the coordinated expression of multiple virulence determinants, regulated by quorum-sensing and two-component systems, allowing adaptation to diverse host niches.
Virulence Factor Arsenal
The cell wall-anchored microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) include clumping factor A (ClfA) and fibronectin-binding proteins (FnBPs), which mediate adherence to fibrinogen and fibronectin on damaged endothelium, initiating endovascular infections such as infective endocarditis [120]D5[134]D5. Protein A (Spa) binds the Fc portion of IgG, interfering with opsonophagocytosis and acting as a B-cell superantigen [120]D5. Secreted toxins produce direct tissue damage: α-hemolysin (Hla) is a pore-forming cytotoxin active against epithelial and endothelial cells and platelets, central to the pathogenesis of necrotizing pneumonia [132]D5[162]D5. Panton-Valentine leukocidin (PVL), a bicomponent synergohymenotropic toxin, targets neutrophils and macrophages, causing cell lysis; a systematic review and meta-analysis found PVL-positive strains strongly associated with skin and soft-tissue infections (SSTIs) but comparatively rare in invasive disease (OR 0.10, 95% for bacteremia), challenging the view that PVL primarily drives poor outcomes in deep-seated infection [111]A1a. Nonetheless, PVL-positive community-acquired MRSA (CA-MRSA) clones, particularly USA300, cause aggressive necrotizing SSTIs and severe community-onset pneumonia, often preceded by influenza-like illness [128]D5[141]D5[192]C4.
Toxic shock syndrome toxin 1 (TSST-1) and staphylococcal enterotoxins (SEs) are superantigens that bypass normal antigen processing by binding directly to MHC class II molecules and T-cell receptor Vβ chains, triggering massive cytokine release ("cytokine storm") leading to multi-organ dysfunction [32]D5[135]D5. Menstrual TSS, historically linked to tampon use, is caused by TSST-1-producing S. aureus strains; a nationwide French ICU series reported that 87% of vaginal isolates from menstrual TSS carried TSST-1 [113]C4[117]B3b. The tst+ clonal complex (CC) 30 methicillin-sensitive S. aureus lineage accounts for nearly half of all TSS cases in the UK, producing more TSST-1 and superantigen bioactivity than tst+ CC30 MRSA strains [188]C4. Exfoliative toxins (ETA, ETB) are serine proteases that cleave desmoglein-1, causing staphylococcal scalded skin syndrome and bullous [120]D5.
Regulatory Systems and Virulence Control
The accessory gene regulator (agr) quorum-sensing system is the master regulator of exoprotein expression; it activates transcription of RNAIII, which upregulates secreted toxins (Hla, PVL, TSST-1) and downregulates surface adhesins at high cell density [131]D5[159]D5. The SaeRS two-component system responds to host signals (e.g., subinhibitory triclosan) and directly activates hla, coa, and nuc [154]D5. ArlRS regulates autolysis and biofilm formation, and its inhibition by small molecules (e.g., 3,4′-dimethoxyflavone) attenuates virulence in murine MRSA infection [155]D5. Subinhibitory concentrations of clindamycin and suppress exotoxin production via ribosomal inhibition, a rationale for their adjunctive use in toxin-mediated staphylococcal disease [126]D5[133]D5. Conversely, β-lactam can upregulate toxin expression in some strains, potentially worsening clinical outcomes [133]D5.
Host-Pathogen Interaction and Immune Evasion
The arginine catabolic mobile element (ACME), acquired horizontally from S. epidermidis, is a hallmark of the USA300 clone and enhances survival on human skin by providing arginine deiminase activity, which helps withstand acidic pH and polyamine stress [141]D5. Staphylococcal complement inhibitor (SCIN) and chemotaxis inhibitory protein of staphylococci (CHIPS) block complement activation and neutrophil chemotaxis [134]D5. The Isd system harvests heme from host hemoproteins for iron acquisition, essential for intramacrophage survival [131]D5. S. aureus can invade and persist within endothelial cells, osteoblasts, and neutrophils, forming intracellular reservoirs that evade antibiotics and immune clearance [134]D5[138]D5.
Biofilm and Persistence
Biofilm formation is a critical virulence attribute in device-associated infections (prosthetic joints, catheters) and chronic osteomyelitis. The polysaccharide intercellular adhesin (PIA), encoded by the ica operon, and extracellular DNA are key matrix components [120]D5[161]C4. Strong biofilm-producing MRSA isolates are more likely to be from clonal complex 8 (CC8) and spa type t008 (adjusted OR 4.54; 95% CI 1.21-17.1) and are associated with higher 90-day readmission rates (aOR 5.43) [161]C4. Small colony variants (SCVs) are a slow-growing, metabolically defective subpopulation that exhibits phenotypic resistance to aminoglycosides and antifolate agents and is frequently recovered from persistent infections in cystic fibrosis airways and device-related infections [138]D5[143]D5[173]D5. SCVs survive within phagolysosomes without active growth, unlike wild-type S. aureus, and require prolonged combination therapy for eradication [138]D5.
Clinical Syndromes Linked to Specific Virulence Factors
| Virulence Factor | Mechanism | Associated Clinical Syndrome | References |
|---|---|---|---|
| Clumping factors, FnBPs | Adhesion to endothelium, ECM | Infective endocarditis, osteomyelitis | [120]D5[134]D5 |
| α-hemolysin (Hla) | Pore-forming cytotoxin | Necrotizing pneumonia, dermonecrosis | [132]D5[162]D5 |
| PVL | Neutrophil lysis | Recurrent SSTIs, , necrotizing pneumonia | [111]A1a[128]D5[141]D5 |
| TSST-1, enterotoxins | Superantigens, cytokine storm | Menstrual and nonmenstrual TSS, atopic dermatitis, sepsis | [32]D5[113]C4[135]D5 |
| Exfoliative toxins | Desmoglein-1 cleavage | Staphylococcal scalded skin syndrome, bullous impetigo | [120]D5 |
| Biofilm (PIA, eDNA) | Matrix formation, immune evasion | , catheter-related bacteremia, chronic osteomyelitis | [120]D5[161]C4[180]B2b |
The success of specific MRSA lineages (e.g., USA300, ST22-PT) arises from the acquisition and maintenance of mobile genetic elements encoding both resistance and virulence determinants, enabling adaptation to both hospital and community settings while maintaining high transmissibility [131]D5[141]D5[171]C4. Understanding these molecular mechanisms is the foundation for developing anti-virulence strategies, including quorum-sensing inhibitors, toxin-neutralizing monoclonal antibodies (e.g., suvratoxumab), and phage therapy, that may complement conventional antibiotics [116]A1b[131]D5[155]D5[158]D5[162]D5.
Pearl: Small colony variants and intracellular persistence explain therapy-refractory chronic infections; biofilm-forming CC8/spa t008 strains predict higher readmission rates.
Epidemiology, Transmission and Risk Factors
- ▸S. aureus bacteremia incidence is approximately 30 per 100,000 person-years in high-income countries, with rates increasing among the elderly.
- ▸Community-associated MRSA incidence was rising before the COVID-19 pandemic, and hospital-onset MRSA bacteremia surged during 2020-2022, linked to recent SARS-CoV-2 infection.
- ▸Major modifiable risk factors include intravascular catheter placement (especially antecubital), prolonged line dwell time, fluoroquinolone exposure, and lack of decolonisation measures in high-risk units.
From its successful colonization strategies emerges a pathogen that exacts a heavy toll: an estimated 300,000 deaths per year from bacteremia alone, with a case fatality rate of 15% to 30% [58]D5. In the United States, the age- and sex-adjusted incidence of S. aureus bacteremia (SAB) is 33.9 per 100,000 person-years, with MSSA (18.7) and MRSA (14.6) contributing similarly [178]B2b. In Denmark, SAB incidence rose 48% from 20.76 to 30.37 per 100,000 person-years between 2008 and 2015, driven by a 90% increase among persons older than 80 years [252]B2c. Skin and soft tissue infections are even more common, with US incidence ranging from 122.7 to 168.9 per 100,000 person-years [239]B2b.
Demographic and Geographic Distribution
SAB incidence is higher in males (46.0 vs 24.4 per 100,000 person-years) and increases with age [178]B2b[252]B2c. Marked ethnic and socioeconomic disparities exist: in New Zealand, rates are highest among Māori and Pacific Peoples and those in areas of high deprivation [104]B2c. In the United States, community-associated MRSA disproportionately affects prisoners, military recruits, athletes, men who have sex with men, and long‑term care residents [37]D5[59]D5[207]D5. Global heterogeneity is substantial, MRSA prevalence among community S. aureus infections in Asia ranges from 2.5% to 39% [219]D5.
Temporal Trends
MRSA bacteremia incidence in the United States declined significantly from 2005 to 2016 (annual percent change [APC] -7.1%), but this reversed with an APC of +5.9% from 2016 to 2019 [245]B2b. Community‑associated MRSA bacteremia was increasing before the pandemic (APC +8.4%) [245]B2b. During 2020‑2022, hospital‑onset MRSA bacteremia exceeded predicted rates, with 18%-22% of cases occurring within 30 days of a positive SARS‑CoV‑2 test [245]B2b. Concurrently, the proportion of community‑onset SSTI due to MRSA peaked at 62% in 2006 and declined to 52% by 2010 [239]B2b.
Transmission
S. aureus spreads through direct contact, contaminated fomites, and, in healthcare, via the hands of colonised workers (carriage rate 4.6% in screened personnel) [220]D5. Patient‑to‑patient transmission is amplified by overcrowding and understaffing [38]D5. Livestock‑associated MRSA (e.g., CC398) can reach humans through occupational exposure [225]D5.
Risk Factors
| Risk Factor | Odds Ratio / Hazard Ratio | Evidence Level |
|---|---|---|
| Hemodialysis | HR 8.51 | 2b [229]B2b |
| Antecubital PVC placement | OR 11.9 (1.5-95.7) | 3b [248]B3b |
| PVC duration ≥4 days | OR 4.0 (1.1-15.2) | 3b [248]B3b |
| Fluoroquinolone exposure | AHR 2.57 (1.84-3.60) | 3b [105]B3b |
| ICU admission + mechanical ventilation (CAP) | OR 8.3 (2.4-32) | 3b [241]B3b |
| Indwelling vascular graft | sHR 3.48 (1.90-6.40) | 2b [240]B2b |
| Nasal MRSA carriage | sHR 2.10 (1.28-3.44) | 2b [240]B2b |
| Prior S. aureus bacteremia (CIED) | HR 2.76 | 2b [229]B2b |
| Injection drug use | Well‑documented | 5 [58]D5[226]B2b |
| Diabetes, obesity, prior | Consistently reported | 5 [43]D5[246]B2b |
Special Considerations
Most metastatic infections occur early: 85% within 7 days of SAB diagnosis [244]B2b. Recurrence risk is elevated with vascular grafts, nasal MRSA carriage, or ‑resistant strains [240]B2b. The COVID‑19 pandemic increased hospital‑onset MRSA bacteremia, likely due to prolonged hospitalisation and immunosuppression [245]B2b. No licensed vaccine exists; prevention relies on infection control, decolonisation (universal chlorhexidine‑mupirocin in ICUs reduces MRSA clinical isolates, HR 0.63; NNT = 54 to prevent one bloodstream infection [18]A1b), and antibiotic stewardship, which reduces MRSA incidence by 37% (IR 0.63) [196]A1a.
These epidemiological patterns and risk profiles directly inform the clinical syndromes discussed in the next section.
Pearl: When evaluating a patient with S. aureus bacteremia, the first 7 days are critical, 85% of metastatic infections manifest within this window, and a short time to blood culture positivity (<13 hours) raises the probability of endocarditis (NPV 96%) [199]B2b[244]B2b.
Clinical Presentation
- ▸S. aureus bacteremia is complicated by metastatic infection in >30% of cases, including endocarditis (~12%), septic arthritis (7%), and vertebral osteomyelitis (~4%) [58].
- ▸Persistent bacteremia ≥2 days on active therapy doubles mortality (39% at 90 days) and strongly predicts deep-seated metastatic foci [28,199].
- ▸CA-MRSA pneumonia presents with hemoptysis and rapid respiratory failure following influenza, driven by Panton-Valentine leukocidin [128,148,272].
Given the high prevalence of colonization and the diverse risk factors outlined previously, Staphylococcus aureus produces a remarkably broad spectrum of clinical illness, from superficial skin infections to rapidly fatal toxin-mediated syndromes. The hallmark of invasive disease is its tendency to disseminate hematogenously, seeding distant organs and prosthetic materials with devastating consequences.
Skin and Soft Tissue Infections
The most common manifestations are s (boils), s, , and [3]A1c[59]D5. Community-acquired MRSA (CA-MRSA) strains, particularly USA300, frequently cause recurrent, deep-seated abscesses that require incision and drainage [54]D5[71]C4. A distinctive feature of CA-MRSA SSTI is its tendency to occur in otherwise healthy young individuals without traditional healthcare exposures [54]D5. Infection often begins at a site of minor skin trauma or hair follicle disruption; the lesion rapidly becomes painful, erythematous, and fluctuant. Surrounding cellulitis is common. Systemic symptoms such as fever may be absent with superficial infections but are present in more extensive disease.
Bacteremia and Endocarditis
Staphylococcus aureus bacteremia (SAB) is a life-threatening condition with a case fatality rate of 15% to 30% [58]D5[262]D5. The key clinical feature is the high frequency of metastatic infection, occurring in more than one-third of cases [58]D5. Common secondary foci include infective endocarditis (≈12%), septic arthritis (7%), (≈4%), spinal epidural abscess, , splenic abscess, and septic pulmonary emboli [58]D5[52]D5[46]D5. Patients often present with high fever, rigors, and a toxic appearance. A critically important clinical clue is persistent bacteremia (positive blood cultures ≥2 days after starting effective ), which is associated with a 90-day mortality of 39% and a significantly increased risk of metastatic complications [28]B2b[58]D5. The presence of a prosthetic valve, cardiac implantable electronic device, or other indwelling hardware raises the likelihood of seeding [265]B2b[264]B2b. Right-sided endocarditis (typically tricuspid valve) is common in and presents with fever, pleuritic chest pain, and hemoptysis due to septic pulmonary emboli [175]D5. Left-sided endocarditis may present with , embolic strokes, or systemic emboli. A short time to blood culture positivity (<13 hours) is independently associated with endocarditis (OR 3.59) and has a negative predictive value of 96% for ruling out endocarditis when longer [199]B2b.
Bone and Joint Infections
Staphylococcus aureus is the predominant cause of acute hematogenous osteomyelitis, septic arthritis, and native vertebral osteomyelitis, accounting for about half of non-tuberculous cases [46]D5[232]D5[255]A1c. Presentation in children is often acute, with fever, limping, or refusal to bear weight; the metaphysis of long bones (femur, tibia, humerus) is most frequently involved [46]D5[290]C4. In adults, vertebral osteomyelitis presents with localized back pain that is constant, progressive, and often worse at night, accompanied by fever in only about half of cases [232]D5[255]A1c. Neurologic deficits (weakness, sensory loss, ) suggest concomitant , a surgical emergency [52]D5. Whole-spine MRI reveals multifocal infection in 18% of cases, which itself carries a 40% in-hospital mortality[294]B3b. (PJI) is a devastating complication, occurring in 19% of patients with preexisting arthroplasty who develop SAB [265]B2b[183]B2b. PJI presents with acute-onset pain, swelling, and erythema of the joint, typically developing a median of 1 day after the first positive blood culture [265]B2b. For prosthetic valves or vascular grafts, infection often presents with persistent fever, leukocytosis, and new-onset insufficiency or pseudoaneurysm [224]D5[264]B2b.
Pneumonia
Staphylococcus aureus causes a spectrum of pulmonary infections: community-acquired, hospital-acquired, and [259]D5. CA-MRSA pneumonia is notable for its aggressive, necrotizing course, often following or other viral respiratory infections [128]D5[148]D5. Presentation is abrupt, with high fever, severe dyspnea, hemoptysis, and rapid progression to respiratory failure [128]D5[272]C4. The disease is mediated in part by (PVL) and usually affects young, immunocompetent patients [128]D5[259]D5. In contrast, healthcare-associated MRSA pneumonia typically arises in older patients with multiple comorbidities and prolonged ventilatory support [259]D5[289]D5. The GLIMP study found that previous MRSA infection or colonization, recurrent skin infections, and severe pneumonia are independently associated with MRSA etiology [260]B2c.
Toxin-Mediated Syndromes
Staphylococcus aureus produces several exotoxins that cause distinct clinical entities:
| Syndrome | Key Features | Toxin / Strain |
|---|---|---|
| (mTSS) | Fever ≥38.9°C, diffuse macular rash, hypotension, desquamation (1-2 weeks later), multi-organ involvement [113]C4 | TSST-1 (menstrual) or enterotoxins (non-menstrual) |
| (SSSS) | Widespread erythema, superficial bullae, sheet-like desquamation; primarily in neonates and young children [292]C4 | Exfoliative toxins A/B |
| Staphylococcal food poisoning | Acute onset of emesis, nausea, and diarrhea within 1-6 hours of ingesting preformed enterotoxin - self-limited | Enterotoxins (SEA-SEE) |
| Necrotizing pneumonia / PVL disease | Hemoptysis, necrotizing cavitary lesions, influenza-like prodrome, rapid respiratory decline [128]D5[272]C4 | PVL + other virulence factors |
mTSS classically occurs in young, menstruating women using tampons, but non-menstrual cases (postsurgical, wound infections) are increasingly recognized [113]C4. SSSS presents as a dermatologic emergency; the cleavage plane is superficial (granular layer), unlike .
Other Foci
Nearly every organ can be involved via hematogenous seeding. presents with acute monoarticular pain, effusion, and inability to bear weight [46]D5[300]C4. (tropical pyomyositis, now seen increasingly in temperate climates) presents with focal muscle pain and swelling, often without an obvious portal of entry [261]D5. infections include meningitis, , and subdural empyema. presents with perineal pain, fever, and urinary retention; S. aureus accounts for 56% of cases in some series [99]C4. is an under-recognized entity in patients with spinal cord injury, presenting with purulent wound drainage, fever, and recurrent sepsis [299]B3b. from right-sided endocarditis or suppurative thrombophlebitis manifests as pleuritic chest pain, cough, and hemoptysis with characteristic radiographic nodules [293]C4.
Red Flags and Atypical Presentations
Any patient with SAB and new back pain, joint swelling, or focal neurologic signs requires immediate imaging for metastatic infection [58]D5[255]A1c. Persistent fever or bacteremia beyond 72 hours of appropriate therapy is a red flag for endocarditis, deep abscess, or an infected implant [28]B2b[206]D5. In children, failure to bear weight or irritability may be the only clue to osteomyelitis [46]D5[290]C4. In immunocompromised hosts, including those on , staphylococcal skin lesions may be mistaken for drug-induced psoriasis but represent generalized abscessing staphyloderma requiring systemic antibiotics [303]C4.
Pearl: For any patient with S. aureus bacteremia, actively ask about and examine for back pain, joint pain, chest pain, headache, and rash, metastatic infection occurs in >30% and may be clinically silent until imaging is performed [58]D5. Persistent bacteremia ≥2 days mandates transesophageal echocardiography and dedicated imaging of the spine and abdomen [199]B2b[28]B2b.
| Syndrome | Key Features | Toxin / Strain |
|---|---|---|
| Staphylococcal toxic shock syndrome (mTSS) | Fever ≥38.9°C, diffuse macular rash, hypotension, desquamation (1-2 weeks later), multi-organ involvement [113]C4 | TSST-1 (menstrual) or enterotoxins (non-menstrual) |
| Staphylococcal scalded skin syndrome (SSSS) | Widespread erythema, superficial bullae, sheet-like desquamation; primarily in neonates and young children [292]C4 | Exfoliative toxins A/B |
| Staphylococcal food poisoning | Acute onset of emesis, nausea, and diarrhea within 1-6 hours of ingesting preformed enterotoxin - self-limited | Enterotoxins (SEA-SEE) |
| Necrotizing pneumonia / PVL disease | Hemoptysis, necrotizing cavitary lesions, influenza-like prodrome, rapid respiratory decline [128]D5[272]C4 | PVL + other virulence factors |
Diagnosis and Workup
- ▸Blood cultures remain the diagnostic gold standard; time to positivity <13 hours identifies high-risk patients for endocarditis (NPV 96%).
- ▸MRSA nares PCR screening has a negative predictive value >95% for MRSA pneumonia and bloodstream infections, enabling safe antimicrobial de-escalation.
- ▸All patients with S. aureus bacteremia require echocardiography; transesophageal imaging is indicated for high-risk features (persistent bacteremia, cardiac device).
Culture of Staphylococcus aureus from a normally sterile site remains the diagnostic gold standard. The cornerstone investigation for suspected bacteremia is at least two sets of aerobic and anaerobic s drawn from separate venipunctures before antimicrobial therapy. A single positive bottle still carries clinical significance, 89.8% of such episodes in a multicenter study represented true infection, and warrants a complete workup [179]B2b.
Culture-Based Diagnosis (Gold Standard)
Blood cultures yield the pathogen in virtually all cases of S. aureus bacteremia (SAB). Time to positivity (TTP), the interval from incubation to automated detection, provides a bedside risk marker. A TTP shorter than 13 hours independently predicts infective endocarditis (odds ratio [OR] 3.59; 95% confidence interval [CI] 2.35-5.3), while a TTP longer than 13 hours carries a negative predictive value (NPV) of 96% for ruling out endocarditis [199]B2b. The ratio of sequential TTPs (second culture TTP divided by first) ≤1.5 also correlates with native valve endocarditis (OR 2.65) [338]B2b.
For skin and soft-tissue infections, wound culture is the test of choice. Purulent material should be aspirated or swabbed; in the absence of purulence, needle aspiration of the leading edge has low yield and is not routinely recommended [2]A1c. Synovial fluid, pleural fluid, and cerebrospinal fluid should be cultured when the corresponding site is involved. In pneumonia, endotracheal aspiration with nonquantitative culture and bronchoalveolar lavage with quantitative culture produce equivalent clinical outcomes [204]A1b.
Molecular and Rapid Diagnostics
Polymerase chain reaction (PCR)-based assays enable species identification and resistance detection within hours of blood culture positivity. The Prove-it sepsis assay (a DNA microarray targeting gyrB, parE, and mecA) shows clinical sensitivity of 94.7% and specificity of 98.8%, and is a mean 18 hours faster than conventional culture [75]B2b.
MRSA nares screening is a powerful tool. A meta-analysis of 22 studies found pooled sensitivity of 70.9% and specificity of 90.3% for predicting MRSA pneumonia, with an NPV of 96.5% at a 10% prevalence [11]B2a. In a nationwide Veterans Affairs cohort, the NPV for ruling out MRSA infection within 7 days was 96.5% across all anatomic sites, and 98.1% for community-acquired pneumonia [263]B2b[11]B2a. The high NPV supports safe de-escalation of empiric anti-MRSA therapy when the nasal swab is negative.
Metagenomic sequencing of plasma microbial cell-free DNA (the Karius test) detected a pathogen in 71% of patients with possible or definite endocarditis, including 50% of blood culture-negative cases, and identified methicillin resistance in two S. aureus detections [97]C4.
Imaging and Ancillary Testing
All patients with SAB should undergo transthoracic echocardiography (TTE). Transesophageal echocardiography (TEE) is recommended in patients at high risk for endocarditis: those with persistent bacteremia (≥48 hours), persistent fever, metastatic foci, or an implantable cardiac device [58]D5[267]D5. TEE increases the diagnostic yield for endocarditis from 2-15% with TTE alone to 14-28% [267]D5.
Imaging to detect metastatic infection is guided by symptoms. MRI with contrast is the test of choice for and [52]D5; CT identifies intra-abdominal abscesses, splenic infarcts, and septic pulmonary emboli [58]D5.
Diagnostic Algorithm
The workup follows a structured pathway:
- Suspected infection → obtain cultures from the relevant sterile site (blood, wound, joint fluid, CSF).
- Positive culture → identify methicillin susceptibility (MSSA vs. MRSA).
- If SAB confirmed → send MRSA nares swab (if not already done) to guide de-escalation.
- Perform TTE in all patients; proceed to TEE if high-risk features are present (persistent bacteremia ≥48 hours, fever >72 hours, metastatic foci, cardiac device).
- Elicit symptoms (back pain, joint pain, abdominal pain) and image accordingly with MRI or CT.
- Determine TTP, if <13 hours, maintain high suspicion for endocarditis [199]B2b.
Differential Diagnosis
The spectrum of S. aureus infection is broad, and mimics vary by syndrome:
| Syndrome | Key Differential | Distinguishing Feature |
|---|---|---|
| Cellulitis | , venous stasis dermatitis, | Necrotizing fasciitis: severe pain out of proportion, systemic toxicity, rapid progression [2]A1c |
| Septic arthritis | Gout, pseudogout, | Synovial fluid culture and crystal analysis; Gram stain and culture positive in septic arthritis |
| Acute osteomyelitis | Bone tumor, stress fracture | MRI shows marrow edema; culture of bone biopsy is diagnostic [255]A1c |
| Endocarditis | Nonbacterial thrombotic endocarditis, | Blood cultures, echocardiography; modified Duke criteria [230]D5 |
| Pneumonia | Viral pneumonia, Streptococcus pneumoniae | Sputum Gram stain and culture; urinary antigen; PCR panels [48]D5 |
Pearl: MRSA nares screening with a negative result provides an NPV >95% for ruling out MRSA pneumonia, allowing safe de-escalation of empiric anti-MRSA therapy in most patients [11]B2a[263]B2b.
Severity Assessment and Risk Stratification
- ▸APACHE-II score ≥14 identifies MRSA BSI patients with 35% clinical failure and 23% mortality.
- ▸Vancomycin AUC₂₄/MIC ratio <211 is associated with a 4-fold increase in attributable mortality.
- ▸Formal ID consultation reduces long-term mortality and recurrence in S. aureus bacteremia.
Once S. aureus is identified, the immediate priority is to assess disease severity and stratify risk, as these determine the intensity of therapy, need for ICU admission, and likelihood of complications. Several validated tools and biomarkers refine this assessment across the spectrum of staphylococcal infections.
Clinical Severity Scores
The APACHE-II score is the strongest predictor of failure in -treated MRSA bloodstream infection (BSI): a cutoff of ≥14 identifies a population with 35% clinical failure and 23% mortality, versus 11% and 4% below that threshold [375]B3b. In infective endocarditis (IE), the Risk-E score and presence of septic shock (12.3% of IE patients) carry in-hospital mortality of 62.5% [370]B2b. For children, the pediatric critical illness score independently predicts 28-day mortality in septic shock [238]B2b.
Microbiological and Host Risk Factors
| Factor | Threshold / Finding | Impact on Prognosis | Source |
|---|---|---|---|
| Vancomycin MIC | ≥1.5 μg/mL (Etest) | Predicts failure in MRSA BSI; not in MSSA [375]B3b[384]B2b | |
| Vancomycin AUC₂₄/MIC | <211 | 4-fold increase in attributable mortality (38% vs 8%) [380]B3b | |
| MRSA vs MSSA | Methicillin resistance | sHR 1.69 for 90-day recurrence [240]B2b | |
| Nasal MRSA carriage | Positive surveillance | sHR 2.10 for recurrence; 7-fold risk of SSTI in athletes [240]B2b[357]B2a | |
| PVL toxin | Present in SSTI isolates | Strongly associated with skin infections, not invasive disease [111]A1a | |
| agr dysfunction | Loss of δ-haemolysin | Linked to persistent bacteremia and treatment failure [183]B2b | |
| Biofilm formation | High MBEC (>128 mg/L) | No independent prognostic value in PJI [183]B2b | |
| Source of BSI | Unknown origin | RR 2.50 for metastatic infection without IE [387]B3b | |
| Delayed antimicrobial therapy | >48 hours from onset | RR 7.16 for metastatic infection [387]B3b |
Biomarkers for Prognosis
At initial presentation, IL-8 and CCL2 classify fatal outcome with 89% sensitivity and 77% specificity [365]B3b. S. aureus cell-free DNA levels correlate with all-cause and attributable mortality, persistent bacteremia, and IE [389]C4. Elevated C-reactive protein (HR 1.05 per mg/dL) and CRP/albumin ratio (AUC 0.777 for severe diabetic foot infection) independently predict poor outcomes [373]B3b[386]C4.
Syndrome-Specific Stratification
- Uncomplicated SAB requires negative follow-up blood cultures at 2-4 days, defervescence within 72 hours, no metastatic infection, and no endocarditis on echocardiography; short-course therapy (<14 days) risks relapse (7.9% vs 0%) [368]B2b.
- IE: Valve culture positivity (OR 2.3), S. aureus etiology (OR 1.8), and septic shock (OR 1.94) independently predict in-hospital mortality [366]B3b[370]B2b.
- Vascular graft infection: Age >75 years and ICU admission are independent predictors of infection-related mortality [264]B2b. Polymicrobial infection (HR 2.22) and higher CRP (HR 1.05) predict all-cause mortality [373]B3b.
- : Vancomycin MIC ≥1.5 mg/L is associated with higher failure rates (23.1% vs 3.4%) [183]B2b.
Formal infectious diseases specialist consultation reduces 10-year mortality (HR 0.42) and risk of new bacteremia (OR 0.45) [392]B3b. These stratification tools directly inform the empiric and definitive decisions discussed in the following sections.
Pearl: The APACHE-II score ≥14 and a vancomycin AUC₂₄/MIC ratio <211 are the two most actionable thresholds for identifying high-risk MRSA BSI patients who may benefit from early ID consultation, repeat blood cultures, and alternative therapy.
Empiric Management, Acute Care and Source Control
- ▸Empiric therapy must cover MRSA when the patient has risk factors or local prevalence >10-20%; de-escalate to a β-lactam as soon as MRSA is ruled out by nares PCR or culture.
- ▸Source control (catheter removal, abscess drainage, debridement) is the highest-yield intervention and must not be delayed; each hour of uncontrolled infection worsens mortality.
- ▸Routine addition of rifampin or gentamicin to standard therapy is not recommended; for persistent MRSA bacteremia, daptomycin plus ceftaroline is a promising salvage combination.
The severity-driven approach outlined above sets the stage for three simultaneous interventions that define the first hours of care: empiric antimicrobial therapy, prompt source control, and supportive measures. Figure 1 integrates these decisions into a single algorithm.
Figure 1: Empiric management algorithm for suspected S. aureus infection. Adapted from IDSA MRSA guidelines [1]A1c and contemporary trial evidence [14]A1b[15]A1b[29]A1b.
Step 1: Select Empiric Antibiotic
Choice depends on infection site, severity, and local MRSA prevalence. Table 1 summarizes first-line regimens.
Table 1: Empiric for S. aureus infections
| Syndrome | Preferred agent(s) | Alternative(s) | Evidence base |
|---|---|---|---|
| Uncomplicated SSTI (abscess/ ) | Incision & drainage ± TMP‑SMX 160/800 mg PO BID or clindamycin 300-450 mg PO TID [394]A1b | 100 mg PO BID | IDSA 2014 [2]A1c |
| Severe SSTI (purulent, systemic toxicity) | 15-20 mg/kg IV q8-12h (target trough 15-20 µg/mL) [1]A1c | 4-6 mg/kg IV q24h [16]A1b; 600 mg IV/PO q12h | IDSA 2011 [1]A1c |
| Hospital‑acquired pneumonia | Vancomycin 15-20 mg/kg IV q8-12h or linezolid 600 mg IV q12h [7]A1b | Ceftaroline 600 mg IV q8h | IDSA 2011 [1]A1c; RCT [7]A1b |
| Bacteremia (suspected MRSA) | Vancomycin 15-20 mg/kg IV q8-12h or daptomycin 6-10 mg/kg IV q24h [1]A1c[16]A1b | Ceftobiprole 500 mg IV q6→8h [14]A1b | IDSA 2011 [1]A1c; ERADICATE [14]A1b |
| MSSA (confirmed) | Cefazolin 25-50 mg/kg IV q8h [22]A1b | Flucloxacillin 2 g IV q6h; cloxacillin 2 g IV q4-6h | CloCeBa [22]A1b; SNAP [15]A1b |
Dosing notes. Bolded doses represent standard starting regimens. Vancomycin requires therapeutic drug monitoring (trough 15-20 µg/mL for serious infections) [1]A1c. Daptomycin dosage is 6 mg/kg for bacteremia; 8-10 mg/kg for endocarditis [1]A1c[16]A1b. All doses require adjustment for renal function, except linezolid (no adjustment needed).
Step 2: Source Control, A First‑Class Decision
Source control is not optional; it is the most modifiable determinant of outcome. Remove all infected intravascular catheters, drain abscesses ≥5 cm, and debride necrotic tissue [1]A1c[58]D5. In S. aureus bacteremia, failure to remove a within 72 h is associated with higher 90‑day mortality risk [58]D5. For native valve endocarditis, early valve surgery is indicated when heart failure, uncontrolled infection, or embolic complications develop [1]A1c[230]D5. Do not delay source control pending culture results.
Step 3: Supportive Care and Monitoring
Obtain at least two sets of blood cultures before antibiotics. MRSA nares polymerase chain reaction (PCR) has a negative predictive value of 96-99% for MRSA bloodstream infection and can guide early de‑escalation of anti‑MRSA therapy [263]B2b. Perform transthoracic echocardiography in all patients with S. aureus bacteremia; transesophageal echocardiography is indicated for those with persistent bacteremia, cardiac devices, or clinical signs of endocarditis [1]A1c[267]D5. Monitor markers of organ dysfunction (creatinine, lactate, platelets) daily.
Step 4: Reassessment and De‑escalation
At 48-72 h, review cultures, MIC results, and clinical trajectory. If the MRSA nares PCR is negative and cultures reveal only MSSA, de‑escalate to cefazolin or an antistaphylococcal penicillin; this reduces nephrotoxicity and cost [15]A1b[22]A1b[263]B2b. If MRSA is confirmed, continue the selected agent and consider combination therapy for persistent bacteremia (see below).
Step 5: Early Oral Switch, Selected Candidates
For clinically stable patients with uncomplicated S. aureus bacteremia or left‑sided endocarditis who have cleared blood cultures and have no uncontrolled source, an early switch to oral antibiotics may be safe. The POET trial demonstrated noninferiority of oral step‑down (median 17 days IV then oral) versus continued IV therapy (composite outcome 9.0% vs 12.1%; difference 3.1%, 95% CI -3.4 to 9.6) [13]A1b. The SNAP trial is accruing data on this strategy [10]D5. Oral options include linezolid 600 mg PO BID or a fluoroquinolone plus [432]D5.
Treatment Failure Protocol
If bacteremia persists >48-72 h despite appropriate empiric therapy: (1) Reassess source control - is there an undrained collection or retained hardware? (2) Obtain repeat blood cultures and imaging (PET‑CT, echocardiography). (3) Consider synergy or salvage therapy: for MRSA, daptomycin 8-10 mg/kg IV q24h plus ceftaroline 600 mg IV q8h has reduced mortality in a small pilot trial (0% vs 26% in‑hospital mortality; P = 0.029) [31]A1b; for MSSA, cefazolin plus rapidly cleared persistent bacteremia in case series [400]C4. (4) Add rifampin only if biofilm‑associated infection (e.g., prosthetic joint) and adequate surgical debridement [407]A1a; routine use is not recommended (ARREST: HR 0.96, 95%) [24]A1b.
What NOT to Do
- Do not routinely add gentamicin - it increases nephrotoxicity without improving survival [1]A1c[16]A1b.
- Do not use rifampin as adjunctive therapy for MRSA bacteremia - it adds drug interactions without benefit [24]A1b.
- Do not delay source control for a completed antibiotic course - every hour of uncontrolled infection worsens outcomes [58]D5.
- Do not rely on vancomycin alone when the MIC is ≥2 µg/mL - consider alternative agents (daptomycin, ceftaroline) [1]A1c[212]A1a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Adding β‑lactam to standard MRSA therapy | CAMERA2 [29]A1b - no benefit in 90‑day mortality (21% vs 16%) and increased AKI (23% vs 6%) | Retrospective series - reduced persistent bacteremia at day 5 (11% vs 20%) | Moderate (RCT vs observational) | Avoid routine addition; may be considered in selected high‑inoculum patients with monitoring for AKI |
| Optimal empiric MSSA agent for pneumonia | Cefazolin - higher treatment failure (OR 5.73) in critically ill [415]B3b | Anti‑staphylococcal penicillins - standard comparator | Moderate (small cohort) | Cefazolin is acceptable for most, but antistaphylococcal penicillins preferred in ICU pneumonia |
Pearl: Start empiric anti‑MRSA therapy when risk factors or local prevalence exceed threshold; obtain an MRSA nares PCR within 24 h to enable rapid de‑escalation to a β‑lactam, which reduces nephrotoxicity (NNT = 17 for AKI prevention [15]A1b) and improves outcomes compared to continued glycopeptide therapy.
| Syndrome | Preferred agent(s) | Alternative(s) | Evidence |
|---|---|---|---|
| Uncomplicated SSTI (abscess/cellulitis) | I&D ± TMP‑SMX 160/800 mg PO BID or clindamycin 300-450 mg PO TID | Doxycycline 100 mg PO BID | IDSA 2014 [2]A1c; Miller 2015 [394]A1b |
| Severe SSTI (purulent, systemic toxicity) | Vancomycin 15-20 mg/kg IV q8-12h (trough 15-20) | Daptomycin 4-6 mg/kg IV q24h; linezolid 600 mg IV/PO q12h | IDSA 2011 [1]A1c |
| Hospital‑acquired pneumonia | Vancomycin 15-20 mg/kg IV q8-12h or linezolid 600 mg IV q12h | Ceftaroline 600 mg IV q8h | IDSA 2011 [1]A1c; Wunderink 2012 [7]A1b |
| Bacteremia (suspected MRSA) | Vancomycin 15-20 mg/kg IV q8-12h or daptomycin 6-10 mg/kg IV q24h | Ceftobiprole 500 mg IV q6→8h | IDSA 2011 [1]A1c; ERADICATE [14]A1b |
| MSSA (confirmed) | Cefazolin 25-50 mg/kg IV q8h | Flucloxacillin 2 g IV q6h; cloxacillin 2 g IV q4-6h | CloCeBa [22]A1b; SNAP [15]A1b |
| Drug | Starting dose | Renal adjustment | Key monitoring |
|---|---|---|---|
| Vancomycin | 15-20 mg/kg IV q8-12h | Trough 15-20 µg/mL; adjust for CrCl | Renal function, trough |
| Daptomycin | 6-10 mg/kg IV q24h | 6 mg/kg q48h if CrCl <30 | CPK weekly |
| Ceftaroline | 600 mg IV q8h | 400 mg q12h if CrCl 30-50; 300 mg q12h if CrCl <30 | CBC with prolonged use |
| Linezolid | 600 mg IV/PO q12h | None | CBC weekly |
| TMP‑SMX | 1-2 DS tabs (160/800 mg) PO BID | Adjust for CrCl; avoid if CrCl <15 | Potassium, creatinine |
| Cefazolin | 25-50 mg/kg IV q8h | Less frequent if CrCl <50 | No routine TDM |
Definitive Therapy: Dosing, PK/PD, Duration and De-escalation
- ▸For MSSA, cefazolin is noninferior to antistaphylococcal penicillins with significantly less acute kidney injury (SNAP, CloCeBa).
- ▸Vancomycin for MRSA should target AUC/MIC 400-600 mg·h/L; Bayesian-guided dosing is preferred over trough monitoring (2020 consensus guidelines).
- ▸Early oral switch (after 5-7 days IV) is safe in carefully selected low-risk S. aureus bacteraemia (SABATO) and stable left-sided endocarditis (POET).
- ▸MRSA nares screening (NPV >96%) is a powerful de-escalation tool; de-escalation is associated with improved outcomes.
Once the organism and its susceptibility profile are confirmed, therapy should be narrowed from empiric coverage. The choice of definitive antibiotic, dose, route, and duration depends on the infection site, severity, and host factors, and is guided by pharmacokinetic and pharmacodynamic (PK/PD) principles, therapeutic drug monitoring (TDM), and evidence for early oral switch.
Definitive Antibiotic Selection
For methicillin-susceptible S. aureus (MSSA), cefazolin is now the preferred agent. The SNAP trial (N=1287) demonstrated noninferiority of cefazolin versus antistaphylococcal penicillins (flucloxacillin/cloxacillin) for 90-day mortality (15.0% vs 17.0%; adjusted OR 0.81, 95% CrI 0.59-1.12; probability of noninferiority 99.2%) and a significant reduction in acute kidney injury (13.9% vs 19.6%; adjusted OR 0.67, 95% CrI 0.50-0.89) [15]A1b. The CloCeBa trial confirmed noninferiority of cefazolin versus cloxacillin for a composite endpoint at day 90 (75% vs 74%; difference -1%, 95% CI -11 to 9) with fewer serious adverse events (15% vs 27%) [22]A1b. A smaller study in MSSA pneumonia found higher treatment failure with cefazolin (OR 5.73, 95%), but this was limited by sample size [415]B3b. For penicillin-susceptible S. aureus (PSSA), benzylpenicillin is an option: the SNAP PSSA domain found noninferiority versus flucloxacillin/cloxacillin but stopped early due to increased AKI in the comparator arm [23]A1b. Dosing: cefazolin 2 g IV every 8 hours (adjust for renal function); flucloxacillin 2 g IV every 6 hours [15]A1b.
For methicillin-resistant S. aureus (MRSA), remains first-line, but dosing must be optimised. The 2020 consensus guidelines recommend an AUC/MIC ratio of 400-600 mg·h/L (assuming broth microdilution MIC of 1 mg/L) [5]A1c. Trough monitoring alone is no longer preferred; Bayesian AUC-guided dosing is recommended where available. (6-10 mg/kg IV once daily) is noninferior to vancomycin for MRSA bacteremia and right-sided endocarditis (treatment success 44.2% vs 41.7%; N=246) [16]A1b. Ceftobiprole (500 mg IV every 6 hours for 8 days, then every 8 hours) was noninferior to daptomycin in complicated S. aureus bacteremia (overall success 69.8% vs 68.7%; adjusted difference 2.0%, 95% CI -7.1 to 11.1) [14]A1b. Ceftaroline is an alternative, though a matched cohort showed no difference in treatment failure versus vancomycin (51.1% vs 57.8%, P=0.47) but more AKI [457]B3b. Daptomycin dose is 6-10 mg/kg IV once daily; ceftobiprole 500 mg IV every 6 hours.
IV-to-Oral Switch
Data now support early oral switch in carefully selected patients. The SABATO trial randomised low-risk S. aureus bacteraemia (no complicated features, removable foci) after 5-7 days of IV therapy to oral versus continued IV. The composite primary endpoint (relapse, deep-seated infection, attributable mortality at 90 days) occurred in 13% (oral) vs 12% (IV), noninferiority was met [256]A1b. The POET trial in stable left-sided endocarditis showed oral switch noninferior to continued IV (composite outcome 9.0% vs 12.1%; difference 3.1%, 95% CI -3.4 to 9.6) [13]A1b. A meta-analysis of four RCTs found no difference in treatment failure (RR 0.99, 95%) [6]A1a. Conditions for oral switch: clinical stability, absence of uncontrolled deep-seated infection, removable foreign body removed, reliable oral absorption, and antibiotic susceptibility allowing oral options. Oral agents for MRSA: 600 mg PO twice daily; for MSSA: cephalexin or cefadroxil (cefadroxil 40 mg/kg/dose up to 1500 mg twice daily for children [468]C4), or clindamycin if susceptible.
Duration of Therapy
Duration is dictated by infection type and clinical response. For uncomplicated S. aureus bacteraemia (defined as negative follow-up blood cultures within 48-72 hours, no endocarditis, no implant, defervescence within 72 hours, and no metastatic foci): 14 days of effective therapy. For complicated bacteraemia (endocarditis, deep-seated infection, persistent bacteraemia ≥48 hours): 4-6 weeks from the first negative culture. The BALANCE trial (N=3608) demonstrated noninferiority of 7 versus 14 days for bloodstream infection overall, but S. aureus was excluded [236]A1b; thus, 7-day therapy for S. aureus bacteraemia is not supported. An algorithm-based approach in staphylococcal bacteraemia reduced mean antibiotic days from 6.2 to 4.4 in simple/uncomplicated cases without increasing adverse outcomes [397]A1b. For skin and soft tissue infections: 5 days (oral) is sufficient for uncomplicated ; abscess drainage plus 5-7 days of (e.g., TMP-SMX, clindamycin) [394]A1b[452]A1b. For osteomyelitis: 4-6 weeks of parenteral or highly bioavailable oral therapy after debridement; longer courses (>6 weeks) did not improve infection-free survival in fracture-related infection [340]B3b.
De-escalation
MRSA nares screening is a powerful stewardship tool. A nationwide VA study (N=561,325 cultures) reported a negative predictive value (NPV) of 96.5% for ruling out MRSA infection within 7 days of screening; NPV for bloodstream infection was 96.5% [263]B2b. This NPV persists at 28 days (95.8%) and in transplant/neutropenic populations (97.5-97.9%) [335]B3b. A microbiology comment that reads "commensal respiratory flora, no S. aureus or P. aeruginosa" increased antibiotic de-escalation from 39% to 73% (adjusted OR 5.5, 95% CI 2.8-10.7) and reduced AKI (31% to 14%) [177]C4. In a national sepsis cohort, de-escalation by day 4 was associated with lower AKI (OR 0.80), ICU admission (OR 0.59), and in-hospital mortality (OR 0.92) [227]B2b. Rapid multiplex PCR panels for pneumonia did not significantly shorten time to anti-MRSA discontinuation (49.1 vs 41.8 hours, P=0.28) in one early study [333]B3b. De-escalation should occur as soon as susceptibility results allow, guided by clinical stability and absence of MRSA on nasal screening.
Dosing Table
| Drug | Indication | Dose | TDM / Monitoring | Key Adjustment |
|---|---|---|---|---|
| Vancomycin | MRSA bacteremia, pneumonia | 15-20 mg/kg IV load, then target AUC 400-600 | AUC/MIC (trough if AUC unavailable) | Renal function; consider alternative if MIC >1 mg/L [5]A1c[467]D5 |
| Daptomycin | MRSA bacteremia, R-sided endocarditis | 6-10 mg/kg IV once daily | Weekly CPK | Renal dose adjustment [16]A1b |
| Ceftobiprole | Complicated S. aureus bacteremia | 500 mg IV q6h × 8d, then q8h | None routine | Renal adjustment [14]A1b |
| Cefazolin | MSSA bacteremia, pneumonia | 2 g IV q8h | None routine | Renal dose adjustment [15]A1b |
| Flucloxacillin | MSSA bacteremia | 2 g IV q6h | None routine | Renal dose adjustment [15]A1b |
| Benzylpenicillin | PSSA bacteremia | 1.8 g IV q4h or 2.4 g IV q6h | None routine | Renal adjustment [23]A1b |
| Linezolid | MRSA (oral switch) | 600 mg PO/IV q12h | Weekly CBC if >2 weeks | No renal adjustment [328]D5 |
| Cefadroxil | MSSA (oral step-down, children) | 40 mg/kg/dose PO BID (max 1500 mg/dose) | None routine | [468]C4 |
Controversies and Guideline Disagreement
No major guideline disagreements were identified for this section in the reviewed evidence. The 2011 IDSA MRSA guidelines [1]A1c remain referenced but are being superseded by newer trial data (SNAP [15]A1b, CloCeBa [22]A1b, ceftobiprole [14]A1b) that inform updated practice.
Pearl: Initiate definitive therapy based on susceptibility within 24-48 hours; vancomycin AUC/MIC target 400-600 is standard for MRSA bacteremia (ASHP/IDSA 2020 [5]A1c); cefazolin is preferred over antistaphylococcal penicillins for MSSA due to lower AKI risk (SNAP [15]A1b, CloCeBa [22]A1b); early oral switch is safe in selected low-risk patients (SABATO [256]A1b; POET [13]A1b).
History and Evolution of Treatment
- ▸Vancomycin's dominance was eroded by MIC creep, nephrotoxicity, and trials showing superior outcomes with linezolid for pneumonia and daptomycin for bacteremia.
- ▸For MSSA, cefazolin is now preferred over antistaphylococcal penicillins based on SNAP and CloCeBa trials demonstrating noninferior efficacy and less acute kidney injury.
The preceding section details contemporary definitive therapy; this chronology traces how that standard was built, and occasionally dismantled, by pivotal clinical trials spanning seven decades.
The Era and Its Limits
Vancomycin, isolated from Streptomyces orientalis in the early 1950s, became the cornerstone for methicillin-resistant Staphylococcus aureus (MRSA) treatment after the first MRSA isolates were reported in 1960 [62]D5[516]D5. By the 2000s, however, concerns mounted: vancomycin MIC creep, treatment failures, and nephrotoxicity from high-dose regimens eroded its status as the “gold standard.” The IDSA 2011 MRSA guidelines formalised vancomycin's role but acknowledged its limitations, recommending therapeutic drug monitoring targeting an AUC/MIC ratio of 400-600 mg·h/L (assuming MIC 1 mg/L) to balance efficacy and safety [1]A1c[5]A1c.
The Anti-MRSA Pipeline: New Agents Challenge Vancomycin
The early 2000s brought agents with novel mechanisms. (6 mg/kg daily) proved noninferior to standard therapy for S. aureus bacteremia and right-sided endocarditis in the pivotal 2006 trial (44.2% vs. 41.7% success) and caused significantly less renal dysfunction (11.0% vs. 26.3%; NNT=7 to prevent one case) [16]A1b. outperformed dose-optimised vancomycin for MRSA nosocomial pneumonia (clinical success 57.6% vs. 46.6%; NNT=9) with similar 60-day mortality but lower nephrotoxicity (8.4% vs. 18.2%) [7]A1b. Tedizolid (200 mg orally once daily for 6 days) matched linezolid for skin infections with a shorter course [398]A1b. Ceftobiprole, a cephalosporin with MRSA activity, was noninferior to daptomycin for complicated S. aureus bacteremia (69.8% vs. 68.7% success) [14]A1b. Omadacycline and dalbavancin broadened options for skin and osteoarticular infections, respectively [17]A1b[428]A1b.
The Anti-Staphylococcal β-Lactam Reappraisal
For methicillin-susceptible S. aureus (MSSA), antistaphylococcal penicillins had been standard, until the SNAP trial showed that cefazolin was noninferior to flucloxacillin/cloxacillin for 90-day mortality (15.0% vs. 17.0%; probability of noninferiority 99.2%) and caused less acute kidney injury (13.9% vs. 19.6%; NNT=18) [15]A1b. The CloCeBa trial confirmed cefazolin's noninferior efficacy for MSSA bacteremia with fewer serious adverse events (15% vs. 27%) and far less AKI (1% vs. 12%) [22]A1b. These results repositioned cefazolin as a first-line agent for MSSA.
Combination Therapy: Successes and Failures
Adding a β-lactam to vancomycin or daptomycin for MRSA bacteremia (CAMERA-2) failed to improve the composite outcome and increased AKI (23% vs. 6%; NNH=6) [29]A1b. Adjunctive for S. aureus bacteremia (ARREST) showed no benefit (hazard ratio 0.96) and caused more drug interactions (6% vs. 2%) [24]A1b. Daptomycin plus fosfomycin raised treatment success by 12% (54.1% vs. 42.0%), but the difference was not statistically significant, and adverse events led to more discontinuations (17.6% vs. 4.9%) [493]A1b.
The Shift to Shorter and Oral Regimens
The POET trial proved that a switch to oral after at least 10 days of intravenous therapy was noninferior for left-sided endocarditis, including S. aureus cases (9.0% vs. 12.1% composite outcome) [13]A1b. The SABATO trial extended this concept to low-risk S. aureus bacteremia, randomising patients after 5-7 days of intravenous therapy; complication rates were similar (13% oral vs. 12% intravenous), supporting early oral switch in selected patients [256]A1b. The ongoing SNAP trial is evaluating early oral switch in a broader population [10]D5.
Decolonization: Proven Prevention
Intranasal mupirocin for S. aureus carriers reduces nosocomial infections (odds ratio 0.49) [500]A1b. Post-discharge decolonisation (chlorhexidine + mupirocin for 5 days twice monthly for 6 months) reduced MRSA infection by 30% (NNT=30) [201]A1b. Universal chlorhexidine bathing in ICUs decreased MRSA acquisition in the REDUCE MRSA trial [498]A1b but not in non-critical-care units (ABATE Infection) [210]A1b. Iodophor antiseptic was inferior to mupirocin for ICU decolonisation [30]A1b; mupirocin consumption above 25 DDD/1000 patient-days correlates with rising resistance [537]B2b.
Failed Frontiers
Several promising approaches failed in phase 3: the V710 S. aureus vaccine paradoxically increased multiorgan failure [508]A1b; the anti-alpha-toxin monoclonal suvratoxumab did not prevent [116]A1b; and exebacase, a lysin targeting MRSA, failed to improve outcomes in the DISRUPT trial (50.0% vs. 60.6% clinical response) [494]A1b.
Pearl: The trajectory of S. aureus treatment, from vancomycin monotherapy to diversified β-lactam, lipopeptide, oxazolidinone, and oral-switch strategies, was shaped by a series of negative trials (CAMERA-2, ARREST) that proved as instructive as the positive ones, each refining the boundary between what helps and what harms.
| Trial | Year | Population | Intervention vs. Comparator | Key Finding | NNT/NNH |
|---|---|---|---|---|---|
| Fowler et al. [16]A1b | 2006 | S. aureus bacteremia/endocarditis | Daptomycin 6 mg/kg vs. standard therapy | Noninferior (44.2% vs. 41.7%); less renal dysfunction (11% vs. 26.3%) | NNT=7 for renal safety |
| Wunderink et al. [7]A1b | 2012 | MRSA nosocomial pneumonia | Linezolid vs. dose-optimised vancomycin | Higher clinical success (57.6% vs. 46.6%); similar 60-day mortality; less nephrotoxicity | NNT=9 for success; NNH=10 for nephrotoxicity |
| CAMERA-2 [29]A1b | 2020 | MRSA bacteremia | Standard therapy + β-lactam vs. standard alone | No difference in composite; more AKI (23% vs. 6%) | NNH=6 for AKI |
| SNAP [15]A1b | 2026 | MSSA bacteremia | Cefazolin vs. flucloxacillin/cloxacillin | Noninferior 90-day mortality (15% vs. 17%); less AKI (13.9% vs. 19.6%) | NNT=18 for AKI prevention |
| POET [13]A1b | 2018 | Left-sided endocarditis (including S. aureus) | Intravenous → oral switch vs. continued IV | Noninferior (9.0% vs. 12.1% composite) | NNT not significant |
| SABATO [256]A1b | 2024 | Low-risk S. aureus bacteremia | Early oral switch (days 5-7) vs. continued IV | Similar complication rate (13% vs. 12%) | NNT not significant |
| Huang et al. [201]A1b | 2019 | Post-discharge MRSA carriers | Chlorhexidine + mupirocin for 6 months vs. education | 30% reduction in MRSA infection | NNT=30 |
| ARREST [24]A1b | 2017 | S. aureus bacteremia | Adjunctive rifampicin vs. placebo | No benefit (HR 0.96); more drug interactions (6% vs. 2%) | NNH=25 for drug interactions |
Antimicrobial Resistance and Stewardship
- ▸MRSA incidence has declined in North America and Europe since peaking around 2005-2008, while Gram-negative resistance continues to rise [237, 579].
- ▸Mupirocin resistance in MRSA correlates with usage volume; consumption exceeding 25 DDD/1000 patient-days is linked to increasing resistance [537].
- ▸Negative MRSA nasal PCR is a powerful stewardship tool (NPV 96.5%) to de-escalate empiric anti-MRSA therapy for pneumonia [11].
The evolution of treatment has been paralleled by a dynamic landscape of antimicrobial resistance, requiring clinicians to understand both the mechanisms that undermine therapy and the stewardship strategies that preserve it.
Mechanisms of Resistance
Staphylococcus aureus has acquired resistance to every antibiotic class introduced. The principal determinant of methicillin resistance is the mecA gene on elements (13 types), encoding PBP2a with low β-lactam affinity [42]D5. Homologues mecC and plasmid-borne mecB also exist [581]C4. resistance occurs via the vanA operon (acquired from enterococci, producing VRSA) or stepwise mutations yielding vancomycin-intermediate S. aureus (VISA) and heteroresistance (hVISA) [55]C4[558]D5[565]D5. resistance arises from 23S rRNA mutations (G2576T) or the cfr methyltransferase [233]C4[416]C4. resistance involves mutations in mprF and cls, sometimes cross-selected by vancomycin [60]D5[558]D5. High-level mupirocin resistance is mediated by mupA; low-level resistance by ileS mutations [306]D5[576]C4. Additional mechanisms include PBP4 alterations [573]D5, bacitracin resistance via bcrABD operons [571]D5, and biofilm-mediated tolerance [46]D5[585]D5.
of Multidrug-Resistant Variants
MRSA remains the dominant multidrug-resistant variant. In the SENTRY program (1997-2016), MRSA accounted for 40.3% of 191,460 isolates globally, peaking at 44.2% in 2005-2008 then declining to 39.0% by 2013-2016 [579]B2c. In US hospitals, MRSA infection incidence fell from 114 to 94 per 10,000 hospitalizations between 2012 and 2017 [237]B2b. VRSA remains rare (9 US cases by 2009) [565]D5, but methicillin-susceptible VRSA has emerged in Brazil [100]C4. Linezolid-resistant S. aureus prevalence is 0.05%, though outbreaks occur in high-use settings [233]C4[416]C4. Mupirocin resistance reaches 34.4% in some MRSA populations, tightly linked to usage volume [576]C4. Regional variation is notable: MRSA exceeds 60% in parts of the Arab League and Brazil [562]D5[563]D5. Refugees and asylum seekers have higher odds of AMR carriage [557]B2a.
Stewardship Principles for Preserving Antibiotic Efficacy
programs (ASPs) reduce MRSA infections by 37% (IR 0.63, 95%) [196]A1a. MRSA nasal PCR screening provides a negative predictive value of 96.5% for MRSA pneumonia, enabling safe de-escalation [11]B2a. Selective digestive decontamination in ICUs does not significantly increase MRSA resistance [449]A1a. Mupirocin use above 25 defined daily doses per 1000 patient-days correlates with rising resistance [537]B2b. Universal glove and gown use in ICUs reduced MRSA acquisition by 2.98 per 1000 patient-days [509]A1b. Enhanced terminal room disinfection with UV light reduced target organism acquisition [25]A1b. In Latin American hospitals, higher ASP scores were associated with 8.59 fewer defined daily doses of anti-MRSA agents [95]C4.
Controversies and Guideline Disagreement
Universal decolonization with chlorhexidine bathing in non-ICU wards did not reduce MRSA/VRE clinical cultures in the ABATE Infection trial [210]A1b, whereas ICU-based decolonization with mupirocin-CHG outperformed iodophor-CHG [30]A1b. Selective decontamination, though not associated with increased resistance in meta-analyses [449]A1a, has limited adoption outside Europe due to unresolved long-term ecological concerns.
Pearl: A negative MRSA nares PCR has a negative predictive value of 96.5% for ruling out MRSA pneumonia, making it a high-yield antimicrobial stewardship tool to avoid unnecessary empiric anti-MRSA therapy [11]B2a.
| Intervention | Effect Metric | Outcome | Reference |
|---|---|---|---|
| Antibiotic stewardship programs | Incidence ratio (IR) | 37% reduction (IR 0.63) | [196]A1a |
| MRSA nares screen (pneumonia NPV) | NPV | 96.5% | [11]B2a |
| SDD/SOD in ICU | OR for MRSA resistance | 1.46 (not significant) | [449]A1a |
| Mupirocin-CHG decolonization threshold | DDD/1000 patient-days | >25 associated with resistance rise | [537]B2b |
| Universal glove & gown (ICU) | MRSA acquisition difference | -2.98 per 1000 patient-days | [509]A1b |
| UV room disinfection | RR for target organisms | 0.70 | [25]A1b |
| Hospital ASP score (Latin America) | DDD change (anti-MRSA) | -8.59 (SE 4.12) | [95]C4 |
Supportive Care and Complications
- ▸Acute kidney injury is the most common therapy-related complication; cefazolin is associated with significantly less nephrotoxicity than antistaphylococcal penicillins (OR 0.225, 95% CI 0.127-0.513) [591].
- ▸Routine addition of rifampin to standard therapy does not improve outcomes and increases adverse events (17% vs 10%); avoid unless required for specific device-related infection [24].
- ▸Delayed appropriate antimicrobial therapy is a key risk factor for metastatic complications (RR 7.16 for metastatic infection without endocarditis) [387].
Resistance-guided antibiotic selection, detailed in the preceding section, must be paired with a systematic approach to supportive care that anticipates the major drivers of morbidity in S. aureus infections. Complications arise both from the infection itself (metastatic seeding, toxin-mediated shock, septic emboli) and from therapy (nephrotoxicity, drug interactions, adverse events). Proactive monitoring and prevention are as critical as antibiotic choice.
Hospital-Acquired and Therapy-Related Complications
| Complication | Frequency | Prevention | |
|---|---|---|---|
| Acute kidney injury ( , antistaph penicillins) | 18.2% vancomycin [7]A1b; 12% cloxacillin [22]A1b | Prefer cefazolin when MSSA [591]A1a; maintain adequate hydration; monitor creatinine | Dose-adjust or switch to alternative ( 6 mg/kg IV daily [16]A1b) |
| Adverse events requiring antibiotic modification ( combination) | 17% vs 10% placebo [24]A1b | Avoid combination therapy unless clear benefit; do not add rifampin routinely [24]A1b[405]B3b | Discontinue rifampin; continue backbone therapy |
| Metastatic infection (endocarditis, osteomyelitis, epidural abscess) | Osteomyelitis recurrence ~40% [46]D5; most often due to S. aureus [52]D5 | Early source control; adequate antibiotic duration; rapid clearance of bacteremia [387]B3b | Prolonged ; surgical debridement/valve replacement as indicated [602]B2b |
| Toxic shock syndrome | Mortality ~8% [113]C4 | Identify superantigen-producing strains; use toxin-suppressing antibiotics (clindamycin, ) [32]D5 | ICU support; IVIG may neutralize superantigen [32]D5 |
| Septic pulmonary emboli / Lemierre-like syndrome | Rare; high morbidity [79]C4 | Prompt treatment of primary infection; consider anticoagulation for jugular thrombosis | Source control; anticoagulation (case-dependent) [79]C4 |
| Coinfection-associated mortality (respiratory virus + S. aureus) | 30-day mortality 31.6% vs 18.0% [612]B2b; odds of death >4× with influenza [616]B2b | Annual influenza vaccination; early antiviral therapy | Broad-spectrum antibiotics covering MRSA; ICU support |
Respiratory Monitoring
Patients with S. aureus pneumonia or sepsis require close respiratory monitoring. Forced vital capacity (FVC) <20 mL/kg or rapid decline suggests impending respiratory failure. Use the table below to guide intubation decisions. Continuous and arterial blood gases are essential.
| Parameter | Threshold for Concern | Action |
|---|---|---|
| FVC | <20 mL/kg | Assess for noninvasive ventilation; prepare for intubation |
| PaO₂/FiO₂ | <200 | Initiate lung-protective ventilation |
| Work of breathing | Accessory muscle use, tachypnea >30/min | Low threshold for intubation |
| Mental status | Worsening confusion, agitation | Secure airway |
Autonomic Complications
Toxin-mediated superantigen activity can cause autonomic instability: arrhythmias, refractory hypotension, paralytic ileus, and urinary retention [32]D5[113]C4. Manage with aggressive fluid resuscitation, vasopressors (norepinephrine first-line), and cardiac monitoring. and urinary catheters are supportive until resolution.
DVT/PE Prophylaxis
Immobilized patients with S. aureus bacteremia or endocarditis are at high risk for venous thromboembolism. Initiate pharmacologic prophylaxis with low-molecular-weight (e.g., 40 mg subcutaneously daily) or unfractionated heparin 5000 units subcutaneously every 8-12 hours, provided no active bleeding or high bleeding risk. Mechanical prophylaxis (sequential compression devices) should be added when anticoagulation is contraindicated.
Pain Management
Pain in S. aureus infections is typically nociceptive (from abscess, osteomyelitis, surgical wounds) and neuropathic (if nerve involvement, e.g., spinal epidural abscess [52]D5). Acetaminophen 650 mg every 6 hours is safe for mild pain. For moderate-severe pain, opioids ( 5-10 mg IV every 4 hours as needed) may be necessary, but avoid NSAIDs in patients with renal impairment or risk of bleeding. Neuropathic pain (persistent radicular symptoms) may respond to gabapentinoids.
Rehabilitation
Early mobilization after source control improves functional outcomes. Physical therapy should begin once the patient is hemodynamically stable and infection is controlled. For patients with osteomyelitis or prosthetic joint infections, weight-bearing restrictions may apply; consult orthopedics. Prolonged hospitalization requires attention to preventing pressure injuries and deconditioning.
Pearl: The single most modifiable complication of S. aureus therapy is acute kidney injury, choosing cefazolin over antistaphylococcal penicillins for MSSA infections significantly reduces nephrotoxicity without sacrificing efficacy [22]A1b[591]A1a.
Prognosis and Natural History
- ▸The case fatality rate of S. aureus bacteremia is 15-30%, driven by host factors, source, and timeliness of source control.
- ▸Persistent bacteremia ≥48 hours is the strongest modifiable predictor of death (90-day mortality 39%).
- ▸Infectious disease consultation and appropriate empirical therapy reduce mortality; the absolute benefit of empirical anti-MRSA coverage is small for common syndromes.
Complications of S. aureus infection, whether metastatic seeding, endocarditis, or septic shock, shape the prognosis more than the index infection itself. Untreated S. aureus bacteremia (SAB) is nearly uniformly fatal. With appropriate therapy, the case fatality rate stands at 15% to 30%, accounting for an estimated 300 000 deaths annually worldwide [58]D5. Understanding the natural history across infection syndromes and the factors that modify outcome is essential for prognostication and treatment intensity.
Treated Outcomes by Syndrome
The outcomes of SAB vary substantially by source, host, and treatment fidelity. The table below summarizes key outcome data from recent trials and cohort studies.
| Syndrome | Key Outcome | Reference |
|---|---|---|
| MSSA bacteremia (cefazolin vs antistaphylococcal penicillin) | 90-day mortality: 15.0% vs 17.0% (adjusted OR 0.81; probability of noninferiority 99.2%) | [15]A1b |
| MRSA bacteremia ( / ± β-lactam) | 90-day mortality: 21% vs 16% (difference not significant) | [29]A1b |
| MRSA nosocomial pneumonia | 60-day mortality: 15.7% vs 17.0% ( vs vancomycin) | [7]A1b |
| Complicated SAB (ceftobiprole vs daptomycin) | 70-day mortality: 9.0% vs 9.1% | [14]A1b |
| Persistent SAB (≥2 days bacteremia) | 90-day mortality: 39% (vs 22% with 1 day) | [28]B2b |
| Infective endocarditis (S. aureus, overall) | 1-year survival: 84.3% with suppressive therapy | [596]C4 |
| (S. aureus, DAIR) | Success rate: hip 69%, knee 54% | [407]A1a |
| Skin abscess (drainage + TMP-SMX) | Cure: 80.5% | [452]A1b |
| Skin abscess (drainage + placebo) | Cure: 68.9% | [499]A1b |
Persistent bacteremia is the single strongest modifiable prognostic marker. Patients with ≥2 days of positive blood cultures despite active therapy have a 90-day mortality of 39% compared with 22% in those clearing within 24 hours; the second day of bacteremia carries the highest adjusted hazard [28]B2b. Short time to blood culture positivity (<13 hours) independently predicts endocarditis (OR 3.59), with a negative predictive value of 96% [199]B2b.
Methicillin resistance influences crude but not adjusted mortality. In a large Australian cohort, MRSA bacteremia had shorter crude survival (14 vs 54 months), but after adjustment for age, comorbidities, and severity, the association disappeared [129]B3b. Similarly, a meta-analysis found no significant mortality difference between high-vancomycin MIC (≥1.5 mg/L) and low-MIC isolates [212]A1a. The adverse prognosis often attributed to MRSA likely reflects the sicker patients it afflicts.
Predictors of Mortality
Multiple factors independently predict death in SAB [262]D5:
- Host: older age, diabetes, chronic kidney disease, cirrhosis, immunosuppression
- Disease-specific: septic shock at presentation, community acquisition (higher endocarditis risk), persistent bacteremia, metastatic foci (e.g., endocarditis, )
- Treatment-related: inappropriate empirical , delayed source control, absence of infectious disease consultation
Inappropriate empirical therapy in MRSA bacteremia is associated with a nearly 2-fold increased odds of death (adjusted OR 1.98) [453]B3b. However, the absolute benefit of anti-MRSA coverage varies by syndrome: for pneumonia it is estimated at 0%, for non-critically ill skin infections 0.1%, and for patients with septic shock 0.6% [621]A1a. This underscores the need to narrow therapy once susceptibilities are known.
Special Populations
- Cystic fibrosis: MRSA respiratory colonization is associated with worse survival (adjusted HR 1.27) and contributes to accelerated lung function decline [82]B2b.
- Children: Treatment failure occurs in 16% of pediatric SAB; rural residence increases the odds 2.3-fold, likely reflecting delayed access to specialized care [296]B3b.
- Older adults: Age >75 years is an independent predictor of infection-related mortality in vascular graft infections (43% 1-year mortality) and post-sternotomy mediastinitis [264]B2b.
Prognostic Tools
The duration of bacteremia and the presence of metastatic infection are the most clinically actionable predictors. An algorithm-based approach to testing and treatment duration has been shown safe and reduces antibiotic days by a mean of 1.8 days [397]A1b. Infectious disease consultation is consistently associated with lower mortality and higher adherence to standards [623]B2a [640]B2b.
Pearl: Persistent bacteremia ≥48 hours is the most powerful modifiable predictor of death; repeat blood cultures at 24-48 hours are mandatory for risk stratification, a single negative follow-up culture at 48 hours reduces 90-day mortality from 39% to 22% [28]B2b.
Prevention and Infection Control
- ▸Universal decolonisation (chlorhexidine + mupirocin) in ICUs reduces all-pathogen bloodstream infection; post-discharge decolonisation in MRSA carriers prevents infection (NNT 30).
- ▸The evidence for active surveillance and contact precautions is mixed; horizontal strategies (hand hygiene, environmental cleaning, and universal decolonisation) may have greater impact.
- ▸No licensed S. aureus vaccine exists; current prevention relies on decolonisation, evidence-based surgical prophylaxis, and antimicrobial stewardship.
Given that S. aureus infections frequently arise from endogenous carriage or nosocomial transmission, prevention strategies must target both the individual carrier and the healthcare environment. The evidence supports a multimodal approach: hand hygiene, environmental cleaning, targeted or universal decolonization in high-risk settings, and evidence-based surgical prophylaxis.
Hand and Environmental Hygiene
Improved hand hygiene compliance reduces healthcare-associated S. aureus bacteraemia (HA-SAB). In the Australian National Hand Hygiene Initiative, a 10% increase in compliance was associated with a 15% decrease in HA-SAB (incidence rate ratio 0.85, 95% CI 0.79-0.93) [665]B2b. The REACH randomised trial demonstrated that a cleaning bundle (optimising technique, product, auditing) increased thoroughness of cleaning (from 64% to 86% for bedrooms) and reduced -resistant enterococci, but did not significantly reduce S. aureus bacteraemia (0.97 to 0.80 per 10 000 occupied bed-days; relative risk 0.82, 95%) [495]A1b. Adding ultraviolet-C (UV-C) to standard terminal disinfection lowered acquisition of target organisms including MRSA (RR 0.70, 95% CI 0.50-0.98) in the BETR Disinfection study [25]A1b.
Decolonisation Strategies
Decolonisation with intranasal mupirocin and chlorhexidine bathing is effective in specific populations. In the REDUCE MRSA cluster-randomised trial, universal decolonisation in ICUs (no screening, all patients bathed with chlorhexidine and received mupirocin) reduced MRSA clinical isolates (hazard ratio 0.63) and all-pathogen bloodstream infection (HR 0.56) compared with screening-and-isolation alone; one bloodstream infection was prevented per 54 patients treated [18]A1b. The ABATE Infection trial extended this to non-critical-care units: universal chlorhexidine bathing plus targeted mupirocin for known MRSA carriers did not significantly reduce MRSA/VRE clinical cultures compared with routine care (p=0.17) [210]A1b. For post-discharge MRSA carriers, the Project CLEAR trial showed that a 6-month regimen of monthly 5-day cycles of chlorhexidine and mupirocin reduced MRSA infection (HR 0.70; NNT 30) and infection-related hospitalisation (HR 0.76) [201]A1b. The HONEYPOT trial found that honey applied to peritoneal dialysis exit sites was not superior to standard care and increased peritonitis risk in patients with diabetes [497]A1b.
Screening and Contact Precautions
The optimal role of active surveillance and contact precautions remains debated. The VA MRSA Prevention Initiative, universal nasal surveillance, contact precautions, hand hygiene, and culture change, was associated with a 62% decline in ICU MRSA infections (from 1.64 to 0.62 per 1000 patient-days) [314]B2c. However, the STAR*ICU cluster-randomised trial found that surveillance plus expanded barrier precautions did not reduce MRSA/VRE transmission compared with existing practice [203]A1b. In a subsequent VA analysis, suspending active surveillance and contact precautions during the pandemic was associated with higher MRSA HAI rates (ICU: 0.65 vs 0.20 per 1000 patient-days; p<0.001) [657]B2b. The SHEA/IDSA/APIC 2023 update lists contact precautions as an “essential practice”, but others argue that evidence from hospitals that discontinued them shows no increase in MRSA acquisition, and that harms (reduced patient contact, environmental waste) may outweigh benefits [655]D5.
Surgical Prophylaxis and Bundles
A bundle of preoperative S. aureus screening, decolonisation (mupirocin + chlorhexidine), and targeted prophylaxis (vancomycin + cefazolin for MRSA carriers) was associated with a 42% reduction in complex S. aureus SSI (rate ratio 0.58, 95% CI 0.37-0.92) across 20 US hospitals [40]B2b. However, a large trial of adding vancomycin to cefazolin in arthroplasty patients without known MRSA colonisation found no benefit (RR 1.28, 95% CI 0.94-1.73) and increased hypersensitivity reactions (1.2% vs 0.5%; RR 2.20) [202]A1b. A 2026 meta-analysis of 1 041 058 arthroplasty patients reported that dual prophylaxis (vancomycin + cefazolin) reduced periprosthetic joint infection (OR 0.64) but increased surgical site infection (OR 1.39) and did not reduce overall SSIs [669]A1a. Routine addition of vancomycin is not recommended; selection should be guided by patient- and pathogen-specific risk [648]D5.
Vaccine Development
Despite decades of research, there is no licensed S. aureus vaccine. The V710 vaccine (targeting iron surface determinant B) failed in a phase 2b/3 trial of cardiothoracic surgery patients and was associated with increased multiorgan failure (HR not calculable from reported data; 31 vs 17 events per 100 person-years;) [508]A1b. A four-antigen vaccine (SA4Ag) showed persistent functional immune responses through 36 months but has not yet demonstrated clinical efficacy [690]C4. Multiple approaches, including targeting protein A and T-helper 17 pathways, are under investigation [647]D5.
and Emerging Tools
post-exposure prophylaxis (doxy PEP) for bacterial STI prevention has been associated with increased tetracycline-resistant S. aureus colonization (18% vs 8% in users vs non-users;) [654]B2b. administered for prophylaxis during the wet season in a haemodialysis unit was associated with a 56% lower rate of S. aureus bloodstream infection [689]C4. Bacteriophage therapy, though investigational, has been used on a compassionate basis for recalcitrant S. aureus infections with safety and feasibility demonstrated in a small case series [692]C4.
Patient Education
Patients colonised with MRSA should receive clear written and verbal instruction on decolonisation technique: chlorhexidine bathing (avoiding eyes, ears, and mucous membranes) and intranasal mupirocin applied to each nostril twice daily for 5 days [201]A1b. Hand hygiene with soap and water or alcohol-based hand rub after touching wounds or dressings is essential. Household contacts of patients with recurrent SSTI may benefit from environmental decontamination (surface disinfection, separate towels, and laundry hygiene), although the evidence for reducing SSTI is strongest in those with a prior year history of infection [642]A1b.
Pearl: Universal decolonisation with chlorhexidine and mupirocin in ICU patients reduces all-cause bloodstream infection (NNT 54) and is more effective than screening-based targeted decolonisation [18]A1b; in non-ICU settings, post-discharge decolonisation for MRSA carriers prevents one infection per 30 patients treated and reduces hospitalisations [201]A1b.
| Strategy | Evidence Summary | Recommendation |
|---|---|---|
| Hand hygiene | 10% increase → 15% reduction in HA-SAB [665]B2b | Essential, monitor compliance |
| Environmental cleaning bundle | Improved thoroughness; reduced VRE but not SAB in one trial [495]A1b | Implement multimodal cleaning |
| UV-C terminal disinfection | Reduced MRSA/VRE acquisition (RR 0.70) [25]A1b | Consider in high-risk settings |
| Universal ICU decolonisation (chlorhexidine + mupirocin) | Reduced MRSA isolates (HR 0.63) and all-BSI (HR 0.56); NNT 54 [18]A1b | Use in ICUs with high endemicity |
| Post-discharge decolonisation (MRSA carriers) | Reduced MRSA infection (HR 0.70; NNT 30) and hospitalisation (HR 0.76) [201]A1b | Offer 6-month cyclic regimen |
| Preoperative screening + decolonisation + targeted prophylaxis | 42% reduction in complex S. aureus SSI [40]B2b | Implement for cardiac and arthroplasty patients |
| Adding vancomycin to cefazolin arthroplasty (no known MRSA) | No benefit; increased hypersensitivity (RR 2.20) [202]A1b[669]A1a | Not recommended routinely |
Special Hosts and Populations
- ▸HIV infection confers a 6-fold higher incidence of CA-MRSA SSTI; nasal screening alone misses at least one third of carriers, so add groin, perirectal, and throat cultures [492, 702].
- ▸In children with S. aureus bacteremia, empiric vancomycin does not improve survival and increases nephrotoxicity (OR 3.1); ID consultation is strongly protective (aOR 0.07) [700].
- ▸In pregnancy, S. aureus bacteremia is frequently associated with injection drug use and infective endocarditis (56%), with poor fetal outcomes (16% death) [726].
These prevention strategies must be tailored to the special hosts whose altered immune defences, physiology, or microbial ecology fundamentally shift the risk-to-benefit balance of every diagnostic and therapeutic decision. The clinician cannot extrapolate from general-population data: host status dictates which S. aureus syndromes occur, which antimicrobials are safe, and what outcomes to expect.
HIV Infection
People living with HIV (PLWH) carry a markedly elevated burden of MRSA. The pooled prevalence of MRSA colonization in HIV-infected individuals is 6.9% (95% CI, 4.8%-9.3%), rising to 8.8% in North American studies [492]B2a. Prior hospitalization (RR 3.11) and incarceration (RR 1.77) are strong predictors [492]B2a. Nasal screening alone underestimates true carriage by at least one third; adding groin, perirectal, and throat cultures increases detection by 19-20% each [492]B2a.
The incidence of CA-MRSA SSTIs is 6-fold higher in HIV-infected patients (996 vs 157 per 100,000; P<0.001) [702]B3b. The predominant strain is USA300, which accounted for 86% of isolates in one cohort [702]B3b. Risk factors include residence in shelters, incarceration, younger age, and being seen in the later epidemic period (2004-2007) [702]B3b. Interestingly, in a cohort with well-controlled HIV (96% had CD4 >200), colonization with Staphylococcus epidermidis was protective, reducing the odds of S. aureus carriage by 80% (aOR 0.20; 95% CI, 0.09-0.45) [727]C4. Behavioural factors, illicit drug use (HR 4.26), public gym use (HR 1.66), predict colonization, while antibacterial soap use is protective (HR 0.50) [728]B2b. CD4 count, HIV RNA level, and antiretroviral use were not independently associated with colonization or SSTI [728]B2b. S. aureus is a leading cause of community-acquired bloodstream infection in PLWH, with mortality rates ranging from 7% to 46% [695]B2a.
Children and Neonates
Paediatric S. aureus bacteremia carries an incidence of 4.4/100,000/year in Australia and New Zealand; Indigenous children, those from lower socioeconomic areas, and neonates are overrepresented [700]B2b. Mortality is infrequent (3%) but one in three children experiences a composite adverse outcome (prolonged stay, ICU admission, relapse, or death) [700]B2b. Predictors of mortality include prematurity (aOR 16.8), multifocal infection (aOR 22.6), necrotizing pneumonia (aOR 38.9), and multiorgan dysfunction (aOR 26.5) [700]B2b. Infectious diseases consultation was strongly protective (aOR 0.07) [700]B2b. Empiric did not improve survival but was associated with nephrotoxicity (OR 3.1) [700]B2b.
Among paediatric acute haematogenous osteomyelitis (AHO), the cefazolin inoculum effect (CzIE; MIC ≥16 μg/mL at high inoculum) is present in 14.4% of MSSA isolates and is independently associated with progression to chronic osteomyelitis (aOR not calculable from reported data) [470]B3b. Meanwhile, penicillin-susceptible MSSA (PSSA) is re-emerging, rising from 0% to 20.4% of paediatric AHO isolates by 2019 [279]B2c, though clinical outcomes resemble those of penicillin-resistant MSSA. Oral step-down therapy with cephalexin or the twice-daily alternative cefadroxil achieves pharmacokinetic/pharmacodynamic targets for MSSA [468]C4[613]B2b. In S. aureus septic arthritis, infection with S. aureus is an independent risk factor for concurrent osteomyelitis (aOR 3.17) [711]B2b.
In paediatric bloodstream infections, S. aureus bacteremia is an independent predictor of definite or possible infective endocarditis [712]B2b. Despite this, an oral switch strategy is used in 58.6% of paediatric S. aureus bacteremia cases at one tertiary centre, with comparable 30-day failure rates (2.4% vs 3.4%) and a significantly shorter hospital stay (13 vs 48 days) [713]B2b. Decolonisation with mupirocin and chlorhexidine in children <6 years showed no significant benefit over a wait-and-see approach (HR 0.92 for <2 years; HR 0.54 for 2-5 years) [722]B2b. Mupirocin resistance in children with recurrent SSTI is non-trivial (14.7% in one series) [715]C4, and qacA/B or smr genes conferring chlorhexidine tolerance are found in 44.9% of nosocomial paediatric isolates [681]C4.
Pregnancy and Postpartum
Pregnancy alters the and consequences of S. aureus infection. In one cohort of 27 pregnant patients with S. aureus bacteremia, 56% had infective endocarditis, 82% had MRSA, and 85% reported active injection drug use [726]C4. Fetal outcomes were poor: 16% of infants/fetuses died during hospitalisation, and 27% of mothers were readmitted within 6 months for infectious complications [726]C4. S. aureus is also a common cause of urinary tract infection in pregnancy, accounting for 22.6% of isolates in one Palestinian cohort, with multidrug resistance in 55.7% of all UTI isolates [77]B2b.
Elderly
The incidence of S. aureus bacteremia in Denmark increased by 48% from 2008 to 2015, driven disproportionately by older adults. Persons >80 years experienced a 90% increase, and those >90 years had an annual increase of 13.0% (p<0.001) [252]B2c. The 30-day case-fatality rate remained stable at 24%, meaning crude population death rates rose by 53% [252]B2c. Age >64 years is also an independent predictor of acute kidney injury during antistaphylococcal therapy (aOR 1.76) [718]B2b.
Cystic Fibrosis
Detection of MRSA in the respiratory tract of patients with cystic fibrosis is associated with worse survival (adjusted HR 1.27; 95% CI, 1.11-1.45) [82]B2b. S. aureus colonisation influences transplant outcomes: in children with CF awaiting lung transplantation, S. aureus infection increased waiting-list survival but decreased post-transplantation survival, contributing to net harm for the majority of listed patients [708]B2b. Co-colonisation with Pseudomonas aeruginosa selects for upregulation of the NorA efflux pump in S. aureus, a partial adaptation to persistent co-colonisation [637]D5.
Other High-Risk Populations
Persons who inject drugs (PWID) are at extreme risk for MRSA SSTI and bacteraemia, particularly in pregnancy [726]C4. Incarceration doubles the risk of MRSA colonisation in HIV-infected individuals (RR 1.77) and amplifies the community spread of USA300 [492]B2a[730]B2c. Indigenous populations in Australia, New Zealand, and Canada bear a disproportionate burden: Māori and Pacific Peoples in New Zealand have the highest rates of S. aureus SSTI and invasive disease, correlated with socioeconomic deprivation [104]B2c. Livestock-associated MRSA (LA-MRSA) can acquire phage-encoded immune evasion cluster genes, increasing household transmission and spillover into the general population [185]B2b.
Pearl: For the elderly and for children with S. aureus bacteremia, an infectious diseases consultation is independently associated with reduced mortality (aOR 0.07 in children) [700]B2b; in febrile neutropenia, combination beta-lactam therapy for MSSA bacteremia is associated with worse outcomes and should be avoided, choose either a narrow- or broad-spectrum beta-lactam, not both [704]B2b.
References
- [1]
Liu C, Bayer A, Cosgrove SE et al.. “Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21208910 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations - [2]
Stevens DL, Bisno AL, Chambers HF et al.. “Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24973422 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [3]
Stevens DL, Bisno AL, Chambers HF et al.. “Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24947530 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [4]
Liu C, Bayer A, Cosgrove SE et al.. “Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21217178 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations - [5]
Rybak MJ, Le J, Lodise TP et al.. “Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 32658968 ↗
L1GUIDELINECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Special Hosts and Populations - [6]
Mourad A, Nwafo N, Skalla L et al.. “Oral Versus Intravenous Antibiotic Therapy for Staphylococcus aureus Bacteremia or Endocarditis: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39290168 ↗
L1SR_OBSCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [7]
Wunderink RG, Niederman MS, Kollef MH et al.. “Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 22247123 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [8]
. “Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.” The Lancet. Infectious diseases (2024). PMID: 38636536 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Prognosis and Natural History, Special Hosts and Populations - [9]
Reddy EA, Shaw AV, Crump JA. “Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2010). PMID: 20510282 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Diagnosis and Workup, Prognosis and Natural History, Special Hosts and Populations - [10]
de Kretser D, Mora J, Bloomfield M et al.. “Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37921609 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [11]
Parente DM, Cunha CB, Mylonakis E et al.. “The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2018). PMID: 29340593 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [12]
McDanel JS, Roghmann MC, Perencevich EN et al.. “Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28379314 ↗
L3COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Complications - [13]
Iversen K, Ihlemann N, Gill SU et al.. “Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis.” The New England journal of medicine (2018). PMID: 30152252 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [14]
Holland TL, Cosgrove SE, Doernberg SB et al.. “Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.” The New England journal of medicine (2023). PMID: 37754204 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [15]
Lee TC, Barina LA, Walls G et al.. “Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.” The New England journal of medicine (2026). PMID: 42308484 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History, Special Hosts and Populations - [16]
Fowler VG, Boucher HW, Corey GR et al.. “Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.” The New England journal of medicine (2006). PMID: 16914701 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [17]
O'Riordan W, Green S, Overcash JS et al.. “Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.” The New England journal of medicine (2019). PMID: 30726689 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [18]
Huang SS, Septimus E, Kleinman K et al.. “Targeted versus universal decolonization to prevent ICU infection.” The New England journal of medicine (2013). PMID: 23718152 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Complications, Prevention and Infection Control - [19]
Corey GR, Kabler H, Mehra P et al.. “Single-dose oritavancin in the treatment of acute bacterial skin infections.” The New England journal of medicine (2014). PMID: 24897083 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Complications - [20]
Bode LG, Kluytmans JA, Wertheim HF et al.. “Preventing surgical-site infections in nasal carriers of Staphylococcus aureus.” The New England journal of medicine (2010). PMID: 20054045 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup - [21]
. “Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.” Lancet (London, England) (2022). PMID: 35065702 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [22]
Burdet C, Saïdani N, Dupieux C et al.. “Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.” Lancet (London, England) (2025). PMID: 41115439 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [23]
. “Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.” Lancet (London, England) (2026). PMID: 42309115 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History - [24]
Thwaites GE, Scarborough M, Szubert A et al.. “Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2017). PMID: 29249276 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [25]
Anderson DJ, Chen LF, Weber DJ et al.. “Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study.” Lancet (London, England) (2017). PMID: 28104287 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control - [26]
Schumm MA, Hadaya JE, Mody N et al.. “Filtering Facepiece Respirator (N95 Respirator) Reprocessing: A Systematic Review.” JAMA (2021). PMID: 33656543 ↗
L2SR_OBSCited in: Definition, Classification and Causative Organisms, Prevention and Infection Control - [27]
Mellett M, Lawandi A, Caya C et al.. “Antibiotic synergy against Staphylococcus aureus: a systematic review and meta-analysis.” Antimicrobial agents and chemotherapy (2025). PMID: 40526084 ↗
L1SR_OBSCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [28]
Kuehl R, Morata L, Boeing C et al.. “Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.” The Lancet. Infectious diseases (2020). PMID: 32763194 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [29]
Tong SYC, Lye DC, Yahav D et al.. “Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.” JAMA (2020). PMID: 32044943 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [30]
Huang SS, Septimus EJ, Kleinman K et al.. “Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial.” JAMA (2023). PMID: 37815567 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [31]
Geriak M, Haddad F, Rizvi K et al.. “Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2019). PMID: 30858203 ↗
L1RCTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [32]
Lappin E, Ferguson AJ. “Gram-positive toxic shock syndromes.” The Lancet. Infectious diseases (2009). PMID: 19393958 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [33]
Davis MF, Iverson SA, Baron P et al.. “Household transmission of meticillin-resistant Staphylococcus aureus and other staphylococci.” The Lancet. Infectious diseases (2012). PMID: 22917102 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship - [34]
Thwaites GE, Edgeworth JD, Gkrania-Klotsas E et al.. “Clinical management of Staphylococcus aureus bacteraemia.” The Lancet. Infectious diseases (2011). PMID: 21371655 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [35]
Nickerson EK, West TE, Day NP et al.. “Staphylococcus aureus disease and drug resistance in resource-limited countries in south and east Asia.” The Lancet. Infectious diseases (2009). PMID: 19179228 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [36]
Moise PA, North D, Steenbergen JN et al.. “Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.” The Lancet. Infectious diseases (2009). PMID: 19778764 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [37]
Aiello AE, Lowy FD, Wright LN et al.. “Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies.” The Lancet. Infectious diseases (2006). PMID: 16728319 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [38]
Clements A, Halton K, Graves N et al.. “Overcrowding and understaffing in modern health-care systems: key determinants in meticillin-resistant Staphylococcus aureus transmission.” The Lancet. Infectious diseases (2008). PMID: 18582835 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications - [39]
Harbarth S, Fankhauser C, Schrenzel J et al.. “Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients.” JAMA (2008). PMID: 18334690 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control - [40]
Schweizer ML, Chiang HY, Septimus E et al.. “Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery.” JAMA (2015). PMID: 26034956 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Causative Organisms, Prevention and Infection Control - [41]
Aiken AM, Mturi N, Njuguna P et al.. “Risk and causes of paediatric hospital-acquired bacteraemia in Kilifi District Hospital, Kenya: a prospective cohort study.” Lancet (London, England) (2011). PMID: 22133536 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Special Hosts and Populations - [42]
Lakhundi S, Zhang K. “Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology.” Clinical microbiology reviews (2018). PMID: 30209034 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [43]
Tong SY, Davis JS, Eichenberger E et al.. “Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.” Clinical microbiology reviews (2015). PMID: 26016486 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [44]
De Oliveira DMP, Forde BM, Kidd TJ et al.. “Antimicrobial Resistance in ESKAPE Pathogens.” Clinical microbiology reviews (2020). PMID: 32404435 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [45]
Becker K, Heilmann C, Peters G. “Coagulase-negative staphylococci.” Clinical microbiology reviews (2014). PMID: 25278577 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [46]
Kavanagh N, Ryan EJ, Widaa A et al.. “Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions.” Clinical microbiology reviews (2018). PMID: 29444953 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Complications - [47]
David MZ, Daum RS. “Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.” Clinical microbiology reviews (2010). PMID: 20610826 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [48]
Gadsby NJ, Musher DM. “The Microbial Etiology of Community-Acquired Pneumonia in Adults: from Classical Bacteriology to Host Transcriptional Signatures.” Clinical microbiology reviews (2022). PMID: 36165783 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [49]
Boggio CMT, Veronese F, Armari M et al.. “Skin microbiota in atopic dermatitis: victim or executioner?” Clinical microbiology reviews (2025). PMID: 40459300 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [50]
Saiman L, Waters V, LiPuma JJ et al.. “Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.” Clinical microbiology reviews (2024). PMID: 39158301 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications - [51]
Schlievert PM, Davis CC. “Device-Associated Menstrual Toxic Shock Syndrome.” Clinical microbiology reviews (2020). PMID: 32461307 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment - [52]
Tande AJ, Currier BL, Osmon DR. “Spinal Epidural Abscess.” The New England journal of medicine (2026). PMID: 42019020 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications - [53]
de Benedictis FM, Kerem E, Chang AB et al.. “Complicated pneumonia in children.” Lancet (London, England) (2020). PMID: 32919518 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History, Special Hosts and Populations - [54]
DeLeo FR, Otto M, Kreiswirth BN et al.. “Community-associated meticillin-resistant Staphylococcus aureus.” Lancet (London, England) (2010). PMID: 20206987 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Prevention and Infection Control - [55]
Rossi F, Diaz L, Wollam A et al.. “Transferable vancomycin resistance in a community-associated MRSA lineage.” The New England journal of medicine (2014). PMID: 24738669 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [56]
Renz N, Trampuz A, Perka C et al.. “Outcome and Failure Analysis of 132 Episodes of Hematogenous Periprosthetic Joint Infections-A Cohort Study.” Open forum infectious diseases (2022). PMID: 35355896 ↗
L3COHORTCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History - [57]
Bruun T, Oppegaard O, Kittang BR et al.. “Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study.” Open forum infectious diseases (2015). PMID: 26734653 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms - [58]
Tong SYC, Fowler VG, Skalla L et al.. “Management of Staphylococcus aureus Bacteremia: A Review.” JAMA (2025). PMID: 40193249 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [59]
Raff AB, Kroshinsky D. “Cellulitis: A Review.” JAMA (2016). PMID: 27434444 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Special Hosts and Populations - [60]
Heidary M, Khosravi AD, Khoshnood S et al.. “Daptomycin.” The Journal of antimicrobial chemotherapy (2018). PMID: 29059358 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [61]
Livermore DM. “Future directions with daptomycin.” The Journal of antimicrobial chemotherapy (2008). PMID: 18829725 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [62]
Moellering RC. “MRSA: the first half century.” The Journal of antimicrobial chemotherapy (2011). PMID: 22010206 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [63]
Tenover FC, Goering RV. “Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology.” The Journal of antimicrobial chemotherapy (2009). PMID: 19608582 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors - [64]
Dryden MS. “Complicated skin and soft tissue infection.” The Journal of antimicrobial chemotherapy (2010). PMID: 20876627 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Empiric Management, Acute Care and Source Control, Special Hosts and Populations - [65]
Troeman DPR, Van Hout D, Kluytmans JAJW. “Antimicrobial approaches in the prevention of Staphylococcus aureus infections: a review.” The Journal of antimicrobial chemotherapy (2019). PMID: 30376041 ↗
L1REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Prevention and Infection Control - [66]
Morgan M. “Methicillin-resistant Staphylococcus aureus and animals: zoonosis or humanosis?” The Journal of antimicrobial chemotherapy (2008). PMID: 18819971 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [67]
Barrett L, Atkins B. “The clinical presentation of prosthetic joint infection.” The Journal of antimicrobial chemotherapy (2014). PMID: 25135085 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup - [68]
Cuervo G, Chesdachai S, Hindy JR et al.. “Clinical Features of Adult Patients with Isolated Pulmonary Valve Endocarditis: A Systematic Review.” Microorganisms (2026). PMID: 42354833 ↗
L4SR_OBSCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Prognosis and Natural History - [69]
Lowenthal A, Weisblum-Neuman H, Birk E et al.. “Clinical Features and Comparison of Kingella and Non-Kingella Endocarditis in Children, Israel.” Emerging infectious diseases (2021). PMID: 33622463 ↗
L3REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, History and Evolution of Treatment, Special Hosts and Populations - [70]
Lee YW, Huh JW, Hong SB et al.. “Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014-2019.” Emerging infectious diseases (2022). PMID: 36287034 ↗
L3REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control - [71]
Moellering RC. “A 39-year-old man with a skin infection.” JAMA (2007). PMID: 18056894 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [72]
Sakoulas G, Olson J, Yim J et al.. “Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2016). PMID: 27572414 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [73]
Totten KMC, Patel R. “Phage Activity against Planktonic and Biofilm Staphylococcus aureus Periprosthetic Joint Infection Isolates.” Antimicrobial agents and chemotherapy (2021). PMID: 34662191 ↗
L5CASE_REPORTCited in: Definition, Classification and Causative Organisms - [74]
. “Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.” Lancet (London, England) (2024). PMID: 39299261 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control, Special Hosts and Populations - [75]
Tissari P, Zumla A, Tarkka E et al.. “Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study.” Lancet (London, England) (2009). PMID: 20004964 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [76]
Sánchez-Villamil JP, Morales-Peña VA, Flórez-Joya JF. “Prevalence of methicillin-resistant Staphylococcus aureus carriers in dental care staff: A systematic review and meta-analysis.” Biomedica : revista del Instituto Nacional de Salud (2026). PMID: 42413096 ↗
L1SR_OBSCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors - [77]
Khatatba LZ, Daraghmeh DN. “Bacterial profiles, antibiotic resistance, and recurrence of UTIs during pregnancy: a prospective cohort study from Palestine.” BMC infectious diseases (2026). PMID: 42426664 ↗
L2COHORTCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [78]
Cusumano JA, Dupper AC, Malik Y et al.. “Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series.” Open forum infectious diseases (2020). PMID: 33269299 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup - [79]
Newman N, Bantikassegn A, West TG et al.. “An Unusual Etiology of Lemierre-Like Syndrome: Preseptal Cellulitis due to Methicillin-Resistant Staphylococcus aureus.” Open forum infectious diseases (2022). PMID: 35531375 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Complications - [80]
Bethe A, Schink AK, Brombach J et al.. “Panton-Valentine Leukocidin-Positive Staphylococcus aureus in Family and Pet Cat.” Emerging infectious diseases (2024). PMID: 39043433 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [81]
Shoji K, Yoshida K, Takenouchi M et al.. “Skin Infections Caused by Panton-Valentine Leukocidin and Methicillin-Susceptible Staphylococcus aureus in Child, Japan.” Emerging infectious diseases (2025). PMID: 40439546 ↗
L4CASE_REPORTCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [82]
Dasenbrook EC, Checkley W, Merlo CA et al.. “Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.” JAMA (2010). PMID: 20551409 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Prognosis and Natural History, Special Hosts and Populations - [83]
Klevens RM, Morrison MA, Nadle J et al.. “Invasive methicillin-resistant Staphylococcus aureus infections in the United States.” JAMA (2007). PMID: 17940231 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [84]
Hogan S, O'Gara JP, O'Neill E. “Novel Treatment of Staphylococcus aureus Device-Related Infections Using Fibrinolytic Agents.” Antimicrobial agents and chemotherapy (2018). PMID: 29203484 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [85]
Hull RC, Wright RCT, Sayers JR et al.. “Antibiotics Limit Adaptation of Drug-Resistant Staphylococcus aureus to Hypoxia.” Antimicrobial agents and chemotherapy (2022). PMID: 36409116 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Prognosis and Natural History - [86]
Gehrke AE, Mendoza-Bertelli A, Ledo C et al.. “Neutralization of Staphylococcus aureus Protein A Prevents Exacerbated Osteoclast Activity and Bone Loss during Osteomyelitis.” Antimicrobial agents and chemotherapy (2022). PMID: 36533935 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors - [87]
Valour F, Trouillet-Assant S, Riffard N et al.. “Antimicrobial activity against intraosteoblastic Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2015). PMID: 25605365 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [88]
Ai Q, Wang S, Chen Z et al.. “Synergistic antibacterial activity and prevention of drug resistance of daptomycin combined with fosfomycin against methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 40530996 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [89]
Truong-Bolduc QC, Wang Y, Lawton BG et al.. “NorA and Tet38 efflux pumps enable Staphylococcus aureus survival in the cystic fibrosis airway environment, resistance to antibiotics, and coinfection with Pseudomonas aeruginosa.” Antimicrobial agents and chemotherapy (2025). PMID: 40631986 ↗
L5OTHERCited in: Definition, Classification and Causative Organisms, Prognosis and Natural History - [90]
Shah S, Clarke LG, Ludwig J et al.. “Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2024). PMID: 38946294 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Empiric Management, Acute Care and Source Control - [91]
Kihlberg P, Bech Johannesen T, Stegger M et al.. “Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2025). PMID: 40492523 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [92]
Goodman AL, Easom N, Bielopolski D et al.. “A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.” The Journal of antimicrobial chemotherapy (2026). PMID: 42396858 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [93]
Huang GJ, Chen ZQ, Long CQ et al.. “Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis.” Frontiers in immunology (2026). PMID: 42382746 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [94]
Berg DM, Binkley A, Foster SD et al.. “Clinical Microbiology in Xylazine-Associated Wound Infections.” Open forum infectious diseases (2025). PMID: 40799792 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [95]
Fabre V, Cosgrove SE, Hsu YJ et al.. “Multicenter Evaluation of Antibiotic Use and Antibiotic Stewardship Programs in Latin American Hospitals.” Open forum infectious diseases (2025). PMID: 40689250 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [96]
Alonso-Menchén D, Bouza E, Valerio M et al.. “Non-nosocomial Healthcare-Associated Infective Endocarditis: A Distinct Entity? Data From the GAMES Series (2008-2021).” Open forum infectious diseases (2023). PMID: 37564744 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms - [97]
Flurin L, Fisher CR, Wolf MJ et al.. “Comparison of Blood-Based Shotgun and Targeted Metagenomic Sequencing for Microbiological Diagnosis of Infective Endocarditis.” Open forum infectious diseases (2023). PMID: 38075017 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup - [98]
Kim DY, Kim UJ, Yu Y et al.. “Microbial Etiology of Pyogenic Vertebral Osteomyelitis According to Patient Characteristics.” Open forum infectious diseases (2020). PMID: 32523973 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Diagnosis and Workup - [99]
McCormick DW, Kaplan J, Whigham C et al.. “The Changing Epidemiology and Microbiology of Patients With Prostate Abscess: Increase in Staphylococcal Infection.” Open forum infectious diseases (2021). PMID: 34805434 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Clinical Presentation - [100]
Panesso D, Planet PJ, Diaz L et al.. “Methicillin-Susceptible, Vancomycin-Resistant Staphylococcus aureus, Brazil.” Emerging infectious diseases (2015). PMID: 26402569 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [101]
Boudebouch N, Sarih M, Chakib A et al.. “Blood Culture-Negative Endocarditis, Morocco.” Emerging infectious diseases (2017). PMID: 29048299 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Clinical Presentation, Diagnosis and Workup - [102]
Baum M, Anuka E, Davidovich-Cohen M et al.. “ST913-IVa-t991 Methicillin-Resistant Staphylococcus aureus among Pediatric Patients, Israel.” Emerging infectious diseases (2024). PMID: 39043440 ↗
L4OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [103]
Xu Q, Almudervar A, Casey JR et al.. “Nasopharyngeal bacterial interactions in children.” Emerging infectious diseases (2012). PMID: 23092680 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [104]
Williamson DA, Zhang J, Ritchie SR et al.. “Staphylococcus aureus infections in New Zealand, 2000-2011.” Emerging infectious diseases (2014). PMID: 24960446 ↗
L2OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [105]
LeBlanc L, Pépin J, Toulouse K et al.. “Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada.” Emerging infectious diseases (2006). PMID: 17073089 ↗
L3OTHERCited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [106]
Silva MJDR, Stephen AH, Dias E et al.. “Aortic Infections-A Narrative Review.” Surgical infections (2026). PMID: 42421298 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [107]
Busti A, Annoni G, Napoleone CP. “Endocarditis in Adults with Congenital Heart Disease.” Methodist DeBakey cardiovascular journal (2026). PMID: 42403547 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms, Epidemiology, Transmission and Risk Factors, Complications - [108]
Deng L, Ling X, Li L et al.. “Advances in Scalp Microbiome Research: Molecular Insights into the Metabolism-Inflammation-Barrier Axis and Dandruff Pathogenesis.” Molecules (Basel, Switzerland) (2026). PMID: 42357491 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [109]
Ramadani A, Marco G, Vazquez O et al.. “Osteoarticular Infections in Immunocompetent Children Due to Atypical, Fastidious or Unusual Bacterial Pathogens: A Review.” Pathogens (Basel, Switzerland) (2026). PMID: 42347261 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [110]
Karthikeyan A, Javaid A, Charway GNA et al.. “Prophages in Skin Pathogens: From Virulence to Therapy.” Pathogens (Basel, Switzerland) (2026). PMID: 42347211 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Causative Organisms - [111]
Shallcross LJ, Fragaszy E, Johnson AM et al.. “The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2012). PMID: 23103172 ↗
L1SR_OBSCited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Prognosis and Natural History - [112]
Deen J, von Seidlein L, Andersen F et al.. “Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review.” The Lancet. Infectious diseases (2012). PMID: 22632186 ↗
L2SR_OBSCited in: Microbiology and Pathogenesis, Diagnosis and Workup - [113]
Berger S, Kunerl A, Wasmuth S et al.. “Menstrual toxic shock syndrome: case report and systematic review of the literature.” The Lancet. Infectious diseases (2019). PMID: 31151811 ↗
L4SR_OBSCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Complications - [114]
Anpalagan K, Dotel R, MacFadden DR et al.. “Does Adjunctive Clindamycin Have a Role in Staphylococcus aureus Bacteremia? A Protocol for the Adjunctive Treatment Domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) Randomized Controlled Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38801783 ↗
L5TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis - [115]
Bart SM, Farley JJ, Bala S et al.. “Geographic Shifts in Antibacterial Drug Clinical Trial Enrollment: Implications for Generalizability.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32161946 ↗
L2TRIAL_NONRANDOMCited in: Microbiology and Pathogenesis - [116]
François B, Jafri HS, Chastre J et al.. “Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.” The Lancet. Infectious diseases (2021). PMID: 33894131 ↗
L1RCTCited in: Microbiology and Pathogenesis, History and Evolution of Treatment, Complications - [117]
Contou D, Colin G, Travert B et al.. “Menstrual Toxic Shock Syndrome: A French Nationwide Multicenter Retrospective Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 33906228 ↗
L3COHORTCited in: Microbiology and Pathogenesis, Severity Assessment and Risk Stratification, Special Hosts and Populations - [118]
Critchley IA, Eckburg PB, Jandourek A et al.. “Review of ceftaroline fosamil microbiology: integrated FOCUS studies.” The Journal of antimicrobial chemotherapy (2011). PMID: 21482569 ↗
L5RCTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [119]
Karlowsky JA, Steenbergen J, Zhanel GG. “Microbiology and Preclinical Review of Omadacycline.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 31367743 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [120]
Gordon RJ, Lowy FD. “Pathogenesis of methicillin-resistant Staphylococcus aureus infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18462090 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [121]
Appelbaum PC. “Microbiology of antibiotic resistance in Staphylococcus aureus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17712742 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [122]
Cameron DR, Howden BP, Peleg AY. “The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21865195 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [123]
Miller LG, Diep BA. “Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18220477 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [124]
Jones RN. “Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20597676 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [125]
Cho SY, Chung DR. “Infection Prevention Strategy in Hospitals in the Era of Community-Associated Methicillin-Resistant Staphylococcus aureus in the Asia-Pacific Region: A Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28475795 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Prevention and Infection Control - [126]
Campbell AJ, Dotel R, Blyth CC et al.. “Adjunctive protein synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections: a systematic appraisal.” The Journal of antimicrobial chemotherapy (2019). PMID: 30307507 ↗
L5SR_OBSCited in: Microbiology and Pathogenesis - [127]
Pham TM, Zhang Y, Nevers M et al.. “Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007-22).” The Lancet. Infectious diseases (2024). PMID: 39151443 ↗
L3COHORTCited in: Microbiology and Pathogenesis - [128]
Hidron AI, Low CE, Honig EG et al.. “Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia.” The Lancet. Infectious diseases (2009). PMID: 19467478 ↗
L5CASE_REPORTCited in: Microbiology and Pathogenesis, Clinical Presentation - [129]
Yaw LK, Robinson JO, Ho KM. “A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study.” The Lancet. Infectious diseases (2014). PMID: 25185461 ↗
L3COHORTCited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History - [130]
Sievert DM, Rudrik JT, Patel JB et al.. “Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18257700 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis, Prevention and Infection Control - [131]
Jiang J-H, Cameron DR, Nethercott C et al.. “Virulence attributes of successful methicillin-resistant Staphylococcus aureus lineages.” Clinical microbiology reviews (2023). PMID: 37982596 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [132]
Grousd JA, Rich HE, Alcorn JF. “Host-Pathogen Interactions in Gram-Positive Bacterial Pneumonia.” Clinical microbiology reviews (2019). PMID: 31142498 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [133]
Hodille E, Rose W, Diep BA et al.. “The Role of Antibiotics in Modulating Virulence in Staphylococcus aureus.” Clinical microbiology reviews (2017). PMID: 28724662 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [134]
Speziale P, Foster TJ, Arciola CR. “The endothelium at the interface between tissues and Staphylococcus aureus in the bloodstream.” Clinical microbiology reviews (2025). PMID: 39807893 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [135]
Spaulding AR, Salgado-Pabón W, Kohler PL et al.. “Staphylococcal and streptococcal superantigen exotoxins.” Clinical microbiology reviews (2013). PMID: 23824366 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Complications - [136]
Frank KL, Del Pozo JL, Patel R. “From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis.” Clinical microbiology reviews (2008). PMID: 18202439 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [137]
Heilbronner S, Foster TJ. “Staphylococcus lugdunensis: a Skin Commensal with Invasive Pathogenic Potential.” Clinical microbiology reviews (2020). PMID: 33361142 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Prognosis and Natural History - [138]
Kahl BC, Becker K, Löffler B. “Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.” Clinical microbiology reviews (2016). PMID: 26960941 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup - [139]
Trastoy R, Manso T, Fernández-García L et al.. “Mechanisms of Bacterial Tolerance and Persistence in the Gastrointestinal and Respiratory Environments.” Clinical microbiology reviews (2018). PMID: 30068737 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [140]
Baker MA, Sands KE, Huang SS et al.. “The Impact of Coronavirus Disease 2019 (COVID-19) on Healthcare-Associated Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34370014 ↗
L3OTHERCited in: Microbiology and Pathogenesis - [141]
Diep BA, Gill SR, Chang RF et al.. “Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus.” Lancet (London, England) (2006). PMID: 16517273 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [142]
Suh GA, Lodise TP, Tamma PD et al.. “Considerations for the Use of Phage Therapy in Clinical Practice.” Antimicrobial agents and chemotherapy (2022). PMID: 35041506 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Antimicrobial Resistance and Stewardship - [143]
Garcia LG, Lemaire S, Kahl BC et al.. “Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data.” The Journal of antimicrobial chemotherapy (2013). PMID: 23485724 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [144]
Moran GJ, Krishnadasan A, Gorwitz RJ et al.. “Methicillin-resistant S. aureus infections among patients in the emergency department.” The New England journal of medicine (2006). PMID: 16914702 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [145]
Köser CU, Holden MT, Ellington MJ et al.. “Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak.” The New England journal of medicine (2012). PMID: 22693998 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [146]
Schuler F, Barth PJ, Niemann S et al.. “A Narrative Review on the Role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia.” Open forum infectious diseases (2021). PMID: 34189162 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [147]
Corsini Campioli C, Go JR, Abu Saleh O et al.. “Antistaphylococcal Penicillin vs Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Spinal Epidural Abscesses.” Open forum infectious diseases (2021). PMID: 33738321 ↗
L3REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control - [148]
Chertow DS, Memoli MJ. “Bacterial coinfection in influenza: a grand rounds review.” JAMA (2013). PMID: 23321766 ↗
L5CASE_REPORTCited in: Microbiology and Pathogenesis, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [149]
Shah A, Romagnoli R, Dhingra N et al.. “Mediastinitis after cardiac surgery, from microbes to management: a systematic review.” Mediastinum (Hong Kong, China) (2026). PMID: 42427474 ↗
L2SR_OBSCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prognosis and Natural History, Prevention and Infection Control - [150]
Orhan Z, Doğan S, Mohamud SM et al.. “Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.” BMC infectious diseases (2026). PMID: 42410515 ↗
L4COHORTCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [151]
Joris G, Jozef D, Petra H et al.. “How stable are antimicrobial susceptibility profiles in serial clinical isolates? A retrospective study informing repeat-testing strategies.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42398659 ↗
L4COHORTCited in: Microbiology and Pathogenesis, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [152]
Palmer A, Carter M, Yeo J et al.. “Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study.” The Medical journal of Australia (2026). PMID: 42289398 ↗
L4COHORTCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Complications, Prognosis and Natural History - [153]
Diekema DJ, Hsueh PR, Mendes RE et al.. “The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program.” Antimicrobial agents and chemotherapy (2019). PMID: 31010862 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [154]
Boyd JM, Price EE, Roman Rodriguez F et al.. “Treatment of Staphylococcus aureus with environmentally relevant concentrations of triclosan activates SaeRS-dependent virulence factor expression.” Antimicrobial agents and chemotherapy (2025). PMID: 40531055 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [155]
Kwiecinski JM, Jelani DA, Fuentes EJ et al.. “Therapeutic Inhibition of Staphylococcus aureus ArlRS Two-Component Regulatory System Blocks Virulence.” Antimicrobial agents and chemotherapy (2022). PMID: 35736133 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [156]
Mahé A, Verneuil N, Coupri D et al.. “D-alanylation of lipoteichoic acids inhibitor provides anti-virulence and anti-resistance effects against methicillin-resistant Staphylococcus epidermidis.” Antimicrobial agents and chemotherapy (2025). PMID: 40116514 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [157]
McConville TH, Austin ED, Geng W et al.. “In Vitro Cytotoxicity and Clinical Correlates of MRSA Bacteremia.” Antimicrobial agents and chemotherapy (2021). PMID: 34748383 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup - [158]
Kong X, Wang B, Chen X et al.. “Hinokiflavone Attenuates the Virulence of Methicillin-Resistant Staphylococcus aureus by Targeting Caseinolytic Protease P.” Antimicrobial agents and chemotherapy (2022). PMID: 35862746 ↗
L5OTHERCited in: Microbiology and Pathogenesis, History and Evolution of Treatment - [159]
Daly SM, Elmore BO, Kavanaugh JS et al.. “ω-Hydroxyemodin limits staphylococcus aureus quorum sensing-mediated pathogenesis and inflammation.” Antimicrobial agents and chemotherapy (2015). PMID: 25645827 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [160]
Gomi S, Price E, Burgoyne H et al.. “Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia.” Antimicrobial agents and chemotherapy (2025). PMID: 40757816 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History - [161]
Luther MK, Parente DM, Caffrey AR et al.. “Clinical and Genetic Risk Factors for Biofilm-Forming Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2018). PMID: 29530854 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors - [162]
Khodaverdian V, Pesho M, Truitt B et al.. “Discovery of antivirulence agents against methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2013). PMID: 23689713 ↗
L5OTHERCited in: Microbiology and Pathogenesis, Prevention and Infection Control - [163]
Guillamet MCV, Vazquez R, Deaton B et al.. “Host-Pathogen-Treatment Triad: Host Factors Matter Most in Methicillin-Resistant Staphylococcus aureus Bacteremia Outcomes.” Antimicrobial agents and chemotherapy (2018). PMID: 29203479 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [164]
Xu W, Yan P, Li Y et al.. “The toxin-antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening.” The Journal of antimicrobial chemotherapy (2025). PMID: 40985144 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [165]
Koszczol C, Bernardo K, Krönke M et al.. “Subinhibitory quinupristin/dalfopristin attenuates virulence of Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2006). PMID: 16895938 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [166]
Deplano A, Hallin M, Bustos Sierra N et al.. “Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium.” The Journal of antimicrobial chemotherapy (2023). PMID: 37358399 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [167]
Gomez-Villegas SI, Rincon S, Carvajal LP et al.. “Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin America.” The Journal of antimicrobial chemotherapy (2025). PMID: 40126549 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [168]
Guo Y, Han R, Zhang G et al.. “Setting of the tentative epidemiological cut-off values of contezolid for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae and Streptococcus agalactiae.” The Journal of antimicrobial chemotherapy (2023). PMID: 36849586 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [169]
Deplano A, Dodémont M, Denis O et al.. “European external quality assessments for identification, molecular typing and characterization of Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2018). PMID: 30099486 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [170]
Pant N, Wallis SC, Roberts JA et al.. “In vitro effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation.” The Journal of antimicrobial chemotherapy (2022). PMID: 35045178 ↗
L5OTHERCited in: Microbiology and Pathogenesis - [171]
Kaneko H, Yanagi Y, Otake S et al.. “The emerging threat of methicillin-resistant Staphylococcus aureus (MRSA) clone ST22-PT, carrying both Panton-Valentine leucocidin and toxic shock syndrome toxin 1 genes.” The Journal of antimicrobial chemotherapy (2023). PMID: 36814074 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [172]
Hanawa T, Tanaka M, Nagano DS et al.. “Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy.” Frontiers in immunology (2026). PMID: 42367797 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [173]
Fairholm JD, Paul GT, Birket S et al.. “Microbial and host innate immune factors affecting the persistence of Staphylococcus aureus in cystic fibrosis airways.” Frontiers in cellular and infection microbiology (2026). PMID: 42318016 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History - [174]
Ge Y, Wang Y, He X et al.. “Comprehensive management of hemodialysis catheter-related bloodstream infections: a narrative review.” Frontiers in cellular and infection microbiology (2026). PMID: 42312032 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors - [175]
de Waha S, Noack T, Kister T et al.. “Tricuspid valve endocarditis in people who inject drugs: strategies to reduce mortality and recurrent infection.” Annals of cardiothoracic surgery (2026). PMID: 42292592 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis, Clinical Presentation - [176]
Calvão J, Iselin C, Wasmayr J et al.. “Pathogenesis of cutaneous T-cell lymphoma: Malignant inflammation, immune reprogramming, and microenvironmental drivers.” The Journal of investigative dermatology (2026). PMID: 42274451 ↗
L5REVIEW_NARRATIVECited in: Microbiology and Pathogenesis - [177]
Musgrove MA, Kenney RM, Kendall RE et al.. “Microbiology Comment Nudge Improves Pneumonia Prescribing.” Open forum infectious diseases (2018). PMID: 30057928 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [178]
Hindy JR, Quintero-Martinez JA, Lahr BD et al.. “Incidence of Monomicrobial Staphylococcus aureus Bacteremia: A Population-Based Study in Olmsted County, Minnesota-2006 to 2020.” Open forum infectious diseases (2022). PMID: 35794939 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Epidemiology, Transmission and Risk Factors - [179]
Go JR, Challener D, Corsini Campioli C et al.. “Clinical Significance of Staphylococcus aureus in a Single Positive Blood Culture Bottle.” Open forum infectious diseases (2021). PMID: 35071685 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Diagnosis and Workup, Severity Assessment and Risk Stratification, Prognosis and Natural History - [180]
Kim JJ, Kang H, Stewart KO. “The Effect of Retained Hardware on Failure Among Prosthetic Joint Infections of the Knee in the Presence and Absence of Staphylococcus aureus.” Open forum infectious diseases (2024). PMID: 38919513 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [181]
Pralea A, Has P, Auld D et al.. “Microbes Causing Spinal Epidural Infection in Patients Who Use Drugs.” Open forum infectious diseases (2024). PMID: 39416991 ↗
L4OTHERCited in: Microbiology and Pathogenesis, History and Evolution of Treatment - [182]
Khamash DF, Mongodin EF, White JR et al.. “The Association Between the Developing Nasal Microbiota of Hospitalized Neonates and Staphylococcus aureus Colonization.” Open forum infectious diseases (2019). PMID: 30949531 ↗
L3OTHERCited in: Microbiology and Pathogenesis - [183]
Muñoz-Gallego I, Viedma E, Esteban J et al.. “Genotypic and Phenotypic Characteristics of Staphylococcus aureus Prosthetic Joint Infections: Insight on the Pathogenesis and Prognosis of a Multicenter Prospective Cohort.” Open forum infectious diseases (2020). PMID: 33005695 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Clinical Presentation, Severity Assessment and Risk Stratification - [184]
Simmons SC, Budavari AI, Kusne S et al.. “Culture-Proven Thorn-Associated Infections in Arizona: 10-Year Experience at Mayo Clinic.” Open forum infectious diseases (2017). PMID: 28480288 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [185]
Sieber RN, Urth TR, Petersen A et al.. “Phage-Mediated Immune Evasion and Transmission of Livestock-Associated Methicillin-Resistant Staphylococcus aureus in Humans.” Emerging infectious diseases (2020). PMID: 33079052 ↗
L2OTHERCited in: Microbiology and Pathogenesis, Special Hosts and Populations - [186]
Coombs GW, Pang S, Daley DA et al.. “Severe Disease Caused by Community-Associated MRSA ST398 Type V, Australia, 2017.” Emerging infectious diseases (2019). PMID: 30561308 ↗
L4OTHERCited in: Microbiology and Pathogenesis, Prognosis and Natural History - [187]
Coombs GW, Pearson JC, O'Brien FG et al.. “Methicillin-resistant Staphylococcus aureus clones, Western Australia.” Emerging infectious diseases (2006). PMID: 16494749 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [188]
Sharma H, Smith D, Turner CE et al.. “Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom.” Emerging infectious diseases (2018). PMID: 29350159 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [189]
Sun L, Chen Y, Wang D et al.. “Surgical Site Infections Caused by Highly Virulent Methicillin-Resistant Staphylococcus aureus Sequence Type 398, China.” Emerging infectious diseases (2019). PMID: 30561317 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [190]
Tristan A, Bes M, Meugnier H et al.. “Global distribution of Panton-Valentine leukocidin--positive methicillin-resistant Staphylococcus aureus, 2006.” Emerging infectious diseases (2007). PMID: 17553275 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [191]
Kajumbula H, Fujita AW, Mbabazi O et al.. “Antimicrobial Drug Resistance in Blood Culture Isolates at a Tertiary Hospital, Uganda.” Emerging infectious diseases (2018). PMID: 29260682 ↗
L2OTHERCited in: Microbiology and Pathogenesis - [192]
Hageman JC, Uyeki TM, Francis JS et al.. “Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season.” Emerging infectious diseases (2006). PMID: 16707043 ↗
L4OTHERCited in: Microbiology and Pathogenesis - [193]
Ferdinands JM, Denison AM, Dowling NF et al.. “A pilot study of host genetic variants associated with influenza-associated deaths among children and young adults.” Emerging infectious diseases (2011). PMID: 22172537 ↗
L3OTHERCited in: Microbiology and Pathogenesis, Complications, Prognosis and Natural History - [194]
Hutchinson K, Banks J, Arnold A et al.. “Orthoplastic management of delayed sternal osteomyelitis and non-union: a retrospective case series applying fracture-related infection principles.” International orthopaedics (2026). PMID: 42329262 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [195]
Shi L, Ruan Y, Wang X et al.. “First fatal human bloodstream infection caused by Macrococcus caseolyticus subsp. caseolyticus in China: genomic insights into virulence and antimicrobial resistance.” Frontiers in cellular and infection microbiology (2026). PMID: 42306534 ↗
L4CASE_REPORTCited in: Microbiology and Pathogenesis - [196]
Baur D, Gladstone BP, Burkert F et al.. “Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2017). PMID: 28629876 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [197]
Tacconelli E, De Angelis G, de Waure C et al.. “Rapid screening tests for meticillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis.” The Lancet. Infectious diseases (2009). PMID: 19695491 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [198]
Nellums LB, Thompson H, Holmes A et al.. “Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2018). PMID: 29779917 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [199]
Strömdahl M, Hagman K, Hedman K et al.. “Time to Staphylococcus aureus Blood Culture Positivity as a Risk Marker of Infective Endocarditis: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39707905 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [200]
Shappell CN, Yu T, Klompas M et al.. “Frequency of Antibiotic Overtreatment and Associated Harms in Patients Presenting With Suspected Sepsis to the Emergency Department: A Retrospective Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40231968 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Prognosis and Natural History - [201]
Huang SS, Singh R, McKinnell JA et al.. “Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers.” The New England journal of medicine (2019). PMID: 30763195 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History, Prevention and Infection Control - [202]
Peel TN, Astbury S, Cheng AC et al.. “Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty.” The New England journal of medicine (2023). PMID: 37851875 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Prevention and Infection Control - [203]
Huskins WC, Huckabee CM, O'Grady NP et al.. “Intervention to reduce transmission of resistant bacteria in intensive care.” The New England journal of medicine (2011). PMID: 21488763 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [204]
. “A randomized trial of diagnostic techniques for ventilator-associated pneumonia.” The New England journal of medicine (2006). PMID: 17182987 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup - [205]
Allegranzi B, Bagheri Nejad S, Combescure C et al.. “Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis.” Lancet (London, England) (2010). PMID: 21146207 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [206]
Minter DJ, Appa A, Chambers HF et al.. “Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37950887 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [207]
Boucher HW, Corey GR. “Epidemiology of methicillin-resistant Staphylococcus aureus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18462089 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [208]
Saravolatz LD, Stein GE. “Oritavancin: A Long-Half-Life Lipoglycopeptide.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 25900171 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Complications - [209]
Dinh A, Ropers J, Duran C et al.. “Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.” Lancet (London, England) (2021). PMID: 33773631 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Special Hosts and Populations - [210]
Huang SS, Septimus E, Kleinman K et al.. “Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial.” Lancet (London, England) (2019). PMID: 30850112 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prognosis and Natural History, Prevention and Infection Control - [211]
Kalra L, Irshad S, Hodsoll J et al.. “Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial.” Lancet (London, England) (2015). PMID: 26343840 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications, Prognosis and Natural History, Prevention and Infection Control - [212]
Kalil AC, Van Schooneveld TC, Fey PD et al.. “Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis.” JAMA (2014). PMID: 25321910 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [213]
Cai Y, Wang R, Liang B et al.. “Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.” Antimicrobial agents and chemotherapy (2010). PMID: 21173186 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Complications - [214]
van Hal SJ, Paterson DL. “Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.” Antimicrobial agents and chemotherapy (2010). PMID: 21078939 ↗
L1SR_OBSCited in: Epidemiology, Transmission and Risk Factors - [215]
Hurley JC. “The perfidious effect of topical placebo: calibration of Staphylococcus aureus ventilator-associated pneumonia incidence within selective digestive decontamination studies versus the broader evidence base.” Antimicrobial agents and chemotherapy (2013). PMID: 23836178 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors - [216]
Heizmann WR, Dupont H, Montravers P et al.. “Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.” The Journal of antimicrobial chemotherapy (2013). PMID: 23772046 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors - [217]
Milstone AM, Voskertchian A, Koontz DW et al.. “Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial.” JAMA (2020). PMID: 31886828 ↗
L1RCTCited in: Epidemiology, Transmission and Risk Factors, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prevention and Infection Control - [218]
Ciapponi A, Bardach A, Sandoval MM et al.. “Systematic Review and Meta-analysis of Deaths Attributable to Antimicrobial Resistance, Latin America.” Emerging infectious diseases (2023). PMID: 37877573 ↗
L2SR_OBSCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [219]
Chuang YY, Huang YC. “Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Asia.” The Lancet. Infectious diseases (2013). PMID: 23827369 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors - [220]
Albrich WC, Harbarth S. “Health-care workers: source, vector, or victim of MRSA?” The Lancet. Infectious diseases (2008). PMID: 18471774 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors - [221]
Otter JA, French GL. “Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe.” The Lancet. Infectious diseases (2010). PMID: 20334846 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup - [222]
Bush K, Bradford PA. “Epidemiology of β-Lactamase-Producing Pathogens.” Clinical microbiology reviews (2020). PMID: 32102899 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [223]
Sauvat L, Verhoeven PO, Gagnaire J et al.. “Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections.” Clinical microbiology reviews (2024). PMID: 39120140 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [224]
Galar A, Weil AA, Dudzinski DM et al.. “Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management.” Clinical microbiology reviews (2019). PMID: 30760474 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [225]
Park S, Ronholm J. “Staphylococcus aureus in Agriculture: Lessons in Evolution from a Multispecies Pathogen.” Clinical microbiology reviews (2021). PMID: 33568553 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment - [226]
Swets MC, Bakk Z, Westgeest AC et al.. “Clinical Subphenotypes of Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38916975 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [227]
Kam KQ, Chen T, Kadri SS et al.. “Epidemiology and Outcomes of Antibiotic De-escalation in Patients With Suspected Sepsis in US Hospitals.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39657050 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [228]
. “Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study.” Lancet (London, England) (2019). PMID: 31257127 ↗
L3CASE_CONTROLCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Special Hosts and Populations - [229]
Bengtsen KH, Falkentoft AC, Le MV et al.. “Incidence of Staphylococcus aureus Bacteremia in Patients Following Implantation of Cardiac Implantable Electronic Devices: A Danish Nationwide Cohort Study.” Open forum infectious diseases (2024). PMID: 39329108 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors - [230]
Wang A, Gaca JG, Chu VH. “Management Considerations in Infective Endocarditis: A Review.” JAMA (2018). PMID: 29971402 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prognosis and Natural History, Prevention and Infection Control - [231]
Hawkey PM, Jones AM. “The changing epidemiology of resistance.” The Journal of antimicrobial chemotherapy (2009). PMID: 19675017 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [232]
Gouliouris T, Aliyu SH, Brown NM. “Spondylodiscitis: update on diagnosis and management.” The Journal of antimicrobial chemotherapy (2010). PMID: 20876624 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Empiric Management, Acute Care and Source Control - [233]
Gu B, Kelesidis T, Tsiodras S et al.. “The emerging problem of linezolid-resistant Staphylococcus.” The Journal of antimicrobial chemotherapy (2012). PMID: 22949625 ↗
L4REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Antimicrobial Resistance and Stewardship - [234]
Ramirez JA, Anzueto AR. “Changing needs of community-acquired pneumonia.” The Journal of antimicrobial chemotherapy (2011). PMID: 21482567 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors, Clinical Presentation, Prognosis and Natural History - [235]
Garcia-Alvarez L, Dawson S, Cookson B et al.. “Working across the veterinary and human health sectors.” The Journal of antimicrobial chemotherapy (2012). PMID: 22855878 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors - [236]
Daneman N, Rishu A, Pinto R et al.. “Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections.” The New England journal of medicine (2024). PMID: 39565030 ↗
L1OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [237]
Jernigan JA, Hatfield KM, Wolford H et al.. “Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.” The New England journal of medicine (2020). PMID: 32242356 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [238]
Wang Y, Chen G, Zhai N et al.. “Risk factors for 28-day mortality and pathogen characteristics of septic shock in children: a 10-year retrospective cohort study.” Frontiers in cellular and infection microbiology (2026). PMID: 42256218 ↗
L2COHORTCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification, Special Hosts and Populations - [239]
Landrum ML, Neumann C, Cook C et al.. “Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010.” JAMA (2012). PMID: 22760291 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [240]
Bae S, Kim ES, Kim HS et al.. “Risk Factors of Recurrent Infection in Patients with Staphylococcus aureus Bacteremia: a Competing Risk Analysis.” Antimicrobial agents and chemotherapy (2022). PMID: 35762799 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Severity Assessment and Risk Stratification - [241]
Rhodes NJ, Rohani R, Yarnold PR et al.. “Machine Learning To Stratify Methicillin-Resistant Staphylococcus aureus Risk among Hospitalized Patients with Community-Acquired Pneumonia.” Antimicrobial agents and chemotherapy (2022). PMID: 36472425 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors - [242]
Svishchuk J, Ebbert K, Waddell B et al.. “Epidemiology and impact of methicillin-sensitive Staphylococcus aureus with β-lactam antibiotic inoculum effects in adults with cystic fibrosis.” Antimicrobial agents and chemotherapy (2023). PMID: 37966229 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [243]
Gross AE, Van Schooneveld TC, Olsen KM et al.. “Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.” Antimicrobial agents and chemotherapy (2014). PMID: 24957843 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [244]
Bae S, Kook MS, Chang E et al.. “Risk and Distribution of Metastatic Infections by Primary Infection Focus in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2025). PMID: 40568004 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [245]
Biggs HM, Li R, Jackson KA et al.. “Trends in Incidence and Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia, Six Emerging Infections Program Surveillance Sites, 2005-2022.” Open forum infectious diseases (2025). PMID: 40453873 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup - [246]
Warren DK, Nickel KB, Wallace AE et al.. “Risk Factors for Surgical Site Infection After Cholecystectomy.” Open forum infectious diseases (2017). PMID: 28491887 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [247]
Kim T, Huh JW, Hong SB et al.. “Epidemiology and Characteristics of Respiratory Syncytial Virus Pneumonia in Critically Ill Adults.” Open forum infectious diseases (2023). PMID: 37035491 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors - [248]
Blauw M, Foxman B, Wu J et al.. “Risk Factors and Outcomes Associated With Hospital-Onset Peripheral Intravenous Catheter-Associated Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 30949543 ↗
L3OTHERCited in: Epidemiology, Transmission and Risk Factors - [249]
Neofytos D, Stampf S, Hoessly LD et al.. “Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update.” Open forum infectious diseases (2023). PMID: 37323422 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Diagnosis and Workup, Prevention and Infection Control - [250]
Molina KC, Lunowa C, Lebin M et al.. “Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections.” Open forum infectious diseases (2022). PMID: 35899276 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, Empiric Management, Acute Care and Source Control - [251]
Stenhem M, Ortqvist A, Ringberg H et al.. “Imported methicillin-resistant Staphylococcus aureus, Sweden.” Emerging infectious diseases (2010). PMID: 20113546 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors, Special Hosts and Populations - [252]
Thorlacius-Ussing L, Sandholdt H, Larsen AR et al.. “Age-Dependent Increase in Incidence of Staphylococcus aureus Bacteremia, Denmark, 2008-2015.” Emerging infectious diseases (2019). PMID: 31002300 ↗
L2OTHERCited in: Epidemiology, Transmission and Risk Factors, History and Evolution of Treatment, Special Hosts and Populations - [253]
Torres Valenzuela LM, Garza-Leon M, Beltran F et al.. “Trends in pathogens causing microbial keratitis in studies conducted in Mexico: a 38-year literature review.” International ophthalmology (2026). PMID: 42319559 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Transmission and Risk Factors - [254]
Akasha R, Binsaleh NK, Abdalla RAH et al.. “Infectious disease outcomes in end-stage renal disease: the influence of dialysis type on patient vulnerability in Hail region.” Frontiers in medicine (2026). PMID: 42428264 ↗
L4OTHERCited in: Epidemiology, Transmission and Risk Factors - [255]
Berbari EF, Kanj SS, Kowalski TJ et al.. “2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26229122 ↗
L1GUIDELINECited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment - [256]
Kaasch AJ, López-Cortés LE, Rodríguez-Baño J et al.. “Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.” The Lancet. Infectious diseases (2024). PMID: 38244557 ↗
L1RCTCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [257]
Derde LPG, Cooper BS, Goossens H et al.. “Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial.” The Lancet. Infectious diseases (2013). PMID: 24161233 ↗
L1RCTCited in: Clinical Presentation, History and Evolution of Treatment, Prevention and Infection Control - [258]
Buehler SS, Madison B, Snyder SR et al.. “Effectiveness of Practices To Increase Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis.” Clinical microbiology reviews (2016). PMID: 26598385 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [259]
Rubinstein E, Kollef MH, Nathwani D. “Pneumonia caused by methicillin-resistant Staphylococcus aureus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18462093 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [260]
Aliberti S, Reyes LF, Faverio P et al.. “Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study.” The Lancet. Infectious diseases (2016). PMID: 27593581 ↗
L2COHORTCited in: Clinical Presentation, Diagnosis and Workup - [261]
Crum-Cianflone NF. “Bacterial, fungal, parasitic, and viral myositis.” Clinical microbiology reviews (2008). PMID: 18625683 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, History and Evolution of Treatment - [262]
van Hal SJ, Jensen SO, Vaska VL et al.. “Predictors of mortality in Staphylococcus aureus Bacteremia.” Clinical microbiology reviews (2012). PMID: 22491776 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [263]
Mergenhagen KA, Starr KE, Wattengel BA et al.. “Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31573026 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [264]
Lamloumi M, Javerliat I, Duran C et al.. “Characteristics and Risk Factors for Mortality of Vascular Graft Infections: a Cohort Study.” Open forum infectious diseases (2026). PMID: 42415734 ↗
L2COHORTCited in: Clinical Presentation, Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [265]
Dufour S, Piroth L, Chirouze C et al.. “Staphylococcus aureus Bloodstream Infection in Patients With Prosthetic Joints in the Prospective VIRSTA Cohort Study: Frequency and Time of Occurrence of Periprosthetic Joint Infection.” Open forum infectious diseases (2019). PMID: 31890721 ↗
L2COHORTCited in: Clinical Presentation - [266]
Shenoy ES, Macy E, Rowe T et al.. “Evaluation and Management of Penicillin Allergy: A Review.” JAMA (2019). PMID: 30644987 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications - [267]
Holland TL, Arnold C, Fowler VG. “Clinical management of Staphylococcus aureus bacteremia: a review.” JAMA (2014). PMID: 25268440 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [268]
Gould IM. “Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2011). PMID: 21521703 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [269]
Nissen JL, Skov R, Knudsen JD et al.. “Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis.” The Journal of antimicrobial chemotherapy (2013). PMID: 23599360 ↗
L2CASE_CONTROLCited in: Clinical Presentation - [270]
Duss FR, Garcia de la Mària C, Croxatto A et al.. “Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report.” The Journal of antimicrobial chemotherapy (2019). PMID: 31298264 ↗
L4CASE_REPORTCited in: Clinical Presentation - [271]
Takayama A, Meguro K, Yokota M et al.. “Atypical X-linked agammaglobulinemia diagnosed in adulthood with arthritis caused by a hypomorphic BTK splice-site variant: a case report and literature review.” Frontiers in immunology (2026). PMID: 42253969 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment, Complications - [272]
Duployez C, Le Guern R, Tinez C et al.. “Panton-Valentine Leukocidin-Secreting Staphylococcus aureus Pneumonia Complicating COVID-19.” Emerging infectious diseases (2020). PMID: 32298228 ↗
L4CASE_REPORTCited in: Clinical Presentation, Complications - [273]
Jewell P, Dixon L, Singanayagam A et al.. “Severe Disseminated Infection with Emerging Lineage of Methicillin-Sensitive Staphylococcus aureus.” Emerging infectious diseases (2019). PMID: 30561304 ↗
L4CASE_REPORTCited in: Clinical Presentation - [274]
Rigaill J, Grattard F, Grange S et al.. “Community-Acquired Staphylococcus argenteus Sequence Type 2250 Bone and Joint Infection, France, 2017.” Emerging infectious diseases (2018). PMID: 30226182 ↗
L4CASE_REPORTCited in: Clinical Presentation - [275]
Bergevin M, Marion A, Farber D et al.. “Severe MRSA Enterocolitis Caused by a Strain Harboring Enterotoxins D, G, and I.” Emerging infectious diseases (2017). PMID: 28418301 ↗
L4CASE_REPORTCited in: Clinical Presentation - [276]
Oh JT, Ambler JE, Cassino C et al.. “Development of a Broth Microdilution Method for Exebacase Susceptibility Testing.” Antimicrobial agents and chemotherapy (2021). PMID: 33903102 ↗
L5OTHERCited in: Clinical Presentation - [277]
Casapao AM, Leonard SN, Davis SL et al.. “Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection.” Antimicrobial agents and chemotherapy (2013). PMID: 23796929 ↗
L3OTHERCited in: Clinical Presentation - [278]
Herren SC, Huemer M, Acevedo CT et al.. “Assessing Antibiotic Tolerance of Staphylococcus aureus Derived Directly from Patients by the Replica Plating Tolerance Isolation System (REPTIS).” Antimicrobial agents and chemotherapy (2021). PMID: 34694884 ↗
L4OTHERCited in: Clinical Presentation - [279]
McNeil JC, Sommer LM, Vallejo JG et al.. “Going Back in Time: Increasing Penicillin Susceptibility among Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children.” Antimicrobial agents and chemotherapy (2023). PMID: 36598265 ↗
L2OTHERCited in: Clinical Presentation, Special Hosts and Populations - [280]
Claeys KC, Smith JR, Casapao AM et al.. “Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.” Antimicrobial agents and chemotherapy (2015). PMID: 25605354 ↗
L3OTHERCited in: Clinical Presentation - [281]
Bayer AS, Mishra NN, Chen L et al.. “Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides.” Antimicrobial agents and chemotherapy (2015). PMID: 26055370 ↗
L4OTHERCited in: Clinical Presentation - [282]
Dangerfield B, Chung A, Webb B et al.. “Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia.” Antimicrobial agents and chemotherapy (2013). PMID: 24277023 ↗
L3OTHERCited in: Clinical Presentation - [283]
Baxi SM, Clemenzi-Allen A, Gahbauer A et al.. “Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.” Antimicrobial agents and chemotherapy (2016). PMID: 27324762 ↗
L2OTHERCited in: Clinical Presentation - [284]
Casapao AM, Davis SL, Barr VO et al.. “Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.” Antimicrobial agents and chemotherapy (2014). PMID: 24550331 ↗
L4OTHERCited in: Clinical Presentation - [285]
San Juan R, Garcia-Reyne A, Caba P et al.. “Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections.” Antimicrobial agents and chemotherapy (2010). PMID: 20855727 ↗
L4OTHERCited in: Clinical Presentation - [286]
Britt NS, Patel N, Shireman TI et al.. “Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2016). PMID: 27999028 ↗
L3OTHERCited in: Clinical Presentation - [287]
Vindel A, Trincado P, Cuevas O et al.. “Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in Spain: 2004-12.” The Journal of antimicrobial chemotherapy (2014). PMID: 24990868 ↗
L2OTHERCited in: Clinical Presentation, Special Hosts and Populations - [288]
Joseph JP, Meddows TR, Webster DP et al.. “Prioritizing echocardiography in Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2012). PMID: 23111851 ↗
L3OTHERCited in: Clinical Presentation - [289]
Van Besien RF, Vazquez Guillamet MC. “The Evolving Etiology of Hospital-Acquired and Ventilator-Associated Pneumonia.” Clinics in chest medicine (2026). PMID: 42203422 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [290]
Comune M, Furnari I, Silvestro E et al.. “Neonatal Osteomyelitis Caused by Staphylococcus aureus: Case Series and Review of the Literature.” Children (Basel, Switzerland) (2026). PMID: 42353950 ↗
L4CASE_REPORTCited in: Clinical Presentation, Complications - [291]
Webb G, Choi J, Younes A et al.. “Comparing clinical manifestations, treatment strategies and outcomes of Staphylococcus lugdunensis bacteraemia versus Staphylococcus aureus bacteraemia - a retrospective cohort study.” Internal medicine journal (2026). PMID: 42250238 ↗
L3COHORTCited in: Clinical Presentation - [292]
Soti Khiabani M, Talari SM, Khodabandeh M. “Ten-Year Epidemiology and Antimicrobial Susceptibility of Pediatric Staphylococcal Scalded Skin Syndrome: A Retrospective Study From a Tertiary Referral Center.” Pediatric dermatology (2026). PMID: 42219159 ↗
L4COHORTCited in: Clinical Presentation - [293]
Ali MN, Gahnug M, Jama AA et al.. “Septic pulmonary embolism in Somali children: a retrospective study from a tertiary hospital.” Frontiers in pediatrics (2026). PMID: 42212102 ↗
L4COHORTCited in: Clinical Presentation - [294]
Schulz SH, Dally FJ, Vogel J et al.. “Whole-Spine MRI Reveals High Prevalence of Multifocal Spondylodiscitis and Identifies a High-Risk Subgroup: A Retrospective Cohort Study of 274 Patients.” Medicina (Kaunas, Lithuania) (2026). PMID: 42195242 ↗
L3COHORTCited in: Clinical Presentation - [295]
Campbell S, MacGregor K, Smith EL et al.. “Clinical Presentation and Outcomes Following Infection With Vibrio spp, Aeromonas spp, Chromobacterium violaceum, and Shewanella spp Water-Associated Organisms in Tropical Australia, 2015-2022.” Open forum infectious diseases (2024). PMID: 38975250 ↗
L3OTHERCited in: Clinical Presentation - [296]
Whittington KJ, Malone SM, Hogan PG et al.. “Staphylococcus aureus Bacteremia in Pediatric Patients: Uncovering a Rural Health Challenge.” Open forum infectious diseases (2023). PMID: 37469617 ↗
L3OTHERCited in: Clinical Presentation, Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [297]
An TJ, Benvenuti MA, Mignemi ME et al.. “Similar Clinical Severity and Outcomes for Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Pediatric Musculoskeletal Infections.” Open forum infectious diseases (2017). PMID: 28480284 ↗
L3OTHERCited in: Clinical Presentation - [298]
Wilson Dib R, Chaftari AM, Hachem RY et al.. “Catheter-Related Staphylococcus aureus Bacteremia and Septic Thrombosis: The Role of Anticoagulation Therapy and Duration of Intravenous Antibiotic Therapy.” Open forum infectious diseases (2018). PMID: 30377625 ↗
L3OTHERCited in: Clinical Presentation, History and Evolution of Treatment - [299]
Bodavula P, Liang SY, Wu J et al.. “Pressure Ulcer-Related Pelvic Osteomyelitis: A Neglected Disease?” Open forum infectious diseases (2015). PMID: 26322317 ↗
L3OTHERCited in: Clinical Presentation - [300]
Meier R, Wirth T, Hahn F et al.. “Pyogenic Arthritis of the Fingers and the Wrist: Can We Shorten Antimicrobial Treatment Duration?” Open forum infectious diseases (2017). PMID: 28491895 ↗
L4OTHERCited in: Clinical Presentation, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [301]
Sinnar SA, Schiff SJ. “The Problem of Microbial Dark Matter in Neonatal Sepsis.” Emerging infectious diseases (2020). PMID: 33080169 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [302]
Bordeau V, Cady A, Revest M et al.. “Staphylococcus aureus Regulatory RNAs as Potential Biomarkers for Bloodstream Infections.” Emerging infectious diseases (2016). PMID: 27224202 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis and Workup - [303]
Prinz JC, Stadler PC. “Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma - GASD syndrome by TNF antagonists.” Frontiers in immunology (2026). PMID: 42344923 ↗
L4CASE_REPORTCited in: Clinical Presentation, Severity Assessment and Risk Stratification, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [304]
Okomo U, Akpalu ENK, Le Doare K et al.. “Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines.” The Lancet. Infectious diseases (2019). PMID: 31522858 ↗
L1SR_OBSCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [305]
Mork RL, Hogan PG, Muenks CE et al.. “Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infection: a prospective cohort study.” The Lancet. Infectious diseases (2019). PMID: 31784369 ↗
L2COHORTCited in: Diagnosis and Workup - [306]
Patel JB, Gorwitz RJ, Jernigan JA. “Mupirocin resistance.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19673644 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [307]
McDanel JS, Perencevich EN, Diekema DJ et al.. “Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 25900170 ↗
L2OTHERCited in: Diagnosis and Workup - [308]
Kadri SS, Lai YL, Warner S et al.. “Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.” The Lancet. Infectious diseases (2020). PMID: 32916100 ↗
L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [309]
den Heijer CD, van Bijnen EM, Paget WJ et al.. “Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S aureus, in nine European countries: a cross-sectional study.” The Lancet. Infectious diseases (2013). PMID: 23473661 ↗
L4OTHERCited in: Diagnosis and Workup, Special Hosts and Populations - [310]
García-Álvarez L, Holden MT, Lindsay H et al.. “Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study.” The Lancet. Infectious diseases (2011). PMID: 21641281 ↗
L4OTHERCited in: Diagnosis and Workup - [311]
Humphries RM, Pollett S, Sakoulas G. “A current perspective on daptomycin for the clinical microbiologist.” Clinical microbiology reviews (2013). PMID: 24092854 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [312]
Perry JD. “A Decade of Development of Chromogenic Culture Media for Clinical Microbiology in an Era of Molecular Diagnostics.” Clinical microbiology reviews (2017). PMID: 28122803 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [313]
Laupland KB, Church DL. “Population-based epidemiology and microbiology of community-onset bloodstream infections.” Clinical microbiology reviews (2014). PMID: 25278570 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [314]
Jain R, Kralovic SM, Evans ME et al.. “Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections.” The New England journal of medicine (2011). PMID: 21488764 ↗
L2OTHERCited in: Diagnosis and Workup, Prevention and Infection Control - [315]
Turner NA, Hamasaki T, Doernberg SB et al.. “Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.” JAMA (2025). PMID: 40802264 ↗
L1OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Complications, Prognosis and Natural History - [316]
Kallen AJ, Mu Y, Bulens S et al.. “Health care-associated invasive MRSA infections, 2005-2008.” JAMA (2010). PMID: 20699455 ↗
L2OTHERCited in: Diagnosis and Workup, Prevention and Infection Control, Special Hosts and Populations - [317]
Saravolatz SN, Martin H, Pawlak J et al.. “Ceftaroline-heteroresistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2014). PMID: 24637680 ↗
L5OTHERCited in: Diagnosis and Workup - [318]
Suzuki Y, Kawada-Matsuo M, Thuan VTT et al.. “D-alanine synthesis and exogenous alanine affect the antimicrobial susceptibility of Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 40503952 ↗
L5OTHERCited in: Diagnosis and Workup - [319]
Chan LC, Basuino L, Diep B et al.. “Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2015). PMID: 25753637 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [320]
Ma D, Arya R, Knapick BA et al.. “Methicillin-resistant Staphylococcus aureus has phenotypic variation in mecA expression that alters antibiotic sensitivity.” Antimicrobial agents and chemotherapy (2026). PMID: 41677252 ↗
L5OTHERCited in: Diagnosis and Workup - [321]
Karau MJ, Schmidt-Malan SM, Cunningham SA et al.. “Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.” Antimicrobial agents and chemotherapy (2021). PMID: 34723626 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [322]
Truong-Bolduc QC, Wang Y, Reedy JL et al.. “Staphylococcus aureus Efflux Pumps and Tolerance to Ciprofloxacin and Chlorhexidine following Induction by Mupirocin.” Antimicrobial agents and chemotherapy (2021). PMID: 34930023 ↗
L5OTHERCited in: Diagnosis and Workup - [323]
Bortolaia V, Kaas RS, Ruppe E et al.. “ResFinder 4.0 for predictions of phenotypes from genotypes.” The Journal of antimicrobial chemotherapy (2020). PMID: 32780112 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [324]
Lenhard JR, Bulman ZP. “Inoculum effect of β-lactam antibiotics.” The Journal of antimicrobial chemotherapy (2019). PMID: 31170287 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [325]
Rudilla H, Pérez-Guillén I, Rabanal F et al.. “Novel synthetic polymyxins kill Gram-positive bacteria.” The Journal of antimicrobial chemotherapy (2018). PMID: 30215733 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [326]
Turner NA, Xu A, Zaharoff S et al.. “Determination of plasma protein binding of dalbavancin.” The Journal of antimicrobial chemotherapy (2022). PMID: 35488862 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [327]
Holland M, Bjanes E, Nizet V et al.. “Bicarbonate modulates delafloxacin activity against MDR Staphylococcus aureus and Pseudomonas aeruginosa.” The Journal of antimicrobial chemotherapy (2022). PMID: 34893834 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [328]
Kaul G, Akhir A, Shukla M et al.. “Nitazoxanide potentiates linezolid against linezolid-resistant Staphylococcus aureus in vitro and in vivo.” The Journal of antimicrobial chemotherapy (2022). PMID: 35748613 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [329]
Hawkey PM. “Pre-clinical experience with daptomycin.” The Journal of antimicrobial chemotherapy (2008). PMID: 18829726 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [330]
Jin Y, Zhou W, Chen W et al.. “Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections.” The Journal of antimicrobial chemotherapy (2025). PMID: 40601387 ↗
L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [331]
Hu J, Chen L, Li G et al.. “Prevalence and genetic characteristics of fosB-positive Staphylococcus aureus in duck farms in Guangdong, China in 2020.” The Journal of antimicrobial chemotherapy (2023). PMID: 36691844 ↗
L5OTHERCited in: Diagnosis and Workup - [332]
Cañas MA, García-de-la-Mària C, García-González J et al.. “Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains.” The Journal of antimicrobial chemotherapy (2025). PMID: 40424179 ↗
L5OTHERCited in: Diagnosis and Workup - [333]
Miller MM, Van Schooneveld TC, Stohs EJ et al.. “Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation.” Open forum infectious diseases (2023). PMID: 37564742 ↗
L3OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [334]
Honkanen M, Jämsen E, Karppelin M et al.. “Periprosthetic Joint Infections as a Consequence of Bacteremia.” Open forum infectious diseases (2019). PMID: 31214625 ↗
L2OTHERCited in: Diagnosis and Workup - [335]
Shaw R, Zander A, Ronnie T et al.. “Assessing the Predictive Value of Methicillin-Resistant Staphylococcus aureus Nares Colonization Among Transplant Recipients and Patients With Neutropenia.” Open forum infectious diseases (2024). PMID: 39050229 ↗
L3OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [336]
Maurer M, McCulloch M, Willey AM et al.. “Detection of Bacteriuria by Canine Olfaction.” Open forum infectious diseases (2016). PMID: 27186578 ↗
L2OTHERCited in: Diagnosis and Workup - [337]
Musher DM, Jesudasen SS, Barwatt JW et al.. “Normal Respiratory Flora as a Cause of Community-Acquired Pneumonia.” Open forum infectious diseases (2020). PMID: 32968689 ↗
L2OTHERCited in: Diagnosis and Workup - [338]
Comba IY, Go JR, Vaillant J et al.. “Sequential Time to Positivity as a Prognostic Indicator in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2024). PMID: 38617074 ↗
L2OTHERCited in: Diagnosis and Workup, Complications - [339]
Phillip KI, Webster AS, Ray SM et al.. “Estimating the Burden of Clinically Significant Staphylococcus aureus Infections and Predictors for Hospitalization for Skin and Soft Tissue Infections, Fulton County, Georgia, 2017.” Open forum infectious diseases (2023). PMID: 38107016 ↗
L2OTHERCited in: Diagnosis and Workup, Antimicrobial Resistance and Stewardship - [340]
Seidelman J, Ritter AS, Poehlein E et al.. “Multisite Study of the Management of Musculoskeletal Infection After Trauma: The MMUSKIT Study.” Open forum infectious diseases (2024). PMID: 38854390 ↗
L3OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [341]
Schneider-Lindner V, Delaney JA, Dial S et al.. “Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom.” Emerging infectious diseases (2007). PMID: 18214170 ↗
L3OTHERCited in: Diagnosis and Workup, Severity Assessment and Risk Stratification, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [342]
Francois P, Harbarth S, Huyghe A et al.. “Methicillin-resistant Staphylococcus aureus, Geneva, Switzerland, 1993-2005.” Emerging infectious diseases (2008). PMID: 18258126 ↗
L4OTHERCited in: Diagnosis and Workup, Special Hosts and Populations - [343]
Lo WT, Lin WJ, Tseng MH et al.. “Methicillin-resistant Staphylococcus aureus in children, Taiwan.” Emerging infectious diseases (2006). PMID: 16965712 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [344]
Alesana-Slater J, Ritchie SR, Heffernan H et al.. “Methicillin-resistant Staphylococcus aureus, Samoa, 2007-2008.” Emerging infectious diseases (2011). PMID: 21749763 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [345]
Johnson JK, Khoie T, Shurland S et al.. “Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone.” Emerging infectious diseases (2007). PMID: 17953091 ↗
L2OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [346]
Wulf M, van Nes A, Eikelenboom-Boskamp A et al.. “Methicillin-resistant Staphylococcus aureus in veterinary doctors and students, the Netherlands.” Emerging infectious diseases (2006). PMID: 17326948 ↗
L4OTHERCited in: Diagnosis and Workup - [347]
Tucker NJ, Chow L, Linde P et al.. “Germanium-embedded bioactive fabric reduces bacterial bioburden and modulates fibroblast and macrophage behavior in vitro.” Frontiers in bioengineering and biotechnology (2026). PMID: 42416535 ↗
L5OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [348]
Getnet F, Marami D, Mohammed S et al.. “Bacterial pathogens and antimicrobial resistance patterns in infections associated with stillbirths and under-five deaths in Ethiopia: a post-mortem surveillance study.” BMC infectious diseases (2026). PMID: 42410519 ↗
L4OTHERCited in: Diagnosis and Workup, Empiric Management, Acute Care and Source Control - [349]
Guo HZ, Xing ZC, Ao T et al.. “Development and validation of a risk prediction model for hospital mortality in adult patients with Staphylococcus aureus bacteremia.” Frontiers in cellular and infection microbiology (2026). PMID: 42394821 ↗
L3OTHERCited in: Diagnosis and Workup - [350]
Ulziijargal J, Faermark E, Khenchbish U et al.. “Bacterial profile and antimicrobial resistance in patients with pulmonary infection: a retrospective tertiary hospital-based study.” BMC infectious diseases (2026). PMID: 42387436 ↗
L4OTHERCited in: Diagnosis and Workup - [351]
Ammoura J, Alshamaa N, Elamin A et al.. “Antimicrobial resistance and microbiological gap analysis for central nervous system-assocaited bacterial pathogens in Nigeria.” Frontiers in microbiology (2026). PMID: 42382344 ↗
L4OTHERCited in: Diagnosis and Workup - [352]
Salam T, Tufael, Siddique MAB et al.. “Multidrug-resistant bacterial infections in a tertiary hospitals: culture positivity, pathogen spectrum, and antibiotic susceptibility.” BMC microbiology (2026). PMID: 42381050 ↗
L4OTHERCited in: Diagnosis and Workup - [353]
Sanderford V, Tabliago NRA, Alnami S et al.. “Impact of early vs delayed initiation of dual antimicrobial salvage therapy on clinical outcomes in MRSA bacteremia.” Microbiology spectrum (2026). PMID: 42379823 ↗
L3OTHERCited in: Diagnosis and Workup - [354]
Ding T, Liu X, Liao F et al.. “Bacterial pathogen spectrum and antimicrobial resistance in positive pus cultures from hospitalized patients at a maternal and child healthcare specialty hospital in Shenzhen, China, 2021-2025.” Frontiers in cellular and infection microbiology (2026). PMID: 42376315 ↗
L4OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [355]
Peng X, Zhou H, Liu W et al.. “In vitro interspecies interactions between methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa: effects on bacterial growth, antibiotic susceptibility, and transcriptomic reprogramming.” Frontiers in cellular and infection microbiology (2026). PMID: 42369189 ↗
L5OTHERCited in: Diagnosis and Workup, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [356]
Falcone M, Russo A, Venditti M et al.. “Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 24046298 ↗
L4TRIAL_NONRANDOMCited in: Severity Assessment and Risk Stratification - [357]
Karanika S, Kinamon T, Grigoras C et al.. “Colonization With Methicillin-resistant Staphylococcus aureus and Risk for Infection Among Asymptomatic Athletes: A Systematic Review and Metaanalysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016). PMID: 27090988 ↗
L2SR_OBSCited in: Severity Assessment and Risk Stratification - [358]
López-Cortés LE, Del Toro MD, Gálvez-Acebal J et al.. “Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 23929889 ↗
L2SR_OBSCited in: Severity Assessment and Risk Stratification - [359]
Bhavnani SM, Ambrose PG, Hammel JP et al.. “Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.” Antimicrobial agents and chemotherapy (2015). PMID: 26711755 ↗
L1RCTCited in: Severity Assessment and Risk Stratification, Prognosis and Natural History - [360]
Bassetti M, Righi E, Fasce R et al.. “Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit.” The Journal of antimicrobial chemotherapy (2007). PMID: 17540673 ↗
L4TRIAL_NONRANDOMCited in: Severity Assessment and Risk Stratification - [361]
Malik U, Armstrong D, Ashworth M et al.. “Association between prior antibiotic therapy and subsequent risk of community-acquired infections: a systematic review.” The Journal of antimicrobial chemotherapy (2018). PMID: 29149266 ↗
L3SR_OBSCited in: Severity Assessment and Risk Stratification - [362]
Panagides V, Cuervo G, Llopis J et al.. “Infective Endocarditis After Transcatheter Versus Surgical Aortic Valve Replacement.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37552784 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [363]
Nelson RE, Evans ME, Simbartl L et al.. “Methicillin-resistant Staphylococcus aureus Colonization and Pre- and Post-hospital Discharge Infection Risk.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30107401 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [364]
Humphreys H, Fitzpatick F, Harvey BJ. “Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant Staphylococcus aureus: are they real, do they matter and why?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26202769 ↗
L5REVIEW_NARRATIVECited in: Severity Assessment and Risk Stratification - [365]
Guimaraes AO, Cao Y, Hong K et al.. “A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30165412 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [366]
García-Granja PE, López J, Vilacosta I et al.. “Impact of Valve Culture in the Prognosis of Active Left-sided Infective Endocarditis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30107544 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [367]
Ebruke BE, Deloria Knoll M, Haddix M et al.. “The Etiology of Pneumonia From Analysis of Lung Aspirate and Pleural Fluid Samples: Findings From the Pneumonia Etiology Research for Child Health (PERCH) Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32710751 ↗
L4OTHERCited in: Severity Assessment and Risk Stratification - [368]
Chong YP, Moon SM, Bang KM et al.. “Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.” Antimicrobial agents and chemotherapy (2012). PMID: 23254436 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [369]
Jin R, Wang M, Ke J et al.. “Correlation between Staphylococcus aureus colonization and disease severity in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in immunology (2026). PMID: 42183252 ↗
L1SR_MA_RCTCited in: Severity Assessment and Risk Stratification - [370]
Pericàs JM, Hernández-Meneses M, Muñoz P et al.. “Outcomes and Risk Factors of Septic Shock in Patients With Infective Endocarditis: A Prospective Cohort Study.” Open forum infectious diseases (2021). PMID: 34189153 ↗
L2COHORTCited in: Severity Assessment and Risk Stratification - [371]
Lim CJ, Cheng AC, Kennon J et al.. “Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study.” The Journal of antimicrobial chemotherapy (2014). PMID: 24710025 ↗
L3CASE_CONTROLCited in: Severity Assessment and Risk Stratification - [372]
van der Meulen LWJ, Bergmans ME, Assil S et al.. “Lack of improvement after short-term topical antistaphylococcal endolysin SA.100 therapy in patients with mild-to-moderate atopic dermatitis: Results from a randomized, vehicle-controlled trial.” British journal of clinical pharmacology (2026). PMID: 42115134 ↗
L1RCTCited in: Severity Assessment and Risk Stratification - [373]
Sousa-Regueiro D, Alonso-Alvarez A, Balboa-Barreiro V et al.. “Determinants of cure and survival in vascular graft and endograft infections: a 13-year single-centre cohort study.” Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2026). PMID: 42119888 ↗
L3COHORTCited in: Severity Assessment and Risk Stratification - [374]
Harris AD, Furuno JP, Roghmann MC et al.. “Targeted surveillance of methicillin-resistant Staphylococcus aureus and its potential use to guide empiric antibiotic therapy.” Antimicrobial agents and chemotherapy (2010). PMID: 20479207 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [375]
Moore CL, Lu M, Cheema F et al.. “Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool.” Antimicrobial agents and chemotherapy (2011). PMID: 21825294 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [376]
Pericàs JM, Cervera C, Garcia-de-la-Mària C et al.. “Relationship between Vancomycin MIC and Virulence Gene Expression in Clonal Complexes of Methicillin-Susceptible Staphylococcus aureus Strains Isolated from Left-Sided Endocarditis.” Antimicrobial agents and chemotherapy (2020). PMID: 31907181 ↗
L4OTHERCited in: Severity Assessment and Risk Stratification - [377]
Ikeh MAC, Fidel PL, Noverr MC. “Prostaglandin E2 Receptor Antagonist with Antimicrobial Activity against Methicillin-Resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2018). PMID: 29263068 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [378]
Van Wart SA, Ambrose PG, Rubino CM et al.. “Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.” Antimicrobial agents and chemotherapy (2013). PMID: 24277021 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [379]
Lefèvre S, Saleh M, Marcellin L et al.. “Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.” Antimicrobial agents and chemotherapy (2012). PMID: 22371888 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [380]
Brown J, Brown K, Forrest A. “Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.” Antimicrobial agents and chemotherapy (2011). PMID: 22123681 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [381]
Meléndez-Carmona MÁ, Mancheño-Losa M, Ruiz-Sorribas A et al.. “Strain-to-strain variability among Staphylococcus aureus causing prosthetic joint infection drives heterogeneity in response to levofloxacin and rifampicin.” The Journal of antimicrobial chemotherapy (2022). PMID: 36124848 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [382]
Lalanne S, Cattoir V, Guerin F et al.. “Differential response to antibiotic therapy in staphylococcal infective endocarditis: contribution of an ex vivo model.” The Journal of antimicrobial chemotherapy (2023). PMID: 37248684 ↗
L5OTHERCited in: Severity Assessment and Risk Stratification - [383]
Kanerva M, Ollgren J, Lyytikäinen O. “Benchmarking antibiotic use in Finnish acute care hospitals using patient case-mix adjustment.” The Journal of antimicrobial chemotherapy (2011). PMID: 21846673 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [384]
López-Cortés LE, Velasco C, Retamar P et al.. “Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?” The Journal of antimicrobial chemotherapy (2015). PMID: 26023210 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification - [385]
Hong M, Xiang W, Kong L et al.. “Corynebacterium Striatum Infective Endocarditis: A Systematic Review.” Journal of inflammation research (2025). PMID: 41403720 ↗
L4SR_OBSCited in: Severity Assessment and Risk Stratification - [386]
Song J, Liu T, Yu Y et al.. “MHR and CRP/Albumin Ratio Correlate with Wagner Grade in Diabetic Foot Ulcers: A Chinese Retrospective Study with Pathogen Analysis.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42267252 ↗
L4COHORTCited in: Severity Assessment and Risk Stratification - [387]
Kato H, Kitaura T, Noma H et al.. “Risk factors for community-acquired metastatic infections without infective endocarditis in patients with Staphylococcus aureus bacteremia: A retrospective cohort study.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 42162662 ↗
L3COHORTCited in: Severity Assessment and Risk Stratification, Complications - [388]
Smit J, Dalager-Pedersen M, Adelborg K et al.. “Influence of Acetylsalicylic Acid Use on Risk and Outcome of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Study.” Open forum infectious diseases (2019). PMID: 31660413 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [389]
Guimaraes AO, Gutierrez J, Maskarinec SA et al.. “Prognostic Power of Pathogen Cell-Free DNA in Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 31041341 ↗
L4OTHERCited in: Severity Assessment and Risk Stratification - [390]
Ross JJ, Ard KL. “Septic Arthritis of the Spinal Facet Joint: Review of 117 Cases.” Open forum infectious diseases (2024). PMID: 38449920 ↗
L4REVIEW_NARRATIVECited in: Severity Assessment and Risk Stratification, Complications, Prognosis and Natural History - [391]
Barshes NR, Clark NJ, Bidare D et al.. “Polymicrobial Foot Infection Patterns Are Common and Associated With Treatment Failure.” Open forum infectious diseases (2022). PMID: 36267251 ↗
L4OTHERCited in: Severity Assessment and Risk Stratification, History and Evolution of Treatment - [392]
Forsblom E, Frilander H, Ruotsalainen E et al.. “Formal Infectious Diseases Specialist Consultation Improves Long-term Outcome of Methicillin-Sensitive Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2019). PMID: 32128337 ↗
L3OTHERCited in: Severity Assessment and Risk Stratification - [393]
Mendy A, Vieira ER, Albatineh AN et al.. “Staphylococcus aureus Colonization and Long-Term Risk for Death, United States.” Emerging infectious diseases (2016). PMID: 27767920 ↗
L2OTHERCited in: Severity Assessment and Risk Stratification, Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [394]
Miller LG, Daum RS, Creech CB et al.. “Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.” The New England journal of medicine (2015). PMID: 25785967 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations - [395]
Baeten D, Baraliakos X, Braun J et al.. “Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2013). PMID: 24035250 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications - [396]
Falagas ME, Giannopoulou KP, Ntziora F et al.. “Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence.” The Journal of antimicrobial chemotherapy (2007). PMID: 17550889 ↗
L4SR_OBSCited in: Empiric Management, Acute Care and Source Control - [397]
Holland TL, Raad I, Boucher HW et al.. “Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial.” JAMA (2018). PMID: 30264119 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications, Prognosis and Natural History - [398]
Prokocimer P, De Anda C, Fang E et al.. “Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.” JAMA (2013). PMID: 23403680 ↗
L1RCTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Complications - [399]
Davey P, Brown E, Fenelon L et al.. “Systematic review of antimicrobial drug prescribing in hospitals.” Emerging infectious diseases (2006). PMID: 16494744 ↗
L2SR_OBSCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [400]
Ulloa ER, Singh KV, Geriak M et al.. “Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 31773134 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [401]
Rybak MJ. “The pharmacokinetic and pharmacodynamic properties of vancomycin.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2006). PMID: 16323118 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [402]
Paterson DL, Depestel DD. “Doripenem.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19527173 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [403]
Rose W, Fantl M, Geriak M et al.. “Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33993226 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [404]
Jordan H, Kozierowski K, Pickles R et al.. “Oritavancin for the Treatment of Staphylococcus aureus Bacteremia-A Retrospective Single-arm Cohort Study.” Open forum infectious diseases (2025). PMID: 40657166 ↗
L4TRIAL_NONRANDOMCited in: Empiric Management, Acute Care and Source Control - [405]
Katragadda S, Baddour LM, Chesdachai S et al.. “Postoperative Treatment Regimens in Patients With Native Valve Endocarditis due to Staphylococcus aureus Who Undergo Valve Replacement or Repair.” Open forum infectious diseases (2025). PMID: 40207048 ↗
L3TRIAL_NONRANDOMCited in: Empiric Management, Acute Care and Source Control, Complications - [406]
Cosimi RA, Beik N, Kubiak DW et al.. “Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.” Open forum infectious diseases (2017). PMID: 28702467 ↗
L5SR_OBSCited in: Empiric Management, Acute Care and Source Control - [407]
Scheper H, Gerritsen LM, Pijls BG et al.. “Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis.” Open forum infectious diseases (2021). PMID: 34258321 ↗
L1SR_OBSCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [408]
Lek A, Wong B, Keeler A et al.. “Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy.” The New England journal of medicine (2023). PMID: 37754285 ↗
L4CASE_REPORTCited in: Empiric Management, Acute Care and Source Control - [409]
Zasowski EJ, Trinh TD, Claeys KC et al.. “Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection.” Open forum infectious diseases (2021). PMID: 35146040 ↗
L3COHORTCited in: Empiric Management, Acute Care and Source Control - [410]
Partridge SR, Kwong SM, Firth N et al.. “Mobile Genetic Elements Associated with Antimicrobial Resistance.” Clinical microbiology reviews (2018). PMID: 30068738 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [411]
Williamson DA, Carter GP, Howden BP. “Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.” Clinical microbiology reviews (2017). PMID: 28592405 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [412]
Septimus EJ, Schweizer ML. “Decolonization in Prevention of Health Care-Associated Infections.” Clinical microbiology reviews (2016). PMID: 26817630 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [413]
Forrest GN, Tamura K. “Rifampin combination therapy for nonmycobacterial infections.” Clinical microbiology reviews (2010). PMID: 20065324 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [414]
Grundmann H, Aires-de-Sousa M, Boyce J et al.. “Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat.” Lancet (London, England) (2006). PMID: 16950365 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [415]
Alomair SM, Al Sulaiman K, Alharbi A et al.. “Effectiveness of cefazolin versus anti-staphylococcal β-lactam for treating methicillin-susceptible Staphylococcus aureus pneumonia in critically ill patients admitted to intensive care units: a multicenter cohort study.” Annals of clinical microbiology and antimicrobials (2026). PMID: 42421008 ↗
L3COHORTCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [416]
Sánchez García M, De la Torre MA, Morales G et al.. “Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.” JAMA (2010). PMID: 20530779 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship - [417]
Kleinhenz M, Beesetty P, Yang C et al.. “Antibiotic Treatment of Staphylococcus aureus Infection Inhibits the Development of Protective Immunity.” Antimicrobial agents and chemotherapy (2022). PMID: 35266822 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Prevention and Infection Control - [418]
Lepelletier D, Maillard JY, Pozzetto B et al.. “Povidone Iodine: Properties, Mechanisms of Action, and Role in Infection Control and Staphylococcus aureus Decolonization.” Antimicrobial agents and chemotherapy (2020). PMID: 32571829 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Prevention and Infection Control - [419]
Zelmer AR, Yang D, Gunn NJ et al.. “Osteomyelitis-relevant antibiotics at clinical concentrations show limited effectivity against acute and chronic intracellular S. aureus infections in osteocytes.” Antimicrobial agents and chemotherapy (2024). PMID: 39194210 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [420]
Molina KC, Morrisette T, Miller MA et al.. “The Emerging Role of β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.” Antimicrobial agents and chemotherapy (2020). PMID: 32312776 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [421]
Truong-Bolduc QC, Wang Y, Ferrer-Espada R et al.. “Staphylococcus aureus AbcA transporter enhances persister formation under β-lactam exposure.” Antimicrobial agents and chemotherapy (2024). PMID: 38364015 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Prognosis and Natural History - [422]
Frapwell CJ, Skipp PJ, Howlin RP et al.. “Antimicrobial Activity of the Quinoline Derivative HT61 against Staphylococcus aureus Biofilms.” Antimicrobial agents and chemotherapy (2020). PMID: 32122902 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [423]
Cooper EC, Curtis N, Cranswick N et al.. “Pristinamycin: old drug, new tricks?” The Journal of antimicrobial chemotherapy (2014). PMID: 24891428 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [424]
Simon S, Frank BJH, Hartmann S et al.. “Dalbavancin in Gram-positive periprosthetic joint infections.” The Journal of antimicrobial chemotherapy (2022). PMID: 35678452 ↗
L3OTHERCited in: Empiric Management, Acute Care and Source Control, Complications - [425]
Laudano JB. “Ceftaroline fosamil: a new broad-spectrum cephalosporin.” The Journal of antimicrobial chemotherapy (2011). PMID: 21482565 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [426]
Hawkey PM. “The growing burden of antimicrobial resistance.” The Journal of antimicrobial chemotherapy (2008). PMID: 18684701 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [427]
Nicholson OA, Levi E. “Outcomes of single-stage excision in infected preauricular sinus: a retrospective cohort study.” International journal of pediatric otorhinolaryngology (2026). PMID: 42391915 ↗
L2COHORTCited in: Empiric Management, Acute Care and Source Control - [428]
Rappo U, Puttagunta S, Shevchenko V et al.. “Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.” Open forum infectious diseases (2018). PMID: 30648126 ↗
L1OTHERCited in: Empiric Management, Acute Care and Source Control, History and Evolution of Treatment, Complications - [429]
Gobao VC, Alfishawy M, Smith C et al.. “Risk Factors, Screening, and Treatment Challenges in Staphylococcus aureus Native Septic Arthritis.” Open forum infectious diseases (2020). PMID: 33511230 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control - [430]
Yang WT, Meisner JA, Maguire C et al.. “Multidisciplinary Guidance to Care for Persons With Xylazine-Associated Wounds.” Open forum infectious diseases (2025). PMID: 40453883 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [431]
Bowen AC, Carapetis JR, Currie BJ et al.. “Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess.” Open forum infectious diseases (2017). PMID: 29255730 ↗
L2REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [432]
Dagher M, Fowler VG, Wright PW et al.. “A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay?” Open forum infectious diseases (2020). PMID: 32523971 ↗
L5REVIEW_NARRATIVECited in: Empiric Management, Acute Care and Source Control - [433]
Moenster RP, Wallace-Lacey A, Western H et al.. “Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.” Open forum infectious diseases (2023). PMID: 37937043 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control - [434]
Randad PR, Larsen J, Kaya H et al.. “Transmission of Antimicrobial-Resistant Staphylococcus aureus Clonal Complex 9 between Pigs and Humans, United States.” Emerging infectious diseases (2021). PMID: 33622471 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control - [435]
Faires MC, Traverse M, Tater KC et al.. “Methicillin-resistant and -susceptible Staphylococcus aureus infections in dogs.” Emerging infectious diseases (2010). PMID: 20031045 ↗
L3OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [436]
David MZ, Crawford SE, Boyle-Vavra S et al.. “Contrasting pediatric and adult methicillin-resistant Staphylococcus aureus isolates.” Emerging infectious diseases (2006). PMID: 16704812 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control - [437]
Carrel M, Perencevich EN, David MZ. “USA300 Methicillin-Resistant Staphylococcus aureus, United States, 2000-2013.” Emerging infectious diseases (2015). PMID: 26484389 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [438]
Zhang QJ, Li YX, Yan YX et al.. “Design, synthesis, anti-MRSA activity evaluation, and mechanism of action study of 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivatives.” European journal of medicinal chemistry (2026). PMID: 42430954 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control, Antimicrobial Resistance and Stewardship - [439]
Liu F, Chen H, Huang Y et al.. “Phage-guided rapid enrichment of copper-protocatechuic acid nanoparticles for targeted antibacterial therapy.” Journal of nanobiotechnology (2026). PMID: 42426746 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [440]
Zhou F, Luan J, Wei L et al.. “Synergistic Magneto-Electro-Thermal Biochemical Cascade Modulation Enables Rapid Healing and Functional Restoration of Infected Wounds.” Acta biomaterialia (2026). PMID: 42425219 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [441]
Zhang JQ, Wang Y, Ou JG et al.. “Inflammation-responsive liposomes co-delivering tobramycin and nitric oxide for overcoming mucus barriers against MRSA pneumonia.” Colloids and surfaces. B, Biointerfaces (2026). PMID: 42424783 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [442]
Lai X, Wang S, Ding C et al.. “Enhanced Antibacterial Properties of Lyotropic Liquid Crystalline Nanoparticles via Curvature Modulation.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 42423613 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [443]
Khairnar SV, Sommers A, Muldiiarova E et al.. “Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against Staphylococcus aureus.” Frontiers in microbiology (2026). PMID: 42422740 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [444]
Boadi AO, Akenten CW, Thye T et al.. “Characterization of secondary bacterial infections in Buruli ulcer disease in Ghana: a focus on antimicrobial resistant Staphylococcus aureus.” BMC infectious diseases (2026). PMID: 42420877 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control - [445]
Fonfara M, Stölzl D, Hartmann J et al.. “Clinical and molecular improvements in pediatric patients with atopic dermatitis treated with dupilumab: an analysis from the TREATKids registry.” The Journal of investigative dermatology (2026). PMID: 42413573 ↗
L2OTHERCited in: Empiric Management, Acute Care and Source Control - [446]
Luan T, Zhang Y, Zhu W et al.. “Crosslinker-free PVA hydrogel incorporating a water-soluble Ir(III) photosensitizer for antibacterial photodynamic applications in wound healing.” Journal of materials chemistry. B (2026). PMID: 42412212 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [447]
Ayhan YE, Sarı Küçük R, Özkan AN et al.. “Guideline-informed vancomycin therapeutic drug monitoring indications in an adult intensive care unit: a retrospective descriptive study.” BMC anesthesiology (2026). PMID: 42410537 ↗
L4OTHERCited in: Empiric Management, Acute Care and Source Control, Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [448]
Moghaddam AM, Ahmadishoar S, Aval SF. “Synthesis of zinc oxide nanoparticles and their effect on biofilm of methicillin-resistant Staphylococcus aureus isolates.” BMC microbiology (2026). PMID: 42410350 ↗
L5OTHERCited in: Empiric Management, Acute Care and Source Control - [449]
Daneman N, Sarwar S, Fowler RA et al.. “Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis.” The Lancet. Infectious diseases (2013). PMID: 23352693 ↗
L1SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [450]
Ong SWX, Pinto R, Mahar RK et al.. “Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial.” The Lancet. Infectious diseases (2025). PMID: 41237792 ↗
L2RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [451]
Freling S, Wald-Dickler N, Banerjee J et al.. “Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36881940 ↗
L3COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications, Prognosis and Natural History - [452]
Talan DA, Mower WR, Krishnadasan A et al.. “Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess.” The New England journal of medicine (2016). PMID: 26962903 ↗
L1RCTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment, Prognosis and Natural History - [453]
Paul M, Kariv G, Goldberg E et al.. “Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2010). PMID: 20947620 ↗
L3SR_OBSCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [454]
Ji X-w, Mak WY, Xue F et al.. “Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD.” Antimicrobial agents and chemotherapy (2025). PMID: 39878492 ↗
L4TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [455]
Schwameis R, Syré S, Marhofer D et al.. “Pharmacokinetics of Cefuroxime in Synovial Fluid.” Antimicrobial agents and chemotherapy (2017). PMID: 28784675 ↗
L4TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [456]
Butler-Laporte G, Cheng MP, Thirion DJG et al.. “Clinical Trials Increase Off-Study Drug Use: A Segmented Time-Series Analysis.” Open forum infectious diseases (2020). PMID: 33209948 ↗
L2TRIAL_NONRANDOMCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [457]
Bitterman R, Awwad A, Darawsha B et al.. “Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study.” The Journal of antimicrobial chemotherapy (2025). PMID: 39871614 ↗
L3COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History - [458]
Taher AQM, Aqel R, Alnajjar M et al.. “Posttraumatic Pseudomonas aeruginosa Osteomyelitis in Mosul and Gaza: A Retrospective Cohort Study, 2018-2022.” Open forum infectious diseases (2024). PMID: 39411226 ↗
L3COHORTCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [459]
Sati H, Carrara E, Savoldi A et al.. “The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance.” The Lancet. Infectious diseases (2025). PMID: 40245910 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [460]
Tacconelli E, Carrara E, Savoldi A et al.. “Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.” The Lancet. Infectious diseases (2017). PMID: 29276051 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [461]
Simor AE. “Staphylococcal decolonisation: an effective strategy for prevention of infection?” The Lancet. Infectious diseases (2011). PMID: 22115070 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [462]
Oehler RL, Velez AP, Mizrachi M et al.. “Bite-related and septic syndromes caused by cats and dogs.” The Lancet. Infectious diseases (2009). PMID: 19555903 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [463]
Magnan C, Plumet L, Morsli M et al.. “A narrative review of coagulase-negative staphylococci in diabetic foot infections.” Clinical microbiology reviews (2025). PMID: 41186420 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [464]
Haddad Kashani H, Schmelcher M, Sabzalipoor H et al.. “Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant Staphylococcus aureus: Current Status of Research and Novel Delivery Strategies.” Clinical microbiology reviews (2017). PMID: 29187396 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [465]
Beenken KE, Campbell MJ, Reyes-Pardo H et al.. “Mechanistic insights into the pathogenesis and therapeutic recalcitrance of Staphylococcus aureus osteomyelitis.” Clinical microbiology reviews (2026). PMID: 41989162 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [466]
Howden BP, Davies JK, Johnson PD et al.. “Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.” Clinical microbiology reviews (2010). PMID: 20065327 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [467]
Álvarez R, López Cortés LE, Molina J et al.. “Optimizing the Clinical Use of Vancomycin.” Antimicrobial agents and chemotherapy (2016). PMID: 26856841 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [468]
Haynes AS, Wei Z, Anderson P et al.. “Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections.” Antimicrobial agents and chemotherapy (2024). PMID: 38597672 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Special Hosts and Populations - [469]
Gonzalez D, Delmore P, Bloom BT et al.. “Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants.” Antimicrobial agents and chemotherapy (2016). PMID: 26926644 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Complications - [470]
McNeil JC, Sommer LM, Boyle M et al.. “Cefazolin Inoculum Effect and Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children.” Antimicrobial agents and chemotherapy (2020). PMID: 32660989 ↗
L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prognosis and Natural History, Special Hosts and Populations - [471]
Canouï E, Kerneis S, Morand P et al.. “Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections.” The Journal of antimicrobial chemotherapy (2022). PMID: 35178577 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [472]
Rampacci E, Felicetti T, Pietrella D et al.. “Drug efflux transporters in Staphylococcus pseudintermedius: in silico prediction and characterization of resistance.” The Journal of antimicrobial chemotherapy (2022). PMID: 36173389 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [473]
Taupin D, Karchmer AW, Davis RB et al.. “Uncomplicated Staphylococcus aureus Bacteremia Treatment Duration and Outcomes at an Academic Medical Center.” Open forum infectious diseases (2020). PMID: 33134421 ↗
L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [474]
Walker B, Heidel E, Shorman M. “Clinical Characteristics and Outcome of Staphylococcus aureus Prostate Abscess, Ten-Year Experience at a Tertiary Care Center.” Open forum infectious diseases (2019). PMID: 31430373 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [475]
Okada N, Niimura T, Saisyo A et al.. “Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System.” Open forum infectious diseases (2023). PMID: 37601729 ↗
L3OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [476]
Sawada K, Inose R, Goto R et al.. “Effectiveness of Noncertified Pharmacist-Led Antimicrobial Stewardship Programs in a Medium-Sized Hospital Without an Infectious Disease Specialist: A Retrospective Pre-Post Study.” Open forum infectious diseases (2023). PMID: 36949877 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [477]
Fabre V, Cosgrove SE, Lessa FC et al.. “Antibiotic Use in Medical-Surgical Intensive Care Units and General Wards in Latin American Hospitals.” Open forum infectious diseases (2024). PMID: 39494448 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [478]
Novak AR, Krsak M, Kiser TH et al.. “Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients.” Open forum infectious diseases (2021). PMID: 35111872 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, Prevention and Infection Control - [479]
Greenfield A, Marsh K, Siegfried J et al.. “Impact of Streptococcus pneumoniae Urinary Antigen Testing in Patients With Community-Acquired Pneumonia Admitted Within a Large Academic Health System.” Open forum infectious diseases (2021). PMID: 34993258 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation, History and Evolution of Treatment - [480]
Nichols CN, Wardlow LC, Coe KE et al.. “Clinical Outcomes With Definitive Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia With Retained Daptomycin and Ceftaroline Combination Therapy vs De-escalation to Monotherapy With Vancomycin, Daptomycin, or Ceftaroline.” Open forum infectious diseases (2021). PMID: 34337094 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [481]
Abbara S, Guillemot D, Smith DRM et al.. “Antimicrobial Resistance as Risk Factor for Recurrent Bacteremia after Staphylococcus aureus, Escherichia coli, or Klebsiella spp. Community-Onset Bacteremia.” Emerging infectious diseases (2024). PMID: 38666612 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [482]
McCaig LF, McDonald LC, Mandal S et al.. “Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care.” Emerging infectious diseases (2006). PMID: 17283622 ↗
L2OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [483]
Legg A, Boast A, Piera K et al.. “Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers.” British journal of clinical pharmacology (2026). PMID: 42414075 ↗
L4OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [484]
Barahim EK, Smith EP, Yong ST et al.. “Evaluation of Antimicrobial Peptide-Antibiotic Combination Treatment for Tackling Ocular and Systemic Staphylococcus aureus Infections.” International journal of molecular sciences (2026). PMID: 42353286 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [485]
Lamilla C, Rubilar O, San Martin I et al.. “Biotechnological Potential of Rhizospheric Bacillus Strains from Lonquimay, Chile, as Producers of Antimicrobial Biosurfactants.” International journal of molecular sciences (2026). PMID: 42353120 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [486]
Bușilă M, Tăbăcaru A, Botezatu AV et al.. “Tuning Anticancer Activity and Antimicrobial Response of ZnO Nanoparticles Through Halogenosilane Surface Modification.” International journal of molecular sciences (2026). PMID: 42353108 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [487]
Cottet C, Kikot PA, Nobile ML et al.. “Active Chitosan Films Enriched with Yerba Mate Kombucha Infusion: Formulation and Characterization.” International journal of molecular sciences (2026). PMID: 42353065 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [488]
da Silva MEB, Kamio ABS, da Silva MGR et al.. “Antimicrobial efficacy of hypochlorite-based gels for disinfecting heat-polymerized and 3D printed denture bases.” The Journal of prosthetic dentistry (2026). PMID: 42348746 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [489]
Kayani A, Raza A, Zhou Q et al.. “Orchestrating Diabetic Wound Healing by a Sunlight-Activated AIEgen-Selenide Nanospray: From Infection Control to Tissue Regeneration.” ACS applied materials & interfaces (2026). PMID: 42347974 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [490]
Gupta N, Bhattacharya S, Lela L et al.. “Advances in phytochemical-derived nanotherapeutics for multimodal eradication of multidrug-resistant Staphylococcus aureus.” Frontiers in pharmacology (2026). PMID: 42344795 ↗
L5REVIEW_NARRATIVECited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [491]
Li K, Wang K, Zhang G et al.. “An Acceptor-Donor-Acceptor Semiconductor Conjugated Polymer-Based Composite Hydrogel for Photothermal/Photodynamic Dual Phototherapy of Infected Wounds.” ACS applied materials & interfaces (2026). PMID: 42333676 ↗
L5OTHERCited in: Definitive Therapy: Dosing, PK/PD, Duration and De-escalation - [492]
Zervou FN, Zacharioudakis IM, Ziakas PD et al.. “Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus colonization in HIV infection: a meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 25031291 ↗
L2SR_OBSCited in: History and Evolution of Treatment, Complications, Special Hosts and Populations - [493]
Pujol M, Miró JM, Shaw E et al.. “Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 32725216 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [494]
Fowler VG, Das AF, Lipka-Diamond J et al.. “Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 38297916 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History - [495]
Mitchell BG, Hall L, White N et al.. “An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial.” The Lancet. Infectious diseases (2019). PMID: 30858014 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History, Prevention and Infection Control - [496]
Ibrahim LF, Hopper SM, Orsini F et al.. “Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial.” The Lancet. Infectious diseases (2019). PMID: 30853250 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Special Hosts and Populations - [497]
Johnson DW, Badve SV, Pascoe EM et al.. “Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.” The Lancet. Infectious diseases (2013). PMID: 24119840 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prevention and Infection Control, Special Hosts and Populations - [498]
Huang SS, Septimus E, Hayden MK et al.. “Effect of body surface decolonisation on bacteriuria and candiduria in intensive care units: an analysis of a cluster-randomised trial.” The Lancet. Infectious diseases (2015). PMID: 26631833 ↗
L1RCTCited in: History and Evolution of Treatment, Prevention and Infection Control - [499]
Daum RS, Miller LG, Immergluck L et al.. “A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.” The New England journal of medicine (2017). PMID: 28657870 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis and Natural History, Special Hosts and Populations - [500]
Perl TM, Cullen JJ, Wenzel RP et al.. “Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections.” The New England journal of medicine (2002). PMID: 12063371 ↗
L1RCTCited in: History and Evolution of Treatment - [501]
Yu VL, Goetz A, Wagener M et al.. “Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis.” The New England journal of medicine (1986). PMID: 3523240 ↗
L2RCTCited in: History and Evolution of Treatment - [502]
Rodvold KA, McConeghy KW. “Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24343828 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [503]
de Jonge E, Schultz MJ, Spanjaard L et al.. “Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial.” Lancet (London, England) (2003). PMID: 14522530 ↗
L1RCTCited in: History and Evolution of Treatment - [504]
Lipsky BA, Armstrong DG, Citron DM et al.. “Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.” Lancet (London, England) (2005). PMID: 16291062 ↗
L1RCTCited in: History and Evolution of Treatment - [505]
Keighley MR, Arabi Y, Alexander-Williams J et al.. “Comparison between systemic and oral antimicrobial prophylaxis in colorectal surgery.” Lancet (London, England) (1979). PMID: 86666 ↗
L1RCTCited in: History and Evolution of Treatment - [506]
Smack DP, Harrington AC, Dunn C et al.. “Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial.” JAMA (1996). PMID: 8805732 ↗
L1RCTCited in: History and Evolution of Treatment - [507]
Pugin J, Auckenthaler R, Lew DP et al.. “Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia. A randomized, placebo-controlled, double-blind clinical trial.” JAMA (Unknown). PMID: 2023353 ↗
L1RCTCited in: History and Evolution of Treatment - [508]
Fowler VG, Allen KB, Moreira ED et al.. “Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.” JAMA (2013). PMID: 23549582 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prevention and Infection Control - [509]
Harris AD, Pineles L, Belton B et al.. “Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial.” JAMA (2013). PMID: 24097234 ↗
L1RCTCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship, Complications, Prevention and Infection Control - [510]
Segers P, Speekenbrink RG, Ubbink DT et al.. “Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial.” JAMA (2006). PMID: 17119142 ↗
L1RCTCited in: History and Evolution of Treatment - [511]
Moran GJ, Krishnadasan A, Mower WR et al.. “Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis: A Randomized Clinical Trial.” JAMA (2017). PMID: 28535235 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [512]
Oliveira DC, Tomasz A, de Lencastre H. “Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus.” The Lancet. Infectious diseases (2002). PMID: 11944188 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [513]
Cetinkaya Y, Falk P, Mayhall CG. “Vancomycin-resistant enterococci.” Clinical microbiology reviews (2000). PMID: 11023964 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [514]
Shirtliff ME, Mader JT. “Acute septic arthritis.” Clinical microbiology reviews (2002). PMID: 12364368 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [515]
Skurray RA, Rouch DA, Lyon BR et al.. “Multiresistant Staphylococcus aureus: genetics and evolution of epidemic Australian strains.” The Journal of antimicrobial chemotherapy (1988). PMID: 2838448 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [516]
Griffith RS. “Vancomycin use--an historical review.” The Journal of antimicrobial chemotherapy (1984). PMID: 6394574 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [517]
Donnelly JP. “Bacterial complications of transplantation: diagnosis and treatment.” The Journal of antimicrobial chemotherapy (1995). PMID: 8601544 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [518]
. “Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.” The Lancet. Infectious diseases (2024). PMID: 38640940 ↗
L2OTHERCited in: History and Evolution of Treatment, Special Hosts and Populations - [519]
Gamell A, Velasco-Arnaiz E, López-Ramos MG et al.. “Off-label use of dalbavancin in children: a case series.” The Journal of antimicrobial chemotherapy (2024). PMID: 38958260 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment, Complications, Special Hosts and Populations - [520]
Belew H, Tegegne BA, Kindie Y et al.. “Bacterial neonatal sepsis, antimicrobial resistance, and risk factors among neonates in Ethiopia: a systematic review and meta-analysis.” Therapeutic advances in infectious disease (2026). PMID: 42222265 ↗
L2SR_OBSCited in: History and Evolution of Treatment - [521]
Gomes AR, Westh H, de Lencastre H. “Origins and evolution of methicillin-resistant Staphylococcus aureus clonal lineages.” Antimicrobial agents and chemotherapy (2006). PMID: 17005800 ↗
L5OTHERCited in: History and Evolution of Treatment - [522]
Liu X, Wang Y, Chang W et al.. “AgrA directly binds to the promoter of vraSR and downregulates its expression in Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2024). PMID: 38259090 ↗
L5OTHERCited in: History and Evolution of Treatment - [523]
Campion JJ, McNamara PJ, Evans ME. “Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.” Antimicrobial agents and chemotherapy (2004). PMID: 15561851 ↗
L5OTHERCited in: History and Evolution of Treatment - [524]
Chen F, Yin Y, Chen H et al.. “Global genetic diversity and Asian clades evolution: a phylogeographic study of Staphylococcus aureus sequence type 5.” Antimicrobial agents and chemotherapy (2024). PMID: 38259089 ↗
L5OTHERCited in: History and Evolution of Treatment - [525]
Rolo J, Worning P, Nielsen JB et al.. “Evolutionary Origin of the Staphylococcal Cassette Chromosome mec (SCCmec).” Antimicrobial agents and chemotherapy (2017). PMID: 28373201 ↗
L5OTHERCited in: History and Evolution of Treatment - [526]
Giulieri SG. “Case Commentary: The hidden side of oxacillin resistance in Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2023). PMID: 37655923 ↗
L5OTHERCited in: History and Evolution of Treatment - [527]
Chen Y, Moran JC, Campbell-Lee S et al.. “Transcriptomic Responses and Survival Mechanisms of Staphylococci to the Antimicrobial Skin Lipid Sphingosine.” Antimicrobial agents and chemotherapy (2021). PMID: 34902269 ↗
L5OTHERCited in: History and Evolution of Treatment - [528]
Petersen ME, Khamas AB, Østergaard LJ et al.. “Combination therapy delays antimicrobial resistance after adaptive laboratory evolution of Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 40084881 ↗
L5OTHERCited in: History and Evolution of Treatment - [529]
León-Sampedro R, Novais C, Peixe L et al.. “Diversity and Evolution of the Tn5801-tet(M)-Like Integrative and Conjugative Elements among Enterococcus, Streptococcus, and Staphylococcus.” Antimicrobial agents and chemotherapy (2016). PMID: 26729505 ↗
L5OTHERCited in: History and Evolution of Treatment - [530]
Strommenger B, Bartels MD, Kurt K et al.. “Evolution of methicillin-resistant Staphylococcus aureus towards increasing resistance.” The Journal of antimicrobial chemotherapy (2013). PMID: 24150844 ↗
L5OTHERCited in: History and Evolution of Treatment - [531]
Jiang N, Wyres KL, Li J et al.. “Evolution and genomic insight into methicillin-resistant Staphylococcus aureus ST9 in China.” The Journal of antimicrobial chemotherapy (2021). PMID: 33822977 ↗
L5OTHERCited in: History and Evolution of Treatment - [532]
Duval J. “Evolution and epidemiology of MLS resistance.” The Journal of antimicrobial chemotherapy (1985). PMID: 3932300 ↗
L5OTHERCited in: History and Evolution of Treatment - [533]
Liu P, Hao Z, Liu M et al.. “Genetic mutations in adaptive evolution of growth-independent vancomycin-tolerant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2021). PMID: 34302174 ↗
L5OTHERCited in: History and Evolution of Treatment - [534]
Olsen JE, Christensen H, Aarestrup FM. “Diversity and evolution of blaZ from Staphylococcus aureus and coagulase-negative staphylococci.” The Journal of antimicrobial chemotherapy (2006). PMID: 16449305 ↗
L5OTHERCited in: History and Evolution of Treatment - [535]
Nuevo JJM, Fortaleza JAG, Cabuhat KSP et al.. “CRISPR-driven strategies to disrupt methicillin-resistant Staphylococcus aureus biofilms: a review.” Frontiers in cellular and infection microbiology (2026). PMID: 42211656 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [536]
Matsuo T, Hayashi K, Uehara Y et al.. “The STAPH Score: A Predictor of Staphylococcus aureus as the Causative Microorganism of Native Vertebral Osteomyelitis.” Open forum infectious diseases (2020). PMID: 33447627 ↗
L3OTHERCited in: History and Evolution of Treatment - [537]
Peterson LR, Samia NI, Skinner AM et al.. “Antimicrobial Stewardship Lessons From Mupirocin Use and Resistance in Methicillin-Resitant Staphylococcus Aureus.” Open forum infectious diseases (2017). PMID: 28702468 ↗
L2OTHERCited in: History and Evolution of Treatment, Antimicrobial Resistance and Stewardship - [538]
Lee YW, Bae S, Yang E et al.. “Clinical and Microbiological Characteristics of Hospital-Acquired Methicillin-Resistant Staphylococcus aureus Bacteremia Caused by a Community-Associated PVL-Negative Strain.” Open forum infectious diseases (2021). PMID: 34676275 ↗
L2OTHERCited in: History and Evolution of Treatment - [539]
Theodore DA, Goodwin RD, Zhang YV et al.. “History of Depression and Increased Risk of Sternal Wound Infection After Cardiothoracic Surgery: A Novel and Potentially Modifiable Risk Factor.” Open forum infectious diseases (2019). PMID: 30949529 ↗
L3OTHERCited in: History and Evolution of Treatment - [540]
Henig O, Pogue JM, Cha R et al.. “Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area With a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial Therapy.” Open forum infectious diseases (2018). PMID: 30402532 ↗
L2OTHERCited in: History and Evolution of Treatment - [541]
Turabelidze G, Lin M, Wolkoff B et al.. “Personal hygiene and methicillin-resistant Staphylococcus aureus infection.” Emerging infectious diseases (2006). PMID: 16704779 ↗
L3OTHERCited in: History and Evolution of Treatment - [542]
Odutola A, Bottomley C, Zaman SA et al.. “Staphylococcus aureus Bacteremia in Children of Rural Areas of The Gambia, 2008-2015.” Emerging infectious diseases (2019). PMID: 30882307 ↗
L2OTHERCited in: History and Evolution of Treatment - [543]
Buck JM, Como-Sabetti K, Harriman KH et al.. “Community-associated methicillin-resistant Staphylococcus aureus, Minnesota, 2000-2003.” Emerging infectious diseases (2005). PMID: 16318692 ↗
L3OTHERCited in: History and Evolution of Treatment - [544]
Brodíková K, Destanque T, Haenni M et al.. “Clonal Complex 398 Methicillin-Resistant Staphylococcus aureus Producing Panton-Valentine Leukocidin, Czech Republic, 2023.” Emerging infectious diseases (2025). PMID: 39714442 ↗
L4OTHERCited in: History and Evolution of Treatment - [545]
Li M, Wang Y, Zhu Y et al.. “Increased Community-Associated Infections Caused by Panton-Valentine Leukocidin-Negative MRSA, Shanghai, 2005-2014.” Emerging infectious diseases (2016). PMID: 27767912 ↗
L4OTHERCited in: History and Evolution of Treatment - [546]
Peters PJ, Brooks JT, McAllister SK et al.. “Methicillin-resistant Staphylococcus aureus colonization of the groin and risk for clinical infection among HIV-infected adults.” Emerging infectious diseases (2013). PMID: 23631854 ↗
L2OTHERCited in: History and Evolution of Treatment - [547]
Moran GJ, Amii RN, Abrahamian FM et al.. “Methicillin-resistant Staphylococcus aureus in community-acquired skin infections.” Emerging infectious diseases (2005). PMID: 15963289 ↗
L4OTHERCited in: History and Evolution of Treatment - [548]
Wuerth BA, Bonnewell JP, Wiemken TL et al.. “Trends in Pneumonia Mortality Rates and Hospitalizations by Organism, United States, 2002-2011(1).” Emerging infectious diseases (2016). PMID: 27532154 ↗
L2OTHERCited in: History and Evolution of Treatment, Prognosis and Natural History - [549]
Lewis HC, Mølbak K, Reese C et al.. “Pigs as source of methicillin-resistant Staphylococcus aureus CC398 infections in humans, Denmark.” Emerging infectious diseases (2008). PMID: 18760004 ↗
L3OTHERCited in: History and Evolution of Treatment - [550]
Lee JH, Cho MC. “Impact of bacteriospermia on sperm DNA fragmentation: a narrative review.” Translational andrology and urology (2026). PMID: 42293827 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [551]
Ansari I, Sindgi RP, Srivastava AK et al.. “Advances in Quorum-Sensing Inhibitors as Novel Therapeutic Targets.” Microbial pathogenesis (2026). PMID: 42285423 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [552]
Ilyas MH, Adio A, Gonzalez-Morgado D et al.. “Social Determinants of Health Are Associated With Increased Risk of Preoperative Methicillin-Resistant Staphylococcus aureus Colonization in Patients Undergoing Total Joint Arthroplasty.” Arthroplasty today (2026). PMID: 42434293 ↗
L2OTHERCited in: History and Evolution of Treatment - [553]
Nathan H, Hiironen I, Harrington P et al.. “Distribution of putative SSI risk factors in adults undergoing open reduction and fixation of long bone fracture.” European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2026). PMID: 42406128 ↗
L2OTHERCited in: History and Evolution of Treatment - [554]
Alexander AM, Loo HQ, Askew L et al.. “Intraspecific diversity of Staphylococcus aureus populations isolated from cystic fibrosis respiratory infections.” Microbiology spectrum (2026). PMID: 42405791 ↗
L4OTHERCited in: History and Evolution of Treatment - [555]
Liu W, Guo W, Xiao D et al.. “Phthalazine-based quaternary ammonium salts: synthesis, biological evaluation and membrane-targeting mechanism against Staphylococcus aureus.” Frontiers in microbiology (2026). PMID: 42404800 ↗
L5OTHERCited in: History and Evolution of Treatment - [556]
Krämer CL, Arndt F, Boschert AL et al.. “Bacterial resistance across habitats: from German schools to the International Space Station.” Frontiers in microbiology (2026). PMID: 42395912 ↗
L5OTHERCited in: History and Evolution of Treatment - [557]
Hermsen ED, Amos J, Townsend A et al.. “Antimicrobial resistance among refugees and asylum seekers: a global systematic review and meta-analysis.” The Lancet. Infectious diseases (2024). PMID: 39527961 ↗
L2SR_OBSCited in: Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [558]
Stryjewski ME, Corey GR. “Methicillin-resistant Staphylococcus aureus: an evolving pathogen.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2014). PMID: 24343827 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [559]
Saravolatz LD, Stein GE. “Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 30060092 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [560]
Mody L, Bradley SF, Galecki A et al.. “Conceptual model for reducing infections and antimicrobial resistance in skilled nursing facilities: focusing on residents with indwelling devices.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21292670 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [561]
Miyakis S, Pefanis A, Tsakris A. “The challenges of antimicrobial drug resistance in Greece.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21690626 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [562]
Rossi F. “The challenges of antimicrobial resistance in Brazil.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 21467020 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [563]
Moghnieh RA, Kanafani ZA, Tabaja HZ et al.. “Epidemiology of common resistant bacterial pathogens in the countries of the Arab League.” The Lancet. Infectious diseases (2018). PMID: 30292478 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [564]
Petit H, de Tymowski C, Dudoignon E et al.. “Epidemiology and Outcomes of Bloodstream Infections in Patients in a Burns Intensive Care Unit: An 8-Year Retrospective Study.” Open forum infectious diseases (2025). PMID: 40182133 ↗
L2COHORTCited in: Antimicrobial Resistance and Stewardship - [565]
Périchon B, Courvalin P. “VanA-type vancomycin-resistant Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2009). PMID: 19506057 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [566]
File TM, Ramirez JA, Wilde AM. “New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus).” Antimicrobial agents and chemotherapy (2025). PMID: 39817764 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [567]
Reynolds R. “Antimicrobial resistance in the UK and Ireland.” The Journal of antimicrobial chemotherapy (2009). PMID: 19675014 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [568]
Livermore DM. “Has the era of untreatable infections arrived?” The Journal of antimicrobial chemotherapy (2009). PMID: 19675016 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [569]
Bisgaard H, Hermansen MN, Buchvald F et al.. “Childhood asthma after bacterial colonization of the airway in neonates.” The New England journal of medicine (2007). PMID: 17928596 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [570]
. “Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.” Lancet (London, England) (2022). PMID: 36423648 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship, Special Hosts and Populations - [571]
Mohamad M, Hurst MM, Elkrewi E et al.. “Nature of bacitracin resistance in Staphylococcus aureus.” Antimicrobial agents and chemotherapy (2025). PMID: 41186227 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [572]
Woosley LN, Castanheira M, Jones RN. “CEM-101 activity against Gram-positive organisms.” Antimicrobial agents and chemotherapy (2010). PMID: 20176910 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [573]
Chatterjee SS, Chen L, Gilbert A et al.. “PBP4 Mediates β-Lactam Resistance by Altered Function.” Antimicrobial agents and chemotherapy (2017). PMID: 28807923 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship - [574]
Cazer CL, Westblade LF, Simon MS et al.. “Analysis of Multidrug Resistance in Staphylococcus aureus with a Machine Learning-Generated Antibiogram.” Antimicrobial agents and chemotherapy (2021). PMID: 33431415 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [575]
Petersiel N, Howden BP, Giulieri S et al.. “An Achilles' heel for methicillin-resistant Staphylococcus aureus? Re-evaluating β-lactam susceptibility of MRSA.” Antimicrobial agents and chemotherapy (2026). PMID: 42405967 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship, Prognosis and Natural History - [576]
Virgillio AM, Felton EA, Jackson JK et al.. “Genomic and Phenotypic Characterization of Mupirocin-resistant Staphylococcus aureus Clinical Isolates.” Open forum infectious diseases (2025). PMID: 40698033 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [577]
Tenover FC, Goff DA. “Surveillance and Stewardship: Where Infection Prevention and Antimicrobial Stewardship Intersect.” Open forum infectious diseases (2023). PMID: 37089778 ↗
L5OTHERCited in: Antimicrobial Resistance and Stewardship, Prevention and Infection Control - [578]
Timbrook TT, Olin KE, Spaulding U et al.. “Epidemiology of Antimicrobial Resistance Among Blood and Respiratory Specimens in the United States Using Genotypic Analysis From a Cloud-Based Population Surveillance Network.” Open forum infectious diseases (2022). PMID: 35873295 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [579]
Diekema DJ, Pfaller MA, Shortridge D et al.. “Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program.” Open forum infectious diseases (2019). PMID: 30895214 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [580]
Wozniak TM, Dyda A, Lee X. “The Increased Length of Hospital Stay and Mortality Associated With Community-Associated Infections in Australia.” Open forum infectious diseases (2022). PMID: 35493114 ↗
L3OTHERCited in: Antimicrobial Resistance and Stewardship - [581]
Becker K, van Alen S, Idelevich EA et al.. “Plasmid-Encoded Transferable mecB-Mediated Methicillin Resistance in Staphylococcus aureus.” Emerging infectious diseases (2018). PMID: 29350135 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [582]
Hsu LY, Tan TY, Jureen R et al.. “Antimicrobial drug resistance in Singapore hospitals.” Emerging infectious diseases (2007). PMID: 18258055 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [583]
Gooskens J, Konstantinovski MM, Kraakman MEM et al.. “Panton-Valentine Leukocidin-Positive CC398 MRSA in Urban Clinical Settings, the Netherlands.” Emerging infectious diseases (2023). PMID: 36913919 ↗
L4OTHERCited in: Antimicrobial Resistance and Stewardship - [584]
Sharma T, Chandley P. “Host-pathogen interactions during ESKAPE-mediated urinary tract infections and ventilator-associated pneumonia: a review.” Folia microbiologica (2026). PMID: 42423835 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [585]
Kiani M, Mehboodi M, Khanbabaie H et al.. “Lactobacillus strains in the prevention and disruption of antimicrobial-resistance in pathogenic microbial biofilms: a review of mechanisms and clinical perspective.” Folia microbiologica (2026). PMID: 42412160 ↗
L5REVIEW_NARRATIVECited in: Antimicrobial Resistance and Stewardship - [586]
Antoniolli A, Ruge T, Biron A et al.. “Emergence of antimicrobial resistance in New Caledonia: 20-year trends from laboratory-based surveillance (2005-2024).” The Lancet regional health. Western Pacific (2026). PMID: 42434433 ↗
L2OTHERCited in: Antimicrobial Resistance and Stewardship - [587]
Piper KR, Buiatte ABG, Souza SSR et al.. “Plasmids of co-circulating Staphylococcus aureus serve as vehicles for antimicrobial resistance sharing across diseased host-species at short timescales.” BMC microbiology (2026). PMID: 42426609 ↗
L3OTHERCited in: Antimicrobial Resistance and Stewardship - [588]
Abrahamian FM, Sakoulas G, Tzanis E et al.. “Omadacycline for Acute Bacterial Skin and Skin Structure Infections.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2019). PMID: 31367742 ↗
L1RCTCited in: Complications - [589]
Corey GR. “Staphylococcus aureus bloodstream infections: definitions and treatment.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2009). PMID: 19374581 ↗
L5CASE_REPORTCited in: Complications - [590]
Boucher HW, Wilcox M, Talbot GH et al.. “Once-weekly dalbavancin versus daily conventional therapy for skin infection.” The New England journal of medicine (2014). PMID: 24897082 ↗
L1RCTCited in: Complications - [591]
Eljaaly K, Alshehri S, Erstad BL. “Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin.” Antimicrobial agents and chemotherapy (2018). PMID: 29437617 ↗
L1SR_OBSCited in: Complications - [592]
Karanika S, Paudel S, Grigoras C et al.. “Systematic Review and Meta-analysis of Clinical and Economic Outcomes from the Implementation of Hospital-Based Antimicrobial Stewardship Programs.” Antimicrobial agents and chemotherapy (2016). PMID: 27246783 ↗
L1SR_OBSCited in: Complications - [593]
Kidd JM, Sakon CM, Oleksiuk LM et al.. “Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.” Antimicrobial agents and chemotherapy (2019). PMID: 31685468 ↗
L4TRIAL_NONRANDOMCited in: Complications - [594]
Holland TL, Shorr AF, Overcash JS et al.. “Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.” The Journal of antimicrobial chemotherapy (2025). PMID: 40155066 ↗
L2TRIAL_NONRANDOMCited in: Complications - [595]
Arbona-Lampaya A, Pérez-Ojeda RA, Santos-Marrero M et al.. “Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer.” The Lancet. Infectious diseases (2025). PMID: 41429139 ↗
L4CASE_REPORTCited in: Complications - [596]
Beaumont AL, Mestre F, Decaux S et al.. “Long-term Oral Suppressive Antimicrobial Therapy in Infective Endocarditis (SATIE Study): An Observational Study.” Open forum infectious diseases (2024). PMID: 38737431 ↗
L4TRIAL_NONRANDOMCited in: Complications, Prognosis and Natural History - [597]
Weber MA, Klein NJ, Hartley JC et al.. “Infection and sudden unexpected death in infancy: a systematic retrospective case review.” Lancet (London, England) (2008). PMID: 18514728 ↗
L4REVIEW_NARRATIVECited in: Complications - [598]
Kristiansen JE, Hendricks O, Delvin T et al.. “Reversal of resistance in microorganisms by help of non-antibiotics.” The Journal of antimicrobial chemotherapy (2007). PMID: 17403708 ↗
L5REVIEW_NARRATIVECited in: Complications - [599]
Principi N, Caironi M, Venturini F et al.. “Daptomycin in paediatrics: current knowledge and the need for future research.” The Journal of antimicrobial chemotherapy (2014). PMID: 25406298 ↗
L5REVIEW_NARRATIVECited in: Complications, Special Hosts and Populations - [600]
Parkins MD, Elborn JS. “Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.” The Journal of antimicrobial chemotherapy (2010). PMID: 20605846 ↗
L5REVIEW_NARRATIVECited in: Complications - [601]
Akita S, Okamura T, Tanigawa K. “Clinical Efficacy and Broad-Spectrum Antimicrobial Activity of pH-Controlled Sodium Hypochlorite Solution (HACCP'ER) in Acute and Chronic Wound Management: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42278958 ↗
L4COHORTCited in: Complications - [602]
Kiefer T, Park L, Tribouilloy C et al.. “Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure.” JAMA (2011). PMID: 22110106 ↗
L2OTHERCited in: Complications - [603]
Renzoni A, Von Dach E, Landelle C et al.. “Impact of Exposure of Methicillin-Resistant Staphylococcus aureus to Polyhexanide In Vitro and In Vivo.” Antimicrobial agents and chemotherapy (2017). PMID: 28784678 ↗
L5OTHERCited in: Complications - [604]
Ortines RV, Liu H, Cheng LI et al.. “Neutralizing Alpha-Toxin Accelerates Healing of Staphylococcus aureus-Infected Wounds in Nondiabetic and Diabetic Mice.” Antimicrobial agents and chemotherapy (2018). PMID: 29311091 ↗
L5OTHERCited in: Complications - [605]
Kwon DH, Lu CD. “Polyamine effects on antibiotic susceptibility in bacteria.” Antimicrobial agents and chemotherapy (2007). PMID: 17438056 ↗
L5OTHERCited in: Complications - [606]
Wasielewski AS, Casapao AM, Jankowski CA et al.. “Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections.” Antimicrobial agents and chemotherapy (2024). PMID: 39324801 ↗
L2OTHERCited in: Complications - [607]
Couderc C, Thiébaut AC, Lawrence C et al.. “Fluoroquinolone Impact on Nasal Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Colonization Durations in Neurologic Long-Term-Care Facilities.” Antimicrobial agents and chemotherapy (2015). PMID: 26416866 ↗
L2OTHERCited in: Complications - [608]
Barlow GD. “Swine flu and antibiotics.” The Journal of antimicrobial chemotherapy (2009). PMID: 19740909 ↗
L5OTHERCited in: Complications - [609]
Shah S, Clarke LG, Balasubramani GK et al.. “Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia.” The Journal of antimicrobial chemotherapy (2025). PMID: 40448546 ↗
L2OTHERCited in: Complications - [610]
Das S, Li J, Iaconis J et al.. “Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.” The Journal of antimicrobial chemotherapy (2019). PMID: 30380060 ↗
L2OTHERCited in: Complications, Special Hosts and Populations - [611]
Eustace MB, Braddick M, Alcorn K et al.. “Central Skull Base Osteomyelitis in Queensland, Australia, 2010-2020.” Open forum infectious diseases (2024). PMID: 39450399 ↗
L4OTHERCited in: Complications, Prognosis and Natural History - [612]
Roberts K, Dewar S, Sutherland RK et al.. “Respiratory Virus Coinfection Is a Risk Factor for Adverse Outcomes During Staphylococcus aureus Bacteremia.” Open forum infectious diseases (2026). PMID: 41859699 ↗
L2OTHERCited in: Complications - [613]
Hiskey L, Saifuddin H, Levy ER et al.. “First-Generation Cephalosporins for Treatment of Acute Hematogenous Osteomyelitis in Children: A Study of Efficacy and Adverse Effects.” Open forum infectious diseases (2023). PMID: 38156049 ↗
L2OTHERCited in: Complications, Special Hosts and Populations - [614]
Richter SE, Miller L, Needleman J et al.. “Risk Factors for Development of Carbapenem Resistance Among Gram-Negative Rods.” Open forum infectious diseases (2019). PMID: 30863785 ↗
L3OTHERCited in: Complications - [615]
Pettigrew MM, Gent JF, Revai K et al.. “Microbial interactions during upper respiratory tract infections.” Emerging infectious diseases (2008). PMID: 18826823 ↗
L2OTHERCited in: Complications, Prevention and Infection Control, Special Hosts and Populations - [616]
McDanel JS, Perencevich EN, Storm J et al.. “Increased Mortality Rates Associated with Staphylococcus aureus and Influenza Co-infection, Maryland and Iowa, USA(1).” Emerging infectious diseases (2016). PMID: 27315549 ↗
L2OTHERCited in: Complications, Prognosis and Natural History - [617]
Saxena S, Thompson P, Birger R et al.. “Increasing skin infections and Staphylococcus aureus complications in children, England, 1997-2006.” Emerging infectious diseases (2010). PMID: 20202439 ↗
L2OTHERCited in: Complications - [618]
Magill SS, Dumyati G, Ray SM et al.. “Evaluating Epidemiology and Improving Surveillance of Infections Associated with Health Care, United States.” Emerging infectious diseases (2015). PMID: 26291035 ↗
L5OTHERCited in: Complications, Prevention and Infection Control - [619]
Kreisel KM, Johnson JK, Stine OC et al.. “Illicit drug use and risk for USA300 methicillin-resistant Staphylococcus aureus infections with bacteremia.” Emerging infectious diseases (2010). PMID: 20735927 ↗
L2OTHERCited in: Complications - [620]
Liang H, Mao ZF, Huang JY et al.. “Case Report: Moxibustion-induced burns leading to disseminated methicillin-resistant Staphylococcus aureus infection in a patient with type 2 diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42272806 ↗
L4CASE_REPORTCited in: Complications - [621]
Carey GB, Holleck JL, Ein Alshaeba S et al.. “Estimated mortality with early empirical antibiotic coverage of methicillin-resistant Staphylococcus aureus in hospitalized patients with bacterial infections: a systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2023). PMID: 36964648 ↗
L1SR_OBSCited in: Prognosis and Natural History - [622]
Tacconelli E, De Angelis G, Cataldo MA et al.. “Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis.” The Journal of antimicrobial chemotherapy (2007). PMID: 17986491 ↗
L1SR_OBSCited in: Prognosis and Natural History - [623]
Paulsen J, Solligård E, Damås JK et al.. “The Impact of Infectious Disease Specialist Consultation for Staphylococcus aureus Bloodstream Infections: A Systematic Review.” Open forum infectious diseases (2016). PMID: 27047985 ↗
L2SR_OBSCited in: Prognosis and Natural History - [624]
Dancer SJ. “Controlling hospital-acquired infection: focus on the role of the environment and new technologies for decontamination.” Clinical microbiology reviews (2014). PMID: 25278571 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History, Prevention and Infection Control - [625]
Kondo Y, Klompas M, McKenna CS et al.. “Association Between the Sequence of β-Lactam and Vancomycin Administration and Mortality in Patients With Suspected Sepsis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39657016 ↗
L2OTHERCited in: Prognosis and Natural History - [626]
Saravolatz L, Gandhi TN, Vaughn VM et al.. “Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40601818 ↗
L2OTHERCited in: Prognosis and Natural History - [627]
Gibert C, Marchetti C, Guery B et al.. “Outcome Predictors of Candida Prosthetic Joint Infections: A Systematic Review and Meta-analysis.” Open forum infectious diseases (2025). PMID: 40463834 ↗
L2SR_OBSCited in: Prognosis and Natural History - [628]
Østergaard L, Voldstedlund M, Bruun NE et al.. “Prevalence and Mortality of Infective Endocarditis in Community-Acquired and Healthcare-Associated Staphylococcus aureus Bacteremia: A Danish Nationwide Registry-Based Cohort Study.” Open forum infectious diseases (2022). PMID: 36540385 ↗
L2COHORTCited in: Prognosis and Natural History - [629]
Plumet L, Costechareyre D, Lavigne J-P et al.. “Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens.” Antimicrobial agents and chemotherapy (2024). PMID: 39248472 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [630]
Marro FC, Abad L, Blocker AJ et al.. “In vitro antibiotic activity against intraosteoblastic Staphylococcus aureus: a narrative review of the literature.” The Journal of antimicrobial chemotherapy (2021). PMID: 34459881 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [631]
Kuehl R, Morata L, Meylan S et al.. “When antibiotics fail: a clinical and microbiological perspective on antibiotic tolerance and persistence of Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2020). PMID: 32016348 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [632]
Seaton RA. “Daptomycin: rationale and role in the management of skin and soft tissue infections.” The Journal of antimicrobial chemotherapy (2008). PMID: 18829721 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [633]
Dancer SJ. “The effect of antibiotics on methicillin-resistant Staphylococcus aureus.” The Journal of antimicrobial chemotherapy (2007). PMID: 18057071 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Natural History - [634]
Ong SWX, Patrikar A, Pinto R et al.. “Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial.” Open forum infectious diseases (2026). PMID: 42338985 ↗
L2TRIAL_NONRANDOMCited in: Prognosis and Natural History - [635]
Lewandowski T, Huang J, Fan F et al.. “Staphylococcus aureus formyl-methionyl transferase mutants demonstrate reduced virulence factor production and pathogenicity.” Antimicrobial agents and chemotherapy (2013). PMID: 23571548 ↗
L5OTHERCited in: Prognosis and Natural History - [636]
Clarke RS, Ha KP, Edwards AM. “RexAB Promotes the Survival of Staphylococcus aureus Exposed to Multiple Classes of Antibiotics.” Antimicrobial agents and chemotherapy (2021). PMID: 34310219 ↗
L5OTHERCited in: Prognosis and Natural History - [637]
Truong-Bolduc QC, Yonker LM, Wang Y et al.. “NorA efflux pump mediates Staphylococcus aureus response to Pseudomonas aeruginosa pyocyanin toxicity.” Antimicrobial agents and chemotherapy (2024). PMID: 38231535 ↗
L5OTHERCited in: Prognosis and Natural History, Special Hosts and Populations - [638]
Klein E, Smith DL, Laxminarayan R. “Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005.” Emerging infectious diseases (2007). PMID: 18258033 ↗
L2OTHERCited in: Prognosis and Natural History - [639]
Gutierrez K, Halpern MS, Sarnquist C et al.. “Staphylococcal infections in children, California, USA, 1985-2009.” Emerging infectious diseases (2013). PMID: 23260060 ↗
L2OTHERCited in: Prognosis and Natural History - [640]
Pastagia M, Kleinman LC, Lacerda de la Cruz EG et al.. “Predicting risk for death from MRSA bacteremia.” Emerging infectious diseases (2012). PMID: 22709685 ↗
L2OTHERCited in: Prognosis and Natural History - [641]
Aguado JM, San-Juan R, Lalueza A et al.. “High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia.” Emerging infectious diseases (2011). PMID: 21749780 ↗
L2OTHERCited in: Prognosis and Natural History - [642]
Robinson AL, Boyle MG, Hogan PG et al.. “Evaluating Personal and Environmental Decolonization Strategies for Children With Skin and Soft Tissue Infection and Their Households - A Randomized Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 41276461 ↗
L1RCTCited in: Prevention and Infection Control, Special Hosts and Populations - [643]
Anderson DJ, Moehring RW, Weber DJ et al.. “Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection).” The Lancet. Infectious diseases (2018). PMID: 29880301 ↗
L2RCTCited in: Prevention and Infection Control - [644]
Gemmell CG, Edwards DI, Fraise AP et al.. “Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.” The Journal of antimicrobial chemotherapy (2006). PMID: 16507559 ↗
L1GUIDELINECited in: Prevention and Infection Control - [645]
Gould FK, Brindle R, Chadwick PR et al.. “Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom.” The Journal of antimicrobial chemotherapy (2009). PMID: 19282331 ↗
L1GUIDELINECited in: Prevention and Infection Control - [646]
Crawford T, Rodvold KA, Solomkin JS. “Vancomycin for surgical prophylaxis?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2012). PMID: 22328468 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [647]
Daum RS, Spellberg B. “Progress toward a Staphylococcus aureus vaccine.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2011). PMID: 22186773 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [648]
Hetem DJ, Bootsma MC, Bonten MJ. “Prevention of Surgical Site Infections: Decontamination With Mupirocin Based on Preoperative Screening for Staphylococcus aureus Carriers or Universal Decontamination?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2015). PMID: 26658054 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [649]
Santos RP, Mayo TW, Siegel JD. “Healthcare epidemiology: active surveillance cultures and contact precautions for control of multidrug-resistant organisms: ethical considerations.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2008). PMID: 18491966 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [650]
Price JR, Cole K, Bexley A et al.. “Transmission of Staphylococcus aureus between health-care workers, the environment, and patients in an intensive care unit: a longitudinal cohort study based on whole-genome sequencing.” The Lancet. Infectious diseases (2016). PMID: 27863959 ↗
L2COHORTCited in: Prevention and Infection Control - [651]
Bojang A, Baines SL, Donovan L et al.. “Genomic investigation of Staphylococcus aureus recovered from Gambian women and newborns following an oral dose of intra-partum azithromycin.” The Journal of antimicrobial chemotherapy (2019). PMID: 31424550 ↗
L4RCTCited in: Prevention and Infection Control - [652]
Dancer SJ. “Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning.” The Lancet. Infectious diseases (2007). PMID: 17974481 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [653]
Okomo U, Fitzgerald F, Feasey N et al.. “Infection prevention and control in low- and middle-income countries: policy, practice, and implementation challenges in sub-Saharan Africa.” Clinical microbiology reviews (2026). PMID: 42132371 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [654]
Soge OO, Thibault CS, Cannon CA et al.. “Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization With Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 40036749 ↗
L2OTHERCited in: Prevention and Infection Control - [655]
Diekema DJ, Nori P, Stevens MP et al.. “Are Contact Precautions "Essential" for the Prevention of Healthcare-associated Methicillin-Resistant Staphylococcus aureus?” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 37738565 ↗
L5OTHERCited in: Prevention and Infection Control - [656]
Zong Z, Wu A, Hu B. “Infection Control in the Era of Antimicrobial Resistance in China: Progress, Challenges, and Opportunities.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020). PMID: 33367579 ↗
L5OTHERCited in: Prevention and Infection Control - [657]
Evans ME, Simbartl LA, McCauley BP et al.. “Active Surveillance and Contact Precautions for Preventing Methicillin-Resistant Staphylococcus aureus Healthcare-Associated Infections During the COVID-19 Pandemic.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37390613 ↗
L2OTHERCited in: Prevention and Infection Control - [658]
Cabral SM, Harris AD, Cosgrove SE et al.. “Adherence to Antimicrobial Prophylaxis Guidelines for Elective Surgeries Across 825 US Hospitals, 2019-2020.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36774539 ↗
L2OTHERCited in: Prevention and Infection Control - [659]
Wyllie D, Paul J, Crook D. “Waves of trouble: MRSA strain dynamics and assessment of the impact of infection control.” The Journal of antimicrobial chemotherapy (2011). PMID: 21948966 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [660]
Cattoir V, Leclercq R. “Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?” The Journal of antimicrobial chemotherapy (2012). PMID: 23208830 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [661]
Edgeworth JD. “Has decolonization played a central role in the decline in UK methicillin-resistant Staphylococcus aureus transmission? A focus on evidence from intensive care.” The Journal of antimicrobial chemotherapy (2010). PMID: 20852273 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [662]
Johnson AP, Davies J, Guy R et al.. “Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years.” The Journal of antimicrobial chemotherapy (2012). PMID: 22223229 ↗
L2REVIEW_NARRATIVECited in: Prevention and Infection Control - [663]
Harbarth S, Samore MH. “Interventions to control MRSA: high time for time-series analysis?” The Journal of antimicrobial chemotherapy (2008). PMID: 18556707 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [664]
. “Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.” The Lancet. Infectious diseases (2025). PMID: 41412141 ↗
L2OTHERCited in: Prevention and Infection Control, Special Hosts and Populations - [665]
Grayson ML, Stewardson AJ, Russo PL et al.. “Effects of the Australian National Hand Hygiene Initiative after 8 years on infection control practices, health-care worker education, and clinical outcomes: a longitudinal study.” The Lancet. Infectious diseases (2018). PMID: 30274723 ↗
L2OTHERCited in: Prevention and Infection Control - [666]
Handapangoda NP, Ruwansiri LP, Vidanapathirana GU et al.. “Prevalence of Streptococcus pneumoniae and Staphylococcus aureus co-colonization in healthy children under five years: a systematic review.” BMC pediatrics (2026). PMID: 41826897 ↗
L3SR_OBSCited in: Prevention and Infection Control, Special Hosts and Populations - [667]
Ter Steeg L, Domínguez-Andrés J, Netea MG et al.. “Trained Immunity as a Preventive Measure for Surgical Site Infections.” Clinical microbiology reviews (2021). PMID: 34585978 ↗
L5OTHERCited in: Prevention and Infection Control - [668]
Khairy TF, Lupien MA, Nava S et al.. “Infections Associated with Resterilized Pacemakers and Defibrillators.” The New England journal of medicine (2020). PMID: 32374963 ↗
L2OTHERCited in: Prevention and Infection Control - [669]
Yang C, Peng C, Yan J et al.. “Cefazolin Alone versus Vancomycin Plus Cefazolin for Intravenous Prophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis.” The Journal of arthroplasty (2026). PMID: 42069021 ↗
L1SR_OBSCited in: Prevention and Infection Control - [670]
Hurley JC. “Arms-Based Meta-Analysis of Microbiological Endpoints of 88 VAP Prevention Studies Using Antimicrobial Versus Non-Antimicrobial Strategies-Towards 'VAP-Zero'?” Antibiotics (Basel, Switzerland) (2026). PMID: 41750518 ↗
L1SR_OBSCited in: Prevention and Infection Control - [671]
Mostofi K, Caragliano G. “Surgical Site Infections in Spine Surgery: A Retrospective Study of 1,578 Procedures with Identification of Tattooed Skin as a Novel Risk Factor Associated with Surgical Site Infection.” The Journal of hospital infection (2026). PMID: 42314879 ↗
L2COHORTCited in: Prevention and Infection Control - [672]
Takahashi H, Taku K, Mizuki K et al.. “Comparison of methicillin-resistant Staphylococcus aureus carriage in a neonatal intensive care unit between pre- and post-COVID-19 pandemic periods, following the introduction of strengthened infection control measures: a retrospective study.” The Journal of hospital infection (2026). PMID: 42162920 ↗
L2COHORTCited in: Prevention and Infection Control - [673]
Nikolić D, Petrović K, Manojlović V et al.. “Increasing Methicillin-Resistant Staphylococcus aureus Burden in 90-Day Groin Surgical Site Infection After Femoral Arterial Exposure: A 15-Year Single-Centre Cohort Study.” International wound journal (2026). PMID: 42117325 ↗
L2COHORTCited in: Prevention and Infection Control - [674]
Molendijk MM, Boekema BKHL, Lattwein KR et al.. “Bacteriophage therapy reduces Staphylococcus aureus in a porcine and human ex vivo burn wound infection model.” Antimicrobial agents and chemotherapy (2024). PMID: 39136463 ↗
L5OTHERCited in: Prevention and Infection Control - [675]
Wei J, Tong K, Wang H et al.. “Dosage, Efficacy, and Safety of Intra-articular Vancomycin for Prophylaxis of Periprosthetic Joint Infection Caused by Methicillin-Resistant Staphylococcus aureus after Total Knee Arthroplasty in a Rat Model.” Antimicrobial agents and chemotherapy (2021). PMID: 34807762 ↗
L5OTHERCited in: Prevention and Infection Control - [676]
Stiefel P, Mauerhofer S, Schneider J et al.. “Enzymes Enhance Biofilm Removal Efficiency of Cleaners.” Antimicrobial agents and chemotherapy (2016). PMID: 27044552 ↗
L5OTHERCited in: Prevention and Infection Control - [677]
Tornero E, García-Ramiro S, Martínez-Pastor JC et al.. “Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty.” Antimicrobial agents and chemotherapy (2014). PMID: 25403662 ↗
L2OTHERCited in: Prevention and Infection Control - [678]
Mao Y, Valour F, Nguyen NTQ et al.. “Multimechanistic Monoclonal Antibody Combination Targeting Key Staphylococcus aureus Virulence Determinants in a Rabbit Model of Prosthetic Joint Infection.” Antimicrobial agents and chemotherapy (2021). PMID: 33903108 ↗
L5OTHERCited in: Prevention and Infection Control - [679]
Diep BA, Hilliard JJ, Le VT et al.. “Targeting Alpha Toxin To Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia.” Antimicrobial agents and chemotherapy (2017). PMID: 28115346 ↗
L5OTHERCited in: Prevention and Infection Control - [680]
Freire MP, Pierrotti LC, Zerati AE et al.. “Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria.” Antimicrobial agents and chemotherapy (2018). PMID: 29987150 ↗
L4OTHERCited in: Prevention and Infection Control - [681]
McNeil JC, Kok EY, Vallejo JG et al.. “Clinical and Molecular Features of Decreased Chlorhexidine Susceptibility among Nosocomial Staphylococcus aureus Isolates at Texas Children's Hospital.” Antimicrobial agents and chemotherapy (2015). PMID: 26666947 ↗
L4OTHERCited in: Prevention and Infection Control, Special Hosts and Populations - [682]
Saint-Genis Q, Marchand S, Chauzy A et al.. “Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery.” The Journal of antimicrobial chemotherapy (2026). PMID: 41744034 ↗
L2OTHERCited in: Prevention and Infection Control - [683]
Pitt-Kendall R, Sun S, Hughes S et al.. “Investigating the cause of increased tetracycline-resistant Neisseria gonorrhoeae in England, 2016-20.” The Journal of antimicrobial chemotherapy (2024). PMID: 38517444 ↗
L2OTHERCited in: Prevention and Infection Control - [684]
Bayston R, Vera L, Mills A et al.. “In vitro antimicrobial activity of silver-processed catheters for neurosurgery.” The Journal of antimicrobial chemotherapy (2009). PMID: 19942617 ↗
L5OTHERCited in: Prevention and Infection Control - [685]
Houston A, Hooker E, Rankin A et al.. “Environmental surface sampling in health and care settings: a scoping review of published guidance.” The Journal of hospital infection (2026). PMID: 42025699 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [686]
Albaloul H, Nemer A, Saini N et al.. “Infectious Diseases: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974008 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control, Special Hosts and Populations - [687]
Pathinathan K, Sial A, Khalil O et al.. “Strategies to prevent post-operative surgical site infection in spinal surgery: a narrative review.” European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2026). PMID: 41936664 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [688]
Bosetti D, Lee A, Catho G et al.. “Beyond Methicillin-resistant Staphylococcus aureus: Prevention Strategies for Health Care-Associated Staphylococcus aureus Infection.” Infectious disease clinics of North America (2026). PMID: 41896065 ↗
L5REVIEW_NARRATIVECited in: Prevention and Infection Control - [689]
Bryce A, Davison S, Currie BJ et al.. “Lower Rates of Staphylococcus aureus Bloodstream Infection in Patients on Hemodialysis Receiving Trimethoprim-Sulfamethoxazole Melioidosis Prophylaxis.” Open forum infectious diseases (2024). PMID: 39130084 ↗
L4OTHERCited in: Prevention and Infection Control - [690]
Creech CB, Frenck RW, Fiquet A et al.. “Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag).” Open forum infectious diseases (2019). PMID: 31993453 ↗
L4OTHERCited in: Prevention and Infection Control - [691]
DeSimone DC, Lahr BD, Anavekar NS et al.. “Temporal Trends of Infective Endocarditis in Olmsted County, Minnesota, Between 1970 and 2018: A Population-Based Analysis.” Open forum infectious diseases (2021). PMID: 33728357 ↗
L2OTHERCited in: Prevention and Infection Control - [692]
Aslam S, Lampley E, Wooten D et al.. “Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States.” Open forum infectious diseases (2020). PMID: 33005701 ↗
L4OTHERCited in: Prevention and Infection Control - [693]
Lesens O, Haus-Cheymol R, Dubrous P et al.. “Methicillin-susceptible, doxycycline-resistant Staphylococcus aureus, Côte d'Ivoire.” Emerging infectious diseases (2007). PMID: 17552109 ↗
L4OTHERCited in: Prevention and Infection Control - [694]
Zilberberg MD, Shorr AF, Kollef MH. “Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005.” Emerging infectious diseases (2008). PMID: 18976563 ↗
L2OTHERCited in: Prevention and Infection Control - [695]
Huson MA, Stolp SM, van der Poll T et al.. “Community-acquired bacterial bloodstream infections in HIV-infected patients: a systematic review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2013). PMID: 24046307 ↗
L2SR_OBSCited in: Special Hosts and Populations - [696]
Rice S, Carr K, Sobiesuo P et al.. “Economic evaluations of interventions to prevent and control health-care-associated infections: a systematic review.” The Lancet. Infectious diseases (2023). PMID: 37001543 ↗
L2SR_OBSCited in: Special Hosts and Populations - [697]
Payne SC, Benninger MS. “Staphylococcus aureus is a major pathogen in acute bacterial rhinosinusitis: a meta-analysis.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17968816 ↗
L1SR_OBSCited in: Special Hosts and Populations - [698]
Doernberg SB, Arias CA, Altman DR et al.. “Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37843115 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations - [699]
Fritz SA, Hogan PG, Camins BC et al.. “Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections.” Antimicrobial agents and chemotherapy (2012). PMID: 23147738 ↗
L2RCTCited in: Special Hosts and Populations - [700]
Campbell AJ, Al Yazidi LS, Phuong LK et al.. “Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 34089594 ↗
L2OTHERCited in: Special Hosts and Populations - [701]
Park DE, Baggett HC, Howie SRC et al.. “Colonization Density of the Upper Respiratory Tract as a Predictor of Pneumonia-Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Pneumocystis jirovecii.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2017). PMID: 28575367 ↗
L3OTHERCited in: Special Hosts and Populations - [702]
Popovich KJ, Weinstein RA, Aroutcheva A et al.. “Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2010). PMID: 20192731 ↗
L3OTHERCited in: Special Hosts and Populations - [703]
Dicko CH, N'Dri DN, Snoussi M et al.. “Etiology, prevalence, and mortality of sepsis among children under five years in Africa: a systematic review and meta-analysis.” BMC infectious diseases (2026). PMID: 42035015 ↗
L1SR_OBSCited in: Special Hosts and Populations - [704]
Aleissa MM, Gonzalez-Bocco IH, Zekery-Saad S et al.. “The Relationship Between Antibiotic Agent and Mortality in Patients With Febrile Neutropenia due to Staphylococcal Bloodstream Infection: A Multicenter Cohort Study.” Open forum infectious diseases (2022). PMID: 35949404 ↗
L2COHORTCited in: Special Hosts and Populations - [705]
Bodey GP. “The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.” The Journal of antimicrobial chemotherapy (2009). PMID: 19372179 ↗
L5REVIEW_NARRATIVECited in: Special Hosts and Populations - [706]
Musicha P, Cornick JE, Bar-Zeev N et al.. “Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study.” The Lancet. Infectious diseases (2017). PMID: 28818544 ↗
L2OTHERCited in: Special Hosts and Populations - [707]
Okike IO, Ribeiro S, Ramsay ME et al.. “Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004-11: an observational study.” The Lancet. Infectious diseases (2014). PMID: 24508198 ↗
L2OTHERCited in: Special Hosts and Populations - [708]
Liou TG, Adler FR, Cox DR et al.. “Lung transplantation and survival in children with cystic fibrosis.” The New England journal of medicine (2007). PMID: 18032764 ↗
L2OTHERCited in: Special Hosts and Populations - [709]
Mohamud SM, Nor LA, Doğan S et al.. “Antimicrobial resistance patterns of Staphylococcus aureus isolates in tertiary hospital in Somalia: a retrospective study.” BMC infectious diseases (2026). PMID: 42087083 ↗
L4COHORTCited in: Special Hosts and Populations - [710]
Sng ECY, Teo DCH, Wong MJ et al.. “Microbiology and clinical characteristics of brain abscess in adults from 3 tertiary hospitals in Singapore - a 11-year multicenter retrospective study.” BMC infectious diseases (2026). PMID: 42062945 ↗
L4COHORTCited in: Special Hosts and Populations - [711]
Wang C, Wang K, Zhu H et al.. “Analysis of risk factors for concurrent osteomyelitis in children with septic arthritis: A retrospective cohort study.” The American journal of emergency medicine (2026). PMID: 42061203 ↗
L2COHORTCited in: Special Hosts and Populations - [712]
Krymko H, Abelson N, El Mahdi N et al.. “Predictors of definite and possible infective endocarditis in children with bacteremia: a reginal cohort study.” European journal of pediatrics (2026). PMID: 41866405 ↗
L2COHORTCited in: Special Hosts and Populations - [713]
Attaianese F, Benhard J, Cohen JF et al.. “Oral switch therapy for paediatric Staphylococcus aureus bloodstream infections: A retrospective study in a tertiary hospital.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41846044 ↗
L2COHORTCited in: Special Hosts and Populations - [714]
Autmizguine J, Melloni C, Hornik CP et al.. “Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.” Antimicrobial agents and chemotherapy (2017). PMID: 29084742 ↗
L4OTHERCited in: Special Hosts and Populations - [715]
McNeil JC, Hulten KG, Kaplan SL et al.. “Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children.” Antimicrobial agents and chemotherapy (2011). PMID: 21282426 ↗
L4OTHERCited in: Special Hosts and Populations - [716]
Szumowski JD, Cohen DE, Kanaya F et al.. “Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.” Antimicrobial agents and chemotherapy (2006). PMID: 17116664 ↗
L2OTHERCited in: Special Hosts and Populations - [717]
Tabor DE, Yu L, Mok H et al.. “Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893.” Antimicrobial agents and chemotherapy (2016). PMID: 27324766 ↗
L4OTHERCited in: Special Hosts and Populations - [718]
Verdejo MÁ, Malano-Barletta D, Pitart C et al.. “Empirical glycopeptide exposure and acute kidney injury during cloxacillin therapy in Staphylococcus aureus bacteremia.” Antimicrobial agents and chemotherapy (2026). PMID: 42080550 ↗
L2OTHERCited in: Special Hosts and Populations - [719]
Kok EY, Vallejo JG, Sommer LM et al.. “Association of Vancomycin MIC and Molecular Characteristics with Clinical Outcomes in Methicillin-Susceptible Staphylococcus aureus Acute Hematogenous Osteoarticular Infections in Children.” Antimicrobial agents and chemotherapy (2018). PMID: 29530845 ↗
L2OTHERCited in: Special Hosts and Populations - [720]
Brahami A, Karlowsky JA, McCracken M et al.. “Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23).” The Journal of antimicrobial chemotherapy (2025). PMID: 40873028 ↗
L4OTHERCited in: Special Hosts and Populations - [721]
Nichol KA, Adam HJ, Golding GR et al.. “Characterization of MRSA in Canada from 2007 to 2016.” The Journal of antimicrobial chemotherapy (2019). PMID: 31505646 ↗
L4OTHERCited in: Special Hosts and Populations - [722]
Helbo T, Boel JB, Bartels MD et al.. “Carriage of methicillin-resistant Staphylococcus aureus in children <6 years old: a retrospective follow-up study of the natural course and effectiveness of decolonization treatment.” The Journal of antimicrobial chemotherapy (2024). PMID: 38334373 ↗
L2OTHERCited in: Special Hosts and Populations - [723]
Song JH, Hsueh PR, Chung DR et al.. “Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study.” The Journal of antimicrobial chemotherapy (2011). PMID: 21393157 ↗
L2OTHERCited in: Special Hosts and Populations - [724]
Villar M, Marimón JM, García-Arenzana JM et al.. “Epidemiological and molecular aspects of rifampicin-resistant Staphylococcus aureus isolated from wounds, blood and respiratory samples.” The Journal of antimicrobial chemotherapy (2011). PMID: 21393177 ↗
L4OTHERCited in: Special Hosts and Populations - [725]
Drewett GP, Jacob M, Culhane B et al.. “Malignant Otitis Externa in Central Australia: A 15-Year Retrospective Review Between 2009 and 2024.” The Medical journal of Australia (2026). PMID: 41837387 ↗
L4REVIEW_NARRATIVECited in: Special Hosts and Populations - [726]
Morelli MK, Veve MP, Shorman MA. “Maternal Bacteremia Caused by Staphylococcus Aureus With a Focus on Infective Endocarditis.” Open forum infectious diseases (2020). PMID: 32766382 ↗
L4OTHERCited in: Special Hosts and Populations - [727]
Sullivan SB, Kamath S, McConville TH et al.. “Staphylococcus epidermidis Protection Against Staphylococcus aureus Colonization in People Living With Human Immunodeficiency Virus in an Inner-City Outpatient Population: A Cross-Sectional Study.” Open forum infectious diseases (2016). PMID: 28018932 ↗
L4OTHERCited in: Special Hosts and Populations - [728]
Crum-Cianflone NF, Wang X, Weintrob A et al.. “Specific Behaviors Predict Staphylococcus aureus Colonization and Skin and Soft Tissue Infections Among Human Immunodeficiency Virus-Infected Persons.” Open forum infectious diseases (2015). PMID: 26380335 ↗
L2OTHERCited in: Special Hosts and Populations - [729]
Stavropoulou E, Ledergerber B, Fourré N et al.. “Infective Endocarditis and Antimicrobial Timing: A Case for Delay?” Open forum infectious diseases (2025). PMID: 41141452 ↗
L2OTHERCited in: Special Hosts and Populations - [730]
Popovich KJ, Zawitz C, Weinstein RA et al.. “The Intersecting Epidemics of Human Immunodeficiency Virus, Community-Associated Methicillin-Resistant Staphylococcus aureus, and Incarceration.” Open forum infectious diseases (2015). PMID: 26543878 ↗
L2OTHERCited in: Special Hosts and Populations - [731]
Koeck M, Como-Sabetti K, Boxrud D et al.. “Burdens of Invasive Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Disease, Minnesota, USA.” Emerging infectious diseases (2019). PMID: 30561319 ↗
L4OTHERCited in: Special Hosts and Populations